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A) THE CARDIOVASCULAR SYSTEM: A GENERAL OVERVIEW 
 
The vascular system is the transportation network within the human body and consists of two 
separate circulating systems: 1) the blood circulation and 2) the lymphatic system.  
 
1) Blood is a fluid that constantly circulates through the complex network of blood vessels 
(arteries and veins). It provides the body with essential nutrition and oxygen (O2), and removes 
waste products. Plasma makes up about half of the blood volume. It has a broad variety of 
functions but importantly it contains proteins that help the blood to clot and transports 
substances such as glucose and other dissolved nutrients. The other half of the blood volume 
consists of blood cells (Figure 1):2 
 
• Red blood cells, carry O2 to the different tissues in the body. 
• White blood cells, control or combat infections. 




2) Extracellular liquid from the various bodily tissues drains into the lymphatic system which then 
organises the recirculation of this back to the blood circulation via lymph nodes. 
 
Figure 1 – Blood vessels transport plasma and blood cells to the tissues/organs of the body. The innermost 
layer of blood vessels consists of endothelial cells.  
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B) STRUCTURE OF A NORMAL BLOOD VESSEL 
 
The anatomical structure of normal arteries consists of a well-designed, trilaminar structure. The 
innermost layer (tunica intima) is made up of an endothelial cell (EC) monolayer (Figure 1), 
which resides on a basement membrane.2 This membrane is built from nonfibrillar collagen such 
as type IV collagen, as well as laminin, fibronectin and other extracellular matrix molecules.2 The 
second layer, the tunica media, lies beneath the intima. The media of elastic arteries (such as 
the aorta) are built from thick and concentric layers of smooth muscle cells (SMCs) enriched with 
layers of elastin-rich extracellular matrix.2 This structure is well-adapted to withstand the kinetic 
energy generated by systolic tension in the walls of the great arteries.2 The third outermost layer 
of arteries, the adventitia, is built from a loose network of collagen fibrils and contains a small 
network of vessels supplying the artery wall (the vasa vasorum) and various nerve endings.2  
 
 
C) ATHEROTHROMBOTIC DISEASE: WHERE PLATELETS AND ECS MEET 
 
“During the last decades, cardiovascular disease (CVD) has become the single largest cause of 
death worldwide. In 2012, CVD caused an estimated 16,7 million deaths (about 29% of all 
deaths).More than 3 million of these deaths occurred before the age of 60 and could have largely 
been prevented”.3  
 
Atherosclerosis is a condition where the arteries become narrowed and hardened due to an 
excessive build-up of cholesterol plaques in the artery wall.2 It is a slow, progressive process that 
only results in clinical symptoms at an advanced stage. The first step in human atherosclerosis is 
the accumulation and aggregation of small lipoprotein particles in the intima.4 Predilected lesion 
sites in arteries are proximal to branching points or bifurcations.5 This results in the local 
adhesion of leucocytes to the endothelium and their penetration into the intima (transcytosis), 
where they accumulate lipids and become lipid-laden macrophages, or foam cells.6 The 
accumulation of foam cells/macrophages results in an ensemble of inflammatory mediators and 
the promotion of inflammation within the plaque which contributes to the development of the 
atherosclerotic lesions.7 Whereas the early stages of atheroma plaque initiation primarily involve 
altered endothelial function and the recruitment and accumulation of leucocytes, the subsequent 
evolution of atheroma into more complex plaques requires the migration of SMC from the tunica 
media into the intima layer. These intimal SMCs proliferate and facilitate the development of an 
extracellular matrix (mainly consisting of type I and III collagen, proteoglycans and decorin), 
ultimately leading to the calcification of areas and a stable atherosclerotic plaque.8, 9   
 
The conventional risk factors for atherosclerosis are listed in Figure 2.10-14 The main risk of 
atherosclerosis is the development of a critical arterial stenosis and/or plaque rupture with 
atherothrombosis (Figure 2), the latter being the predominant reason for acute cardiovascular 
events.15 Atherothrombosis is the formation of a thrombus within an artery resulting from an 
atherosclerotic plaque rupture. It can no longer be considered a disease of the developed world 
since myocardial infarction and stroke are increasingly prevalent worldwide and occur across all 
socioeconomic strata. By 2025, cardiovascular mortality on a worldwide scale will likely surpass 
that of every major disease group, including infection, cancer and trauma.16, 17  
 
! Introduction ! !
! 5!
Atherotic plaque rupture usually occurs at the weakest point (the “shoulder” of the plaque), where 
the cap is often very thin and most heavily infiltrated with inflammatory cells.17 Once this plaque 
is disrupted, the highly thrombogenic lipid-rich core is exposed to the bloodstream. This core 
has an abundance of tissue factor, and triggers platelet activation, aggregation and the formation 
of a superimposed thrombus, leading to (sub)total vessel occlusion and subsequent ischaemic 
symptoms distal to it.18, 19 Depending on the localisation and degree of occlusion, this may lead 






Figure 2 – Overview of atherosclerosis risk factors. Atherosclerosis involves the development of stable and/or 




The most critical processes in the formation of (unstable) plaques and subsequent 
intraluminal thrombus formation are endothelial dysfunction and platelet 
aggregation, resulting in (sub)total vessel occlusion. Given the focus of this thesis, 
I will now further elaborate on the role and function of endothelial cells (including 




D) ENDOTHELIAL CELLS  
 
The total human endothelial cell (EC) surface is composed of approximately 1 to 6×1013 cells. Its 
calculated weight is approximately 0,1 kg and it covers a surface area of 1 to 7.000 m2.20 ECs line 
the vessels of every organ system and are essential for regulating blood cells and controlling the 
flow of nutrient substances, which are diverse biologically-active molecules. This gate-keeper 
role of the endothelium is effected through: a) the presence of various membrane-bound 
receptors, that bind a variety of molecules e.g., growth factors, coagulant and anticoagulant 
proteins, low-density lipoprotein [LDL], serotonin, endothelin-1 etc.; and b) through specific 
junctional proteins and receptors that organise cell-cell and cell-matrix interactions.21 
 
The endothelium also plays a pivotal role in the regulation of blood flow.2 This is partly due to the 
capacity of quiescent ECs for generating an active antithrombotic surface, responsible for 
facilitating the transit of plasma and cellular constituents through the vasculature. Disruptions to 
this cellular homeostasis, such as those seen at sites of inflammation or high hydrodynamic shear 
stress, alter these activities and switch ECs in favour of a prothrombotic and antifibrinolytic 
micro-environment.21 Blood flow is also partly regulated by ECs in a paracrine manner through 
the secretion and uptake of vasoactive substances by the endothelium, triggering the constriction 
and dilatation of specific vascular beds in response to stimuli such as endotoxin.21 
Arteries supply tissues with oxygen and nutrients, whereas the broad network of lymphatic 
vessels absorb and filter interstitial fluids from these same tissues.22 Although blood vessels 
mostly remain quiescent throughout life, they retain the capacity to rapidly form new vessels 
(sprouting) in response to local injuries or under pathological conditions such as cancer. The 
pivotal players in this process of neo vessel formation are ECs. In this neovascularization process 
(also called angiogenesis) there are three different EC subtypes which each carry out a highly 
specific role and are crucial for neo-capillary formation, itself an essential component of 
angiogenesis23. Tip cells are ECs with a highly migratory/non-proliferative phenotype. Their 
function is to guide and pull the new sprout in the correct direction. In addition, stalk cells 
elongate the newly formed sprout through their highly proliferative phenotype (Figure 3). Finally, 
quiescent phalanx cells mark the more mature part of the vessel and are typically cobblestone 
shaped.24 
The differentiation of ECs into one of these subtypes is mainly driven by vascular endothelial 
growth factor (VEGF) whose production is triggered via hypoxic tissues and macrophages that are 
trying to regain an oxygen and nutrient supply via stimulating the formation of new vessels. This 
has been thoroughly studied in retinal angiogenesis where a continuous rise in VEGF 
concentration eventually reaches the existing vascular front and allows VEGF to bind to the VEGF 
receptor 2 (VEGFR2) in ECs, directing these ECs towards a tip cell phenotype. The newly-
differentiated tip cells then force their neighbouring ECs to adopt a stalk cell phenotype via the 
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Notch ligand delta-like 4. This Notch ligand binds to Notch receptors in adjacent ECs, forcing the 
release of the Notch intracellular domain (NICD) that initiates the reprogramming of the cell to 
express the decoy VEGFR1-receptor at the expense of VEGFR2, a process that triggers reduced 
VEGF sensitivity and stimulates stalk cell behavior.25 Tip/stalk specification is a very dynamic 
process in which, through continuous cell shuffling, ECs with the highest VEGFR2/VEGFR1 
expression ratio (and thus the highest VEGF responsiveness) are continuously at the tip of the 
new vessel sprout.26 If a tip cell encounters another tip cell or a pre-existing vessel, both will fuse 
together to form a lumenised, perfused vessel (a process called anastomosis). The newly-formed 
vessel sprout then matures, and the ECs adopt a more quiescent, non-proliferative and non-
migratory, cobblestone-like phalanx cell phenotype.27 These cells are marked with high VEGFR1 
levels and low VEGF responsiveness, therefore they are able to stay quiescent for years.27   
 
These EC-driven roles are important in many body processes, but particularly in wound closure, 






Figure 3 – A) Endothelial tip cells migrate towards an angiogenic stimulus, and are followed by a column of 
proliferating stalk cells. B) This process results in the formation of new vessels via branching and anastomosis 
to produce a new (collateral) vascular network.   
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Platelets have attracted a growing interest among scientists and clinicians as their role has 
extended beyond haemostasis to many physiological and/or pathophysiological conditions such 
as wound healing, inflammation, infectious diseases, maintenance of endothelial barrier function, 
angiogenesis and tumour metastasis. In the last few decades, enormous progress has been made 
in our understanding of the role of platelets in haemostasis and other processes. Platelets 
circulate in the blood in a resting state but they are able to react immediately following injury to 
the vessel wall by adhering to the exposed collagen and then forming a plug by platelet–platelet 
interaction to effectively seal the injured vessel wall and prevent excessive blood loss. Similar 






Platelet aggregation is mediated by signalling events that are induced by various primary platelet 
agonists (e.g. thrombin, ADP and collagen). These agonists induce a conformational change in the 
platelet integrin αIIbβ3 receptor which allow it to bind to soluble fibrinogen and von Willebrand 
factor (VWF), thereby inducing platelet cross-linking.29 These platelet-platelet interactions that 
occur during the process of aggregation then initiate multiple secondary signalling events to 
further activate the platelet, e.g., calcium mobilisation, protein tyrosine phosphorylation, 
cytoskeletal rearrangements and the release of platelet dense bodies or α-granules. The released 
dense body contents include ADP which, alongside the platelet activation-induced generation of 
thromboxane A2 (TXA2), further adds to platelet stimulation.29  
 
Following initial platelet aggregation, the formation of a stable platelet aggregate involves many 
factors, such as the generation of stabilising fibrin, however there are three mechanisms that 
appear to predominate in this process (adapted from Nanda et al.)30:  
1. Shear. Platelet thrombi partially occlude arteries, which increases the shear rate within 
these arteries and induces further platelet stimulation.  
2. The generation of autocrine loops. Platelet activation induces the release of four platelet 
stimuli: ADP, TXA2, sCD40L and Gas6.  
3. Platelet–platelet contacts (a type of “outside-in signalling”). Platelet-platelet contacts 
within the aggregate further induce platelet stimulation by the activation of various 
surface receptors, the so-called “aggregation-induced aggregation receptors”. Although 
the mechanisms underlying this process are not fully understood, they are clearly of 
fundamental importance to platelet thrombus formation as the release of the four 
autocrine stimuli is aggregation-dependent. Aggregation-induced signalling is the 
cornerstone to the formation of stable aggregates, especially when aggregation is 









Platelet receptor-ligand interactions are essential for a) the mobilisation and adhesion of 
circulating platelets at sites of damaged ECs, b) the subsequent activation of those platelets, and 
c) platelet aggregation and thrombus formation. The initial trigger for platelet aggregate 
formation is specific sequences on exposed collagen fibrils that are recognised by the GPVI 
(collagen) receptor. This process induces potent platelet activation and complements the (minor) 
activation brought about by the GPIb-VWF interaction. Together these result in the activation of 
intracellular signalling and induce the high-affinity state of the β–integrins at the platelet surface, 
allowing firm platelet adhesion to collagen via the α2β1 integrin.31 Platelet aggregation then 
occurs via platelet spreading and platelet-fibrinogen interactions through the αIIbβ3-receptor.32To 
maintain haemostasis, this process requires additional fine-tuning via many more receptors, all 
synergising to control platelet activation and arrest blood loss.33 The most important platelet 
receptors involved in platelet adhesion and aggregation are listed below:  
 
- Collagen Receptors. Collagen is essential for platelet adherence and platelet plug 
formation. Integrin α2β1 and the CD148-GPVI-FcRγ-complex are considered the major 
receptors for collagen binding and platelet activation.34  
 
- Integrins. These receptors are crucial for the metabolism and adhesion/aggregation of 
platelets. The most important platelet integrins are: α5β1, the principal platelet receptor 
for fibronectin; α6β1, the laminin receptor; αIIbβ3, the fibrinogen-induced platelet 
aggregation receptor that is considered to be the principal receptor for platelet adhesion 
in vivo; and αvβ3, the vitronectin receptor.35, 36 
 
- Receptors involved in the amplification phase. TXA2 is synthesised by activated 
platelets and ADP/ATP are released by damaged red blood cells and platelet dense 
granules. These all amplify the development of the platelet aggregate. The major 
receptors involved are the ADP-controlled receptors P2Y1 and P2Y12, the ATP-controlled 
ion channel P2X1, the TXA2/prostaglandin H2 receptor, the thrombin protease-activated 
receptors (PAR1-4), the prostaglandin E2 receptors EP1, EP3 and EP4 and the prostacyclin 
(PGI2) receptor.37, 38  
 
- Receptors involved in the stabilisation phase. See below. 
 
- Receptors involved in the negative regulation of platelet activation. The 
essential role of NO and PGI2 in platelets in preventing uncontrolled thrombosis is well-
established.33 The major players involved in attenuating platelet thrombus formation are 
PECAM-1/CD36, the immunoglobulin superfamily member G6b-B and the pituitary 
adenylate cyclase-activating polypeptide (PACAP).39-41 
 
 
Given the subject of this thesis and the role of PEAR1 in sustained platelet aggregation (discussed 







PLATELET STABILISATION RECEPTORS 
 
The stabilisation of platelet aggregates is a dynamic process that requires contact-dependent 
signalling via various receptors and outside-in signalling through integrins, particularly the αIIbβ3 
receptor. Once ligand binding has occurred, αIIbβ3 signalling triggers essential events for 
thrombus stabilisation, namely cytoskeletal reorganization, enlargement of platelet aggregates, 
clot retraction, platelet degranulation and the development of a procoagulant surface.42  
 
The major receptors involved in platelet stabilisation are: 
 
1.  The ephrin-binding Eph-kinase receptors 
 
Blocking the interactions between the Eph receptors and ephrin attenuates clot retraction via the 
reduced phosphorylation of β3. This inhibits platelet aggregation at lower agonist concentrations 
and results in a reduced size of collagen-induced thrombi under arterial flow conditions, causing 
premature thrombus disaggregation. 
 
2.  Gas-6 
 
Gas-6 organises αIIbβ3-triggered outside-in signalling via PI3K/Akt, and stimulates the 
phosphorylation of β3 and the subsequent retraction of the clot.43 These effects result in an 
enhancement and perpetuation of the thrombus-stabilising role of ADP.44 
 
3.  The tetraspanin superfamily 
 
The tetraspanin superfamily member CD151 is known to regulate fibrinogen-binding proteins 
such as the αIIbβ3 integrin receptor. Platelets lacking CD151 are reported to form smaller and 
unstable thrombi in vivo.45 The absence of platelet TSSC6 (Tumour-suppressing subchromosomal 
transferable fragment cDNA 6), another member of the tetraspaning superfamily, is also reported 
to affect the secondary stability of arterial thrombi upon vascular injury in vivo, by regulating 
integrin αIIbβ3 “outside-in” signalling events.46 
 
4.  TLT-1 
 
TREM-like transcript-1 (TLT-1) facilitates platelet aggregation through its interaction with a 
ligand or ligands exposed on activated platelets. It is assumed that TLT-1 interacts with αIIbβ3 to 
facilitate the interaction between platelets and fibrinogen and thus platelet aggregation.47, 48 
 
5.  P-Selectin/PSGL-1 Couple 
 
PSGL-1 (P-selectin glycoprotein ligand-1) is the primary ligand for the P-selectin receptor and is 
constitutively found on all leukocytes. The capacity of leukocytes and activated platelets to roll 
along the venous endothelium is orchestrated via transient interactions between P-selectin and 
PSGL-1.  
The formation of a fibrin network upon activation of the coagulation cascade is a critical event 
that contributes to thrombus stability. Recent laser injury-induced thrombosis studies in tissue 
factor (TF)-deficient mice have revealed that this fibrin formation depends on monocyte-derived 
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TF carried by microvesicles with only a minimal contribution of vessel wall TF. The TF-containing 
microvesicles can be captured by the thrombus via the interaction between (activated) platelet 
surface expressed P-selectin and the PSGL-1 present on the microvesicles, thus delivering TF to 
the growing thrombus. Mice lacking either PSGL-1 or P-selectin display thrombi with little TF and 
a reduced thrombin generation, resulting in smaller sized thrombi.49, 50 
 
6.  PEAR1 
 
Although the presence and function of various surface receptors on platelets and ECs has been 
clarified, it is thought that not all the platelet receptors and their downstream signalling cascades 
have been discovered. In 2005, Nanda et al. identified a novel platelet stabilisation receptor that 
is mainly expressed on platelets and ECs and called it PEAR1 (Platelet Endothelial Aggregation 














Figure 4 – Overview of the different stages of thrombus formation ranging from inactivated, circulating 
platelets to the aggregation of activated platelets and the formation of stable thrombi.  
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F) PLATELET ENDOTHELIAL AGGREGATION RECEPTOR 1 
 
In 2005 Nanda et al.29 designed a study to identify novel platelet proteins involved in platelet 
proximity-induced activation. They sought not only to identify novel receptors on platelets but to 
specifically identify those that become phosphorylated upon platelet-platelet interactions, 
irrespective of the activation state of the platelet. This was performed firstly via a proteomics 
approach (they identified aggregation-induced aggregation receptors that became tyrosine-
phosphorylated upon platelet aggregation), and secondly via a bioinformatics approach (profiling 
the RNA of platelets using oligonucleotide-based microarrays in order to identify novel signalling 
membrane proteins during platelet aggregation). They found that both techniques converged on 
two different groups of proteins that had not yet been described in platelets, the SLAM family of 
proteins (which had been thoroughly studied in immune cells) and a novel protein they termed 
PEAR1 (Platelet Endothelial Aggregation Receptor 1).29, 30  
 
PEAR1 (also known as JEDI-1 or MEGF-12) is a 1034-amino acid type 1 membrane protein 
consisting of fifteen epidermal growth factor (EGF)-like repeats in its extracellular domain.29 The 
intracellular domain contains five proline-rich domains, which can interact with Src homology 3 
(Sh3)-domain-containing proteins, as well as four potential tyrosine phosphorylation sites (Tyr-
804, Tyr-925, Tyr-943 and Tyr-979).29 The highest levels of PEAR1 expression are found in 
platelets, megakaryocytes and ECs.29 Nanda et al. demonstrated that platelet PEAR1 is a surface-
expressed protein that, upon aggregation, becomes tyrosine phosphorylated. This 
phosphorylation was found to be an oligomerisation-dependent event and could be inhibited by 
the αIIbβ3-antagonist eptifibatide. This indicated that PEAR1 tyrosine phosphorylation was 
dependent on platelet-platelet surface contacts between activated platelets. Interestingly, they 
also showed that platelet-platelet contacts (induced by the centrifugation of washed platelets) 
also resulted in PEAR1 tyrosine phosphorylation. This is in contrast to other secondary signalling 
molecules that require platelet activation to signal. Finally, Nanda et al. demonstrated that this 
contact-induced PEAR1 phosphorylation was not inhibited by eptifibatide, implying that platelet-
platelet contact can induce PEAR1 phosphorylation independent of previous platelet activation.29  
 
PEAR1 mRNA expression has also been previously observed in early hematopoietic progenitor 
cells and in cells known to support haematopoiesis, more specifically in bone marrow stromal and 
osteogenic cells.51 This implies that PEAR1 may have a controlling function during 
haematopoiesis. Krivtsov et al.51 reported a role for PEAR1 in the fine-tuning of haematopoiesis 
by exerting negative effects on the stem/progenitor cell compartment. They provided convincing 
evidence in favour of a potentiating role for PEAR1 in the negative regulation of Notch-signalling 
and thus in the regulation of haematopoiesis.51 However, a role for PEAR1 in processes such as 
megakaryopoiesis or white blood cell differentiation remains to be elucidated. 
 
 
G) THE ROLE OF GENETIC VARIATION IN PLATELET PEAR1 
 
Aspirin is widely used for the inhibition of platelets and the prevention of arterial thrombosis 
through inhibition of cyclo-oxygenase 1 (COX1), which produces TXA2 in platelets. Nevertheless, 
acute coronary artery disease (CAD) events still incidentally occur in the presence of aspirin if 
platelet aggregation is not sufficiently suppressed.52 It is known that considerable heterogeneity 
exists both in native platelet aggregation and in the magnitude of platelet suppression by 
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aspirin.53-56 Although well-described, the reason for this phenotypic heterogeneity is not 
completely known. Genetic factors are thought to play an important role in this 
heterogeneity. Genetic variants in COX1 itself are uncommon, accounting for only a small portion 
of platelet responsiveness to aspirin.57 Therefore many studies have investigated whether genetic 
variations in signalling pathways proximal to the COX1/thromboxane A2-pathway could be 
responsible for the residual platelet function during aspirin treatment.58 Like the well-known 
heterogeneity in platelet response to aspirin, the overall platelet responsiveness to various 
agonists seems to vary between individuals, even though it has been shown that platelet 
responsiveness is inherited39 and remains constant within an individual.59, 60  
 
As previously discussed, PEAR1 is known to be activated by platelet-platelet contact.29 Several 
studies have investigated whether inherited variations in PEAR1 are responsible for modified 
agonist-induced aggregation in native platelets and alter the expression and/or function of this 
platelet receptor. Table 1 provides a literature overview of the identified single nucleotide 
polymorphisms (SNPs) in PEAR1 and their reported effects on platelet function. These data 
(especially SNP rs12041331) illustrate that genetic variants in PEAR1 are associated with altered 
platelet function.  
 
 





$ * * *
rs41299597$ Expression*!* !*Platelet*activation* Jones*et*al.39*





$ * * *
rs412773215$ ?* !*Platelet*activation* Jones*et*al.39*





$ *  *
rs11264579 ?* !*Platelet*activation* Jones*et*al.39*



























 * * *
A = Adenine; C = Cytosine; G = Guanine; T = Thymine  
* AMI = Acute Myocardial Infarction 
** A paradoxical effect of rs12041331 on cardiovascular phenotypes has been observed; the A-allele is associated with a better 
aspirin response but is also associated with a higher cardiovascular event rate  
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H) PEAR1 SIGNALLING IN PLATELETS 
 
The genetic studies conducted on PEAR1 have all pointed towards an important regulatory role 
for this protein in human platelet activation. In 2012, Kauskot et al. were the first to provide 
evidence of a role for PEAR1 during platelet activation and platelet aggregation.1 Their study 
showed that “PEAR1, already present in the membrane of resting platelets, was also released from 
α-granules during platelet activation, further raising its membrane expression. Platelet contacts 
between the PEAR1 EMI domain and an unidentified surface ligand (itself equally exposed during 
platelet activation) triggers rapid PEAR1 phosphorylation, thus initiating a signalling cascade that 
culminates in PI3K/Akt activation, reinforcing αIIbβ3 activation and, consequently, platelet 
aggregation.” They concluded that PEAR1 phosphorylation results in the persistent activation of 
Akt and amplified αIIbβ3 activation, hence it stabilises platelet aggregates. 
 
Activation of PEAR1 results in the recruitment of c-Src, p85/PI3K, Fyn and Lyn (but not Syk), 
ultimately leading to progressive and long-lasting Src-dependent PI3K/Akt/αIIbβ3 signalling, 
confirming that PEAR1 is a functional platelet contact receptor (Figure 1). c-Src-dependent 
tyrosine phosphorylation of PEAR1 appears to be sufficient to initiate downstream signalling 
events. Activation of PEAR1 requires clustering of at least two membrane-PEAR1-receptors, as 
done by divalent PEAR1- antibodies or (unknown) PEAR1 ligand(s).  
 
Although Kauskot et al. have unravelled the downstream signalling pathways of PEAR1 
engagement in platelets, the ligand involved in PEAR1 activation during platelet aggregation is yet 
to be identified and could hold the key to fully understanding the mechanism and function of this 
receptor.  





I) ENDOTHELIAL PEAR1 
 
Nanda et al.29 found that PEAR1 was highly expressed in human umbilical vein ECs (HUVECs). 
Experimental studies identified PEAR1 as a candidate gene that may be linked to kidney injury in 
the salt-sensitive Dahl rat,69 rats developing a kidney injury that became more severe as blood 
pressure rose in response to salt loading. Renal biopsies in this study revealed a significantly 
lower nephron number in the salt-sensitive Dahl rat compared to controls,69 suggesting a 
possible link between kidney damage and the development of hypertension. In a separate study 
in humans, Olivi and Vandenbriele et al. randomly recruited 1973 people and genotyped their 
PEAR1 gene. They looked for associations between changes in blood pressure or incidence of 
hypertension with genetic variation in PEAR1. They found no significant association between 
systolic and diastolic blood pressure changes and nine SNPs in PEAR1 (rs2768762, rs2644620, 
rs1256688, rs2768744, rs6671392, rs822441, rs11264581, rs12137505 and rs749256).70 
However, the most potent SNP in PEAR1 (rs12041331) was not analysed in this association study. 
 
Although PEAR1 has be linked to both kidney injury in the salt-sensitive Dahl rat70 and 
cardiovascular outcome,66 the function of endothelial PEAR1 and its underlying signalling 






J) PEAR1/JEDI1: AN ENGULFMENT RECEPTOR OF SENSORY NEURON CORPSES 
 
In the developing mammalian central nervous system, extensive neuronal cell death (around 50% 
of the neurons generated71) occurs during the ontogenesis of the sensory ganglia.72 Programmed 
cell death and phagocytosis are essential for the development and maintenance of a functional 
nervous system.72 Although the regulation of this naturally-occurring cell death is well-known, 
very little is known about the process of removal of the dead neurons from the nervous system.73 
Glial cells and microglia (which result from the differentiation of invaded macrophages) are 
known to be implicated in the clearance of these apoptotic neurons.74, 75 The engulfment process 
used by these specific phagocytic cells, including macrophages and dendritic cells (microglia), is 
known to be a complex interaction between an array of receptors on these phagocytes that are 
able to register 'find me' and 'eat me' signals exposed by neighbouring dying cells and 'don't eat 
me' cues from healthy cells.76, 77 However, the function of glial cells in engulfment and the 
underlying molecular mechanisms involved in this process are still to be explored.  
 
Figure 5 – Scheme for the PEAR1 signalling pathway. In resting platelets, low amounts of PEAR1 are 
found on the platelet surface. During platelet activation with various platelet agonists, the expression of both 
PEAR1 and its ligand increase at the surface.1 Interactions between PEAR1 and its ligand on adjacent platelets 
induce the formation of a complex comprising at least two PEAR1 receptors. Dimeric (or oligomeric) PEAR1 
complexes are rapidly tyrosine phosphorylated in a SFK-dependent manner (they are inhibited by the SFK 
inhibitor PP1), and transiently recruit additional c-Src and Fyn. Phosphorylated PEAR1 avidly binds to p85-PI3K, 
leading to strong and sustained activation of Akt at Ser473 via PI3K (which is inhibited by the PI3K-inhibitor 
LY294002 and by PP1). PI3K activation amplifies αIIbβ3 activation, thus sustaining platelet aggregation. 
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In 2009, Wu et al. 78 reported that satellite glial cell (SGC) precursors were the primary cell type 
responsible for dead neuron clearance. They identified two receptors responsible for this 
engulfment process on SGCs: MEGF-10 and PEAR1. They found that the extracellular domain of 
PEAR1 was able to recognise a signal on the surface of a dying neuron and showed that 
overexpression of PEAR1 and MEGF-10 significantly increased the binding of SGCs to neuronal 
corpses, thus enhancing the glial cell-mediated engulfment of dead neurons. They also showed 
that knocking down PEAR1 in glial cells (via a short hairpin RNA construct; shRNA) resulted in a 
decreased capacity of SGCs to engulf apoptotic bodies, further indicating that endogenous PEAR1 
is necessary for neuronal corpse clearance during the development of the embryonic dorsal root 
ganglia.  
 
How PEAR1 transduces its signals in SGCs remained unknown until 2012 when Scheib et al. 73 
reported that activation of PEAR1 by an unknown ligand in SGCs resulted in the recruitment of 
Syk. This association was enhanced by Src family kinase-mediated phosphorylation of PEAR1. 
Interaction with Syk was necessary to mediate phagocytosis. Syk inhibition in glial cells reduced 
their engulfment capacity and Syk was therefore identified as a crucial mediator for PEAR1 
signalling in glial cells.73 This is in contrast to platelets, where Kauskot et al. reported that 
platelet activation leads to an interaction between PEAR1 and Fyn or Src, but not Syk.1 In 2014, 
Sullivan et al. 79 reported that, in SGCs, PEAR1 mediates engulfment through the recruitment of 
GULP (the mammalian homologue of CED-6, an important adaptor protein for the regulation of 
engulfment in Drosophila), which then associates with clathrin to facilitate phagocytosis. They 
showed that GULP and clathrin associate with PEAR1 and that this is essential for PEAR1-mediated 





This introduction has provided a background on the general function of platelets 
and endothelial cells. In addition to describing the limited literature available on 
PEAR1, it highlights some important questions that exist concerning the role of 
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AIMS OF THE STUDY 
 
In this thesis, we aim to study the contribution of PEAR1-signalling to the 
(patho)physiologic role of megakaryocytes/platelets and endothelial cells (ECs): 
 
This was studied via:  
! A short hairpin based knockdown strategy of PEAR1 in megakaryocytes and ECs,  
! Activation of platelet PEAR1 with a physiological and various non-physiological ligands, 
! Unravelling the role of PEAR1 in platelets and ECs in a Pear1-/- mouse model  
 
Our results can be grouped under four different chapters (summarized in Figure 1):  
 
 
         In Chapter I, we studied the role of PEAR1 in differentiating CD34+ human hematopoietic 
stem cells via lentiviral knockdown of PEAR1 and we confirmed our findings via a morpholino 




         In Chapter II, we sought to identify the extracellular physiological ligand for PEAR1 on 
human platelets by creating a protein microarray representing the secretome and receptor 
repertoire of the human platelet. 
         In Chapter III, we studied whether PEAR1-signalling mediates Dextran Sulphate induced 
human and murine platelet aggregation. This hypothesis was validated via aggregation 





         In Chapter IV, we studied the role for PEAR1 in EC biology. We sought whether PEAR1 plays 
a role in EC proliferation, migration and tube formation in vitro and whether it plays a role in 
(neo)angiogenesis in vivo using a Pear1-/- mouse model. 







Figure 1 – Aims of the study – In this thesis we will study the role of PEAR1 in megakaryopoiesis (1), we will 
identify both a physiological (2) and non-physiological (3) ligand for platelet PEAR1 and we will study the role 
for PEAR1 in EC proliferation, migration and tubulogenesis and study its role in (neo)angiogenesis (4).  
Chapter I – Illustration from “Prima musculorum Tabula – de humanum corporis fabrica libri septem” –  
A. Vesalius, 1543  
!




Platelet& Endothelial& Aggregation& Receptor31& (PEAR1)& participates& in& platelet& aggregation&
via&sustaining&αIIbβ3&activation.&To&investigate&the&role&of&PEAR1&in&platelet&formation,&we&
monitored& and& manipulated& PEAR1& expression& in# vitro& in& differentiating& human& CD34+&
hematopoietic&stem&cells&and& in#vivo# in#zebrafish&embryos.&PEAR1&expression&rose&during&
CD34+&cell&differentiation&up& to&megakaryocyte&maturation.&Two&different& lentiviral& short&
hairpin& knockdowns& of& PEAR1& increased& CFU3MK& cell& numbers& 23fold& vs.& control& in&
clonogenic&assays,&without&substantially&modifying&MK&maturation.&Knockdown&of&&PEAR1&
resulted& in&a&23fold& reduction&of& the&PTEN&expression&and&modulated&gene&expression&of&
several& PI3K3Akt& and& Notch& pathway& genes.& In& zebrafish,& Pear1& expression& increased&
progressively&during&the&first&3&days&of&embryo&development.&Both&ATG&and&splice3blocking&
PEAR1&morpholino& enhanced& thrombopoiesis,& without& affecting& erythropoiesis.&Western&
blots& of& 33day3old& Pear1& knockdown& zebrafish& revealed& elevated& Akt& phosphorylation,&
coupled& to& transcriptional& downregulation& of& the& PTEN& isoform&Ptena.& Neutralization& by&
morpholinos&of&Ptena,&but&not&of&Ptenb,&phenocopied&the&Pear1&zebrafish&knockdown&and&
triggered&enhanced&Akt&phosphorylation&and&thrombocyte&formation.& In&summary,& this& is&
the& first& demonstration& that& PEAR1& influences& the& PI3K/PTEN& pathway,& a& critical&






PEAR1& is& a& type31& membrane& protein& with& an& EMI& domain,& epidermal& growth& factor3like&
repeats& (EGF3like& repeats)& and&multiple& cytoplasmic& tyrosines& and&prolines.1,&2&We& recently&
reported& that& interactions& between& PEAR1,& Src& family& kinases& (C3src& and& Fyn)& and& the&
p85/Phosphoinosite& 33kinase& (PI3K)& subunit& constitute& a& signalling& complex,& causing&
sustained& αIIbβ3& activation& via& Akt& phosphorylation.1& In& addition& to& its& role& in& platelet&
function,& a& potential& role& for& PEAR1& in& hematopoietic& cell& regulation& has& been& proposed.3&
The& stable& overexpression& of& PEAR1& in&mouse& bone&marrow& cells,& using& retroviral& vectors&
decreased&the&number&of&myeloid&progenitors&during& in#vitro&clonogenic&assays,&suggesting&




of& MKs& matured& from& bone& marrow& precursor& cells.& Megakaryopoiesis& and& MK&
differentiation& are& complex& processes& controlled& by& a& series& of& transcription& factors& and&
regulated& by& a& variety& of& cytokines& and& chemokines.4,&5& Differentiation& requires& a& dynamic&





dual& specificity& protein& phosphatase& and& an& inositol& phospholipid& phosphatase& that&
dephosphorylates& phosphatidylinositol& 3,4,53trisphosphate& (PIP3),& thus& producing&
phosphatidylinositol& 4,53bisphosphate& (PIP2)& and& thereby& negatively& regulating& oncogenic&
and& non3oncogenic& PI3K/Akt& signaling.10& Indeed,& the& constitutive& activation& of& PI3K/Akt&
signalling&promotes& the&uncontrolled&growth&of&hematopoietic&cells& in&commonly&detected&
myeloproliferative&disorders&(MPDs)&and&lymphomas.9&PTEN# inactivation&appears&to&be&one&
of& the& major& causes& of& the& constitutive& activation& of& PI3K/Akt.& Reduced& PTEN& expression&
and/or& activity& in& myeloid& and& lymphocytic& leukaemia& have& been& linked& to& mutations,&
epigenetic& repression& or& post3translational& inhibition.10& Pten& deletion& in& mouse&
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hematopoietic& stem& cells& (HSCs)& predisposes& to& MPD.& Furthermore,& increased&





Using&PEAR1&knockdown&strategies& in#vitro& in& cell& cultures&and& in#vivo& in& the&zebrafish,&we&
demonstrate&a&role&for&PEAR1&in&MK&precursor&proliferation&and&thrombocyte&formation&via&
regulation&of&the&PI3K/PTEN&pathway.&!!
MATERIALS AND METHODS 
!
Human CD34+ differentiation in vitro  
Human&CD34+&HSCs&were&separated&by&magnetic&cell&sorting&from&buffy&coats,&and&isolated&from&healthy&donor&






Inhibition of PEAR1 expression by siRNA 
Two& silencing& RNA& (siRNA)& sequences& for& human& PEAR1,& GCACGCTGCTCATGTGAAA& (referred& to& below& as&
shPEAR131461)& and& GCAGCTACATGGAGATGAA& (shPEAR132938),& were& developed& using& siSearch& software&





Generation of lentiviral transfer plasmids  
Lentiviral& vectors& encoding&miR303based&knockdown&hairpins&derived& from& the&aforementioned& siRNAs&were&
generated& for& stable& knockdown& as&previously& described12& (referred& to& as& miR_PEAR1_1461& and&
miR_PEAR1_2938)&together&with&control&hairpins&directed&against&the&monomeric&red&fluorescent&protein&from&
Discosoma# corallimorpharian,& DsRed& (miR_DsRed).& All& constructs& (pGAE3SFFV3BsdR3miR_PEAR1_14613WPRE;&










plasmids& pGAE3SFFV3BsdR3miR_PEAR1_14613WPRE& and&pGAE3SFFV3BsdR3miR_PEAR1_2938& 3WPRE,& to&
generate& LV_miR_PEAR1_1461& and& LV_miR_PEAR1_2938,& respectively.& Likewise& controls& with& miR3based&
hairpins&that&target&the&mRNA&of&DsRed,&were&generated,&resulting& in&LV_miR_DsRed,&respectively.&The& latter&
vector&will&be&referred&to&as&“control”& throughout&the&text.&Stable&PEAR1&knockdown&cells&and&controls&were&
generated& following& lentiviral& transduction.& Typically,& CD34+& cells& (5& x& 105)&were& transduced& twice& in& 963well&
plates&(on&the&day&of&isolation&and&the&day&after).&&
&
Cell proliferation and CFU-assays 
Colony3forming& unit& (CFU)–MK& (megakaryocytic& colonies)& and& CFU3E& (erythrocyte& colonies)& potential& was&
assessed& as& previously& described.& Human& CD34+& cells& (5& ×& 103)& were& cultured& in& Megacult3C& 04973,&
supplemented&with&recombinant&cytokines&according&to&the&manufacturer's& instructions.&The&number&of&CFU3




PCR and real-time quantitative RT-PCR (qRT-PCR) 
Total& mRNA& was& extracted& with& TRIzol& (Invitrogen,& Carlsbad,& CA,& USA)& for& zebrafish& embryos& or& using& the&
Qiagen& kit& (RNeasy&mini& kit)& for& cultured& cells.& cDNAs& were& synthesized& using&M3MLV& reverse& transcriptase&
(Invitrogen).!
Human& gene& expression&was&measured&using& FAM3labeled& TaqMan& assay& products& (Applied&Biosystems,& Life&
Technologies,& Gent,& Belgium)& or& via& regular& SYBR& Green& RT3PCR& (IDT,& Leuven,& Belgium).& Zebrafish& gene&
expression&was&measured&using&a&SYBR&Green&assay&developed&for&zebrafish.&All&genes&were&normalized&to&the&
housekeeping&genes&human&glyceraldehyde333phosphate&dehydrogenase&(GAPDH)&or&β3actin&(ACTB),&zebrafish&
β3actin& (Actb)&or&elfa.&Quantitative&PCR& (qRT3PCR)& reactions&were&analysed&using& the&ABI&7000& real3time&PCR&
machine&(Life&Technologies).&Expression&was&quantified&via&the&ΔΔCt&method14&and&expressed&in&arbitrary&units&
(defined&in&figure&legends)&or&in&percentage&compared&to&control.&Expression&of&genes&included&in&the&PI3K/Akt&
(reference& PAHS3058A)& and& Notch& (reference& PAHS3059A)& RT2& Profiler& signaling& were& analyzed& by& qRT3PCR&
(SABioscience,& Qiagen).& Cell& populations& transduced& by& control& lentivirus& were& used& as& a& reference& for&
LV_miR_PEAR13transduced&cells.&&
&
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Western blot analysis 
Western& blot& analyses& were& performed& as& previously& reported.1& The& following& antibodies& were& used:& anti3
PEAR13EC&(1/1000)&(R&D),&anti3Histone&deacetylase31&(HDAC31)&(1/1000;&H351,&Santa&Cruz&Biotechnology),&anti3
Akt3P& (1/500),& anti3Akt& (1/1000)& (Cell& signalling),& anti3GFP& (Green& fluorescent& protein;& 1/1000)& (Rockland,&
Gilbertsville,&PA,&USA)&and&anti3PTEN&(1/500,&Heidelberg,&Germany).&Mature&red&blood&cell&lysates&were&isolated&
as& described.15& Peripheral& blood& mononuclear& cells& (PBMC)& were& isolated& via& Ficoll3paque& (BD)& density&
centrifugation,&after&which&residual&platelets&and&platelet3leukocyte&conjugates&were&eliminated&via&magnetic&
cell& sorting,& using& a& home3made& anti3β3& monoclonal& antibody,& to& capture& platelet&αIIbβ3.& The& use& of& flow&
cytometry& and& immunohistochemical& staining& are& detailed& in& the& online& data& supplement&
(www.bloodjournal.org).&
&
Zebrafish whole-mount in situ hybridization (WISH)  











Protein& expression& levels& of& CD41& (αIIb& integrin)& and& CD42b& (GPIbα)&were& measured& by& flow& cytometry& using&
specific& antibodies& from& BD& Biosciences& (Erembodegem,& Belgium).& Polyploidy& was& analysed& after& anti3CD41&
labelling&and&DNA&staining&with&0.01&mg/mL&propidium&iodide&(Sigma&Aldrich,&Bornem,&Belgium)&and&the&DNA&
content&was&measured&in&CD413positive&cells.&Incorporation&of&Pacific&Blue3A&labelled&53Ethynyl32’3deoxyuridine&
(EDU,& Invitrogen,&Molecular&Probes,&Ghent,&Belgium)& in&maturing&CD34+& cells&was&determined&after&CD61& (β3&












Validation of the PEAR1 ATG morpholino in vitro   
A&linker&containing&40&base&pairs&before&and&behind&the&site&of&the&PEAR1&MO&sequence&was&cloned&in&frame&









Microinjection of morpholino antisense oligonucleotides (MOs) 
The& transgenic& zebrafish& lines& CD41:eGFP,& a& kind& gift& from& dr.& L.& Zon& (Hematology& Division,& Brigham& and&
Women's&Hospital's,& Boston,&MA,&USA)& and&GATA1:dsred,& a& kind& gift& from&dr.& A.& Luttun& at& our& centre,&were&
used.&&Zebrafish&embryos&were&injected&with&a&start&codon&(ATG)&or&splice3blocking&MO&vs.&a&control&MO&into&13&
to& 23cell3stage& embryos.& All& MOs& were& designed& by& Gene3Tools& LLC& (Philomath,& OR,& USA).& Embryos& were&













PEAR1 expression during human megakaryocyte differentiation 
Immunohistochemical& staining&of&normal&human&bone&marrow&showed&PEAR1&positivity& in&
MKs& and& revealed& that& granulocyte& precursors,& but& not&mature& granulocytes& were& PEAR1&
positive&(Fig.&1A).&Also&PEAR1&positive&osteoblasts&and&endothelial&cells&were&observed&(not&
shown);& platelets& were& strongly& positive,& whereas& erythrocyte& precursors& were& PEAR1&
negative&(Fig.&1A).&Western&blots&of&isolated&blood&cells&confirmed&the&presence&of&PEAR1&in&
platelets& and& its& absence& in& red& blood& cells& and& PBMCs& (Fig.& 1B).& During& in& vitro&
differentiation& of& CD34+& cells,& more& detailed& RT3PCR& and& qRT3PCR&measurements& showed&
that& both& PEAR1& and& ITGA2B& (CD41)& were& very& low& at& day& 0,& but& that& their& GAPDH&
normalized&expression&increased&in&parallel&from&day&6&to&12,&in&contrast&to&expression&of&a&
more& stable& reference,& such& as& hypoxanthine& guanine& phosphoribosyl& transferase& (HPRT)&
(Fig.&1C).&Similar&results&were&seen&for&both&genes,&when&tested&in&RT3PCR&vs.&ACTB&(β3actin)&
(Fig.& 1C).& Flow& cytometry& and& western& blot& analysis& evidenced& membrane& PEAR1& protein&
expression&in&differentiated&CD34+&cells&after&6&and&10&days&of&maturation&initiation&(Fig.&1D).&








human& bone&marrow& sections,& at& 630& and& 10003fold&magnification;&megakaryocytes& (*),&myeloid& precursors&
(white&arrows)&and&erythroid&precursors&(black&arrows)&are&indicated.&B)&Western&blot&for&PEAR1&in&red&blood&
cell& lysates& (RBC),& platelets& and& peripheral& blood& mononuclear& cells& (PBMC)& vs.& GAPDH& control.& C)& PEAR1,&
ITGA2B&(CD41)&and&HPRT&expression&on&day&0,&day&6&and&day&12&in&CD34+&cells&by&qRT3PCR&vs.&GAPDH&control&
and&by&RT3PCR&vs.#ACTB&(β3actin)&control.&D)&Flow&cytometric&measurement&of&PEAR1&on&the&membrane&in&103





PEAR1 in megakaryocyte differentiation: proliferation vs. maturation 
Transduction& of& freshly& isolated& human& CD34+& cells& with& LV_miR_PEAR1_1461& decreased&
PEAR1& mRNA& levels& by& 90%,& compared& to& LV_miR_DsRed& transduction& (Fig.& 2A).&
Correspondingly,&protein&synthesis&at&day&10&had&dropped&strongly&upon&transduction&with&
LV_miR_PEAR1_1461,& when& investigated& via& western& blots& (Fig.& 2A).& Calculation& of& the&
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degree& of& protein& expression& suppression& for& transduction& with& both& viral& vs.& the& control&
vectors&yielded&up&to&84394%&expression&inhibition&(Fig.&2A,&single&experiment&comparison).&
During&CD34+&cell&differentiation,&proliferating&cell&numbers&reach&a&plateau&between&day&10&
and& 14.19& Trypan& blue& counting& of& the& cells,& 10& days& after& transduction& with&
LV_miR_PEAR1_1461& or& LV_miR_PEAR1_2938& detected& >95%& cell& viability& and& uncovered&
2.432.83fold&higher&cell&numbers&of&differentiating&MKs&following&PEAR1&mRNA&knockdown,&
compared& to& control& (p<0.01& vs.& control;& p<0.05& between& both& vectors)& (Fig.& 2B).& More&
stringent&clonogenic&assay&cultures&with& separate&counting&of&CFU–MK&and&CFU3E&colonies&
on&day&6&and&10,&confirmed&that&LV_miR_PEAR1_1461&transduction&doubled&CFU3MK&colony&
numbers,& compared& to& control;&without& affecting&CFU–E& colony& formation& (Fig.& 2C).& These&




were& analysed& at& day& 10& for& expression& of& the& typical&MK& and& platelet&markers& CD41& and&
CD42b,&as&well&as&for&their&ploidy.&Fig.&2D&shows&a&fractional&shift&towards&positivity&at&day&10&
for&both&markers&and&shows&that,&in&addition&to&megakaryoblasts,&a&more&mature&cell&subset&
was& present,& strongly& positive& for& CD41& and& CD42b.& The& proportion& of& all& CD41+CD42+&
positive& cells& at& day& 10&was& not&modified& by& the& LV_miR_PEAR1& vector& treatment& (79& vs.&
77%,& Fig.& 2D).& Also& the& percentages& of& strongly& positive& CD41+CD42+& subpopulations&were&
not& different& (15.7& vs.& 14%,& Fig.& 2D,& upper& right& population& in& Q2).& & Correspondingly,& no&
major& effect& was& observed& on& the& histogram& during& propidium& iodide& staining& of& the&
matured&cells,&suggesting&the&mature&subset&to& largely&be&the&4N&MK&precursor&population&
(Fig.&2E).&A&non3significant&trend&for&a&higher&ploidy&was&observed&for&the&8N&fraction&in&the&
absence& of& PEAR1.& Therefore,& to& specifically& investigate& the& proliferation& rate& in& the& late&











Figure! 2:! PEAR1! knockdown! via! lentiviral! vector! transduction.! A)& PEAR1& expression& at& day& 10,& after&
transduction&of&human&CD34+&with&control&(LV_miR_DsRed)&or&LV_miR_PEAR1_1461&vector,&analysed&via&qRT3
PCR& (left& panel)& and& western& blotting& with& PEAR13EC& Ab,& using& HDAC31& as& loading& control& (middle& panel).&
Relative&suppression&of&the&GAPDH3normalized&PEAR1&protein&expression&at&day&11,&following&transduction&of&






after& transduction& of& human&CD34+&with& control& or& LV_miR_PEAR1_1461& (n=3);& Ploidy& histogram& for& control&
and& LV_miR_PEAR1_1461& treated& CD34+& cells& on& day& 12& (n=3).& 1& A.U.& represents& 1& copy& for& 105& copies& of&
housekeeping&gene.&
&
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Gene (de)regulation by PEAR1 knockdown in megakaryocyte progenitors 
Several& transcription& factors&have&been& implicated& in&megakaryopoiesis.20,&21&Therefore,&we&
measured&the&expression&of&GATA31,&PU31,&RUNX1,&FLI31&and&NF3E2&during&MK&maturation&in&





RUNX1& expression& was& tampered& following& PEAR1& knockdown,& preserving& 33fold& higher&
RUNX1&mRNA&levels&(Fig.&3A),&i.e.&RUNX1&drops&more&in&control&than&in&LV_miR_PEAR1_1461&
treated&cells.&
Next,& to& characterize& PEAR1& target& genes& in& MKs& grown& from& cytapheresis& isolates,& we&
compared& control& and& LV_miR_PEAR1_1461& transduced& CD34+& cell& cultures& on& day& 12& by&
profiler&qRT3PCR&analysis.&The&Notch&and&the&PI3K/Akt&pathway&have&been&coupled&to&PEAR1&




were& significantly& altered& following&PEAR1&knockdown& in&differentiated&CD34+& cells.&Genes&
over3&and&underexpressed&in&the&PEAR1&depleted&cells&vs.&control&cells&are&listed&according&to&
the& fold& change& (Fig.& 3B& and& Fig.& 4).& Interestingly,& we& found& that& a& target& of& the& Notch&
pathway,& HES1,& was& upregulated& without& expression&modification& of& the& Notch& receptors&
(Fig.&3B&and&Fig.&4).&PTEN,&a&phosphatase&regulating&the&PI3K&pathway,&and&CCND1&(cyclin&D1)&
were& both& downregulated& (Fig.& 3B).& Recently,& 2& different& authors& described& how& HES1,& a&
target& of& the& Notch& pathway,& negatively& regulates& the& transcription& of& PTEN& during&
megakaryopoiesis& and& in& mouse& thymocytes.22,& 23& Therefore,& we& choose& to& confirm& such&
regulation,&using&a&separate&set&of&primers.&Fig.&3C&and&3D&show&for&this&set&of&primers&that&
PEAR1&knockdown&upregulated&the&Notch&target&HES1,& in&parallel&with&the&downregulation&
of& PTEN.& Western& blots& for& PTEN& confirmed& lower& protein& expression& for& the& PEAR1&
knockdown,&both&in&LV_miR_PEAR1_1461&and&LV_miR_PEAR1_2938&treated&CD34+&cells&(Fig.&





with& lower&PTEN&activity& in&LV_miR_PEAR1&treated&CD34+&cells,& responsible& for&diminished&






mRNA& expression& of& the& indicated& transcription& factors& on& day& 11& in& CD34+& cells& transduced&with& control& or&
LV_miR_PEAR1_1461&vectors&vs.&GAPDH.&B)&List&of&genes&involved&in&the&Notch&and&PI3K/Akt&pathways&under3&
or&overexpressed&in&RT2&profiler&analysis&in&the!shPEAR1&knockdown,&expressed&in&fold&change.&C)&qRT3PCR&for&
PTEN& mRNA& in& CD34+& cells& 10& days& after& transduction& with& control& and& LV_miR_PEAR1_1461,& relative& to&
GAPDH;&western&blot&for&PTEN&at&day&10&after&transduction&with&control&and&LV_miR_PEAR1_2938,&relative&to&
GAPDH& in& two& separate& analyses& (A& and& B).& D)& qRT3PCR& for& HES1& mRNA& in& CD34+& cells& at& day& 10& after&
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shPEAR1 group vs. control group 
Human Notch signalling pathway Human PI3K/AKT signalling pathway 
Gene Symbol 
Fold 
Difference  Gene Symbol 
Fold 
Difference 
         
ADAM10 1,17  ADAR 0,83 
ADAM17 1,93  AKT1 0,91 
AES 1,83  AKT2 0,61 
AXIN1 1,77  AKT3 0,51 
CBL 1,43  APC 0,55 
CCNE1 1,96  BTK ND 
CD44 2,45  CASP9 0,54 
CDC16 1,47  CCND1 -5,14 
CDKN1A 0,7  CD14 2,36 
CFLAR 1,57  CDC42 0,63 
CHUK 1,65  CDKN1B 0,71 
CTNNB1 1,73  CHUK 0,83 
DLL1 2,04  CSNK2A1 0,69 
DTX1 1,17  CTNNB1 0,52 
EP300 1,24  EIF2AK2 0,61 
ERBB2 1,07  EIF4B 0,99 
FIGF 1,06  EIF4E 0,77 
FOS 2,07  EIF4EBP1 1,05 
FOSL1 1,13  EIF4G1 0,71 
FZD1 1,36  ELK1 0,81 
FZD2 1,45  FASLG 0,52 
FZD3 2,07  FKBP1A 0,77 
FZD4 1,37  FOS 2,07 
FZD6 1,79  FOXO1 0,76 
FZD7 1,78  FOXO3 0,56 
GBP2 2,39  MTOR 0,82 
GLI1 1,22  GJA1 0,74 
GSK3B 1,32  GRB10 0,88 
HDAC1 1,49  GRB2 0,86 
HES1 2,26  GSK3B 0,81 
HEY1 1,38  HRAS ND 
HEYL 0,91  HSPB1 ND 
HOXB4 1,54  IGF1 0,68 
HR 1,03  IGF1R 0,67 
IFNG -2,87  ILK -2,15 
IL17B 1,21  IRAK1 0,78 
IL2RA 1,3  IRS1 -3,35 
JAG1 1,39  ITGB1 0,67 
JAG2 1,07  JUN ND 
KRT1 1,19  MAP2K1 0,78 
LFNG 1,44  MAPK1 0,62 
LMO2 2,1  MAPK14 0,74 
LOR 1,11  MAPK3 ND 
LRP5 1,18  MAPK8 0,62 
MAP2K7 1,86  MTCP1 0,83 
MFNG 1,19  MYD88 1,07 
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MMP7 1,49  NFKB1 1,01 
MYCL1 0,83  NFKBIA 0,85 
NCOR2 0,67  PABPC1 0,88 
NEURL 1,17  PAK1 0,62 
NFKB1 1,7  PDGFRA 0,59 
NFKB2 1,32  PDK1 -2,4 
NOTCH1 1,4  PDK2 0,68 
NOTCH2 1,58  PDPK1 0,77 
NOTCH2NL 1,59  PIK3CA 0,95 
NOTCH3 1,47  PIK3CG 0,69 
NOTCH4 1,27  PIK3R1 0,82 
NR4A2 1,64  PIK3R2 1,15 
NUMB 2,2  PRKCA -3,05 
PAX5 1,06  PRKCB 0,71 
KAT2B 1,73  PRKCZ 0,65 
PDPK1 1,71  PTEN -2,405 
POFUT1 1,51  PTK2 0,62 
PPARG 1,47  PTPN11 0,68 
PSEN1 2,18  RAC1 1,45 
PSEN2 1,27  RAF1 0,98 
PSENEN 1,31  RASA1 0,84 
PTCRA 0,57  RBL2 0,97 
RFNG 1,22  RHEB 0,88 
RUNX1 1,14  RHOA ND 
SEL1L 1,15  RPS6KA1 0,82 
SH2D1A 1,71  RPS6KB1 0,97 
SHH 2,02  SHC1 0,57 
STIL 1,83  SOS1 0,84 
SNW1 1,99  SRF ND 
SMO 1,21  TCL1A 1,09 
STAT6 1,86  TIRAP -2,1 
SUFU 1,42  TLR4 0,94 
TEAD1 1,88  TOLLIP ND 
TLE1 2,06  TSC1 1,01 
WISP1 1,33  TSC2 ND 
WNT11 0,88  WASL 2,7 




PEAR1 silencing in zebrafish boosts thrombocyte production 
First,& Pear1& expression& was& studied& by& semi3quantitative& RT3PCR& during& the& early&
development& of& zebrafish.& Pear1& mRNA& appeared& at& 24& hours& post& fertilization& (hpf),&
progressively&rising&till&day&4&(Fig.&5A).&It&was&also&detected&in&adult&zebrafish&blood&(Fig.&5B),&
and&was&abundantly&present&in&the&nervous&system&(Fig.&5C,&F,&G),&in&somites&(Fig.&5D)&and&in&
a& putative& yolk& sac& gland& (Fig.& 5E),& as& demonstrated& by& in# situ& staining& for& Pear1& mRNA.&&
Staining&with&the&sense&probe&was&negative&(Fig.&5H),&but&Pear1&mRNA&was&barely&detected&
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Next,& we& investigated& the& function& of& PEAR1& in& CD41:eGFP& zebrafish,& which& express& GFP&
under& control& of& the&CD41&promoter.& First,& the&potency&of& the&PEAR1&MOs&was& tested&on&
Pear1&gene&expression&in&an&in#vitro&luciferase&assay&and&by&RT3PCR&(Figure&6)&and&on&Pear1&





(up& to&50&  µM),&no&effects&were&observed.&However,& at& a& concentration&equivalent& to&100&
µM,&42%&of&the&fish&presented&a&mild&(23%)&to&severe&(19%)&phenotype,&whereas&treatment&
with&a&control&MO&had&no&effect&on&fish&development.&Defective&development&of&the&nervous&
system&was&observed& (absence&of& eyes& and&head).& Increasing& concentrations&of& Pear1&MO&
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confirmed& elevated& GFP& expression& in& the& fish& (Fig.& 7D).& To& study& the& effect& of& Pear1&
depletion&on&the&development&of&hematopoietic&stem&cells&and&erythrocytes,&qRT3PCR&was&
carried&out&for&Scl&and&Gata31,&on&243hpf&embryos.&No&expression&differences&were&observed&
for& these& lineage&markers,&with& only& a& partial& specificity& in& zebrafish,& compared& to& human&
HSC&(Fig.&7E).&&
At& higher&MO& concentrations,& the& thrombocyte& count& dropped,& related& to& developmental&
problems&(Fig.&6E).&Correspondingly,&when&GATA1:dsred&fish&embryos&were&injected&with&the&
PEAR1&MO& (50&µM),& no& differences&were& observed& in& the& development& of& red& blood& cells&
(Fig.&7F).&Erythrocyte&cell&maturation&was&also&studied&by&direct&staining&of&red&blood&cells&in&





















































Figure! 6.& A)& In# vitro& luciferase& testing& efficiency& of& the& PEAR1& ATG&MO& for& zebrafish&Pear1.& & B)& PCR& testing&
efficiency& of& the& PEAR1& splice& MO.& Embryos& were& injected& with& control& or& splice3blocking& PEAR1& MO.& The&
phenotype&was&analysed&for&developmental&problems.&A&mild&phenotype&was&defined&by&a&curly&tail,&a&severe&
phenotype& by& nervous& system&developmental& defects.& C)& left& panel:& distribution& of& phenotypes& for& different&
MO&concentrations.&Right&panel:&pictures& illustrating&all&phenotypes.&D)& left&panel:&distribution&of&phenotypes&
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Figure! 7:! Pear1! in! zebrafish! is! a! negative! regulator! of! thrombocyte! production.!A)&Western&blot& for&Pear1&
(Pear13EC&Ab)&in&zebrafish,&non3injected,&injected&with&control&MO&or&Pear1&ATG&MO&3dpf;&total&Akt&served&as&
loading&control.&B)&Analysis&of&the&number&of&GFP3positive&cells&in&the&tail&at&2&dpf&after&PEAR1&MO&injection&vs.&
control.& C)& Pear1& knockdown& and& thrombocyte& production.& Photography& of& CD41:eGFP& fish& at& 3& dpf& after&
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PEAR1 transcriptionally regulates PTEN, modulating Akt phosphorylation 
PEAR1& activates& PI3K& and& triggers& Akt& phosphorylation& in& platelets.1& Both& PI3K& and& the&
phosphatase& PTEN& are& necessary& for& platelet& formation,& via& controlling& Akt&
phosphorylation.11& Therefore,&Akt&phosphorylation&was& investigated& in& the& zebrafish&Pear1&
knockdown& 3& dpf,& after& injection& of& Pear1& MO& or& control& MO.& Pear1& depletion& induced&
elevated&Akt&phosphorylation&in&total&zebrafish&extracts&(Fig.&8A).&The&importance&of&PI3K&in&
this&process&is&illustrated&by&the&addition&of&the&PI3K&inhibitor&LY294002,&added&to&the&water&
30& hpf.& Added& at& this& time& point,& LY294002& was& not& lethal,& but& disrupted& Akt&
phosphorylation&and&thrombocyte&formation&(Fig.&8B,&Fig.&9).&Similarly&to&the&effect&of&PEAR1&
neutralization& in& CD34+& cells& during& MK& differentiation& in# vitro& (Fig.& 3),& Pten& was&
downregulated& in& the& Pear1& knockdown.& Because& the& zebrafish& genome& encodes& 2& Pten&
genes& Ptena& and& Ptenb,& expression& of& both& was& analysed& by& qRT3PCR& after& Pear1& MO&
injection.&Ptena#was&potently&dowregulated&and&Ptenb&weakly&(Fig.&8C).&Therefore,&the&role&
of& each& phosphatase& was& analysed& separately& in& thrombocyte& production& and& Akt&
phosphorylation.& In& agreement& with& earlier& findings,25& the& inactivation& of& only& a& single&
isoform&did&not&affect&fish&development&at&3&dpf&(Fig.&9B).&Also,&both&the&injection&of&Ptena&or&
Ptenb&MO& increased& Akt& phosphorylation,& even& though& the& thrombocyte& count& was& only&





dpf& in& zebrafish&after& injection&of& control&or&Pear1& splice3blocking&MO.&B)&Western&blot& for&GFP&and&Akt3P& in&
whole&fish&after&treatment&with&LY294002&or&DMSO,&added&at&30&hpf&and&analysed&3dpf,&with&Akt&as&a&loading&
control.& C)&mRNA& expression& of& Ptena& and& Ptenb& by& qRT3PCR& 3& dpf& after& injection& of& control& or& Pear1&MO,&











was& used& as& control.& Phenotype&was& analysed& at& 50& hpf.& B)& PTENa&or& PTENb&MO&were& injected& at&
concentrations& necessary& to& increase& Akt3P& (600& µM).& The& phenotype& was& analysed& at& 3& dpf.& C)&
Pictures&of&zebrafish&at&3&dpf&with&white& light& (left&panels)&and& fluorescent& light& (right&panels)&after&
treatment& of& zebrafish& with& the& PI3K& inhibitor& LY294002& (50&µM),& in& combination& with& control& or&
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Supplemental data: Expression regulation of hematopoietic transcription factors in 
CD34+ cells.  
Figure&10&describes&the&expression&of&GATAD1,&PUD1,&RUNX,&FLID1&and&NFDE2&in&differentiating&
CD34+& cells,& treated& with& the& control& vector& LV_miR_dsRed& over& time.& GATA31& is& an&
important& transcription& factor& in& haematopoiesis,& required& in&multipotent& progenitors& and&
committed&precursors&during&erythrocyte,&as&well&as&megakaryocyte&maturation26.&A&lack&of&
GATA31& in& the& MK& lineage& leads& to& decreased& polyploidization& and& a& lack& of& cytoplasmic&
maturation.27& Interestingly,& GATA31& deficient& megakaryocytes,& with& reduced& size& and&
polyploidization,&express&nearly&103fold&less&cyclin&D&and&103fold&more&p16&as&their&wild3type&
counterparts.28& Although& these& authors& demonstrated& that& cyclin& D1& is& a& direct& GATA31&
target& in& megakaryocytes,& we& found& a& strong& reduction& for& CCND1& expression& in& PEAR1&










a& fundamental& role& for& RUNX1& in& megakaryopoiesis& with& marked& decrease& of&
polyploidization& and& cytoplasmic& development& of& MKs,& similarly& to& what& is& observed& for&
GATA31.27& Since&detailed& studies&via&gene&profiling,& investigating& the& interrelation&between&
polyploidization& and&megakaryocyte& differentiation& concluded& that& there&were& no&marked&
changes&during&ploidization&in&the&level&of&transcription&factors&involved&in&the&regulation&of&
MK3specific& genes& (GATA31,& FOG31,& FLI31,& SCL/TAL1&and&AML1)&or&platelet&production& (NF3





committed& precursors,& processes& more& pronounced& in& control& cultures& than& in&
LV_miR_PEAR1&treated&cultures&with&enhanced&proliferation&of&non3committed&precursors.&
The& finding& by& Nagai& et& al.& that& siRNA3mediated& depletion& of& RUNX1& in& megakaryocyte3
induced& UT37/GM& cells& resulted& in& up3regulation& of& the& expression& of& megakaryocytic&
markers&and&polyploidization,&while&cell&proliferation&was&down3regulated30&is&in&agreement&
with& the&RUNX1&downregulation,&which&we&observed&during&differentiation&of&CD34+& cells,&
essentially& to& the& level& of& 4N& and& 8N& fractions.& These& authors& further& showed& that&
overexpression&of&RUNX1&decreased&the&activity&of&megakaryocytic&gene&promoters&in&TPO3
treated&UT37/GM&cells.&Despite&the&existence&of&a&regulatory&loop&connecting&RUNX1,&GATA3





















and& that& it& is& a& negative& regulator& of& MK& progenitor& cell& proliferation,& but& not& of& MK&
maturation.& These& observations&were& confirmed& in& zebrafish,&where& knockdown&of& PEAR1&
enhances& thrombopoiesis& but& not& erythropoiesis.& The& expression& of& various& genes,&
implicated&in&the&PI3K/Akt&and&Notch&pathways,&as&well&as&in&gene&transcription&was&mildly&to&
moderately& modified& in& the& PEAR1& knockdowns.& PTEN,& a& phosphatase& that& regulates& the&
degree& of& Akt& phosphorylation& during&megakaryopoiesis,& was& also& downregulated.& Hence,&




coinciding& with& the& expression& of& CD41& and& GATA31.& The& parallelism& in& the& expression&
profiles&of&PEAR1&and&GATA1& is& in& line&with&the&presence&of&GATA31&binding&sites& in&the&5’3
upstream&sequence&of&the&PEAR1&promoter,&identified&via&the&TFMATRIX&transcription&factor&
binding& site& profile& database& (http://www.cbrc.jp/research/db/TFSEARCH.html)& and& as&
reported&by&Farnham&et&al.32&Whereas&progressive&upregulation&of&NF3E2&is&not&surprising&for&




of& RUNX1& in& UT37/GM& cells& caused& upregulation& of& megakaryocyte& markers& and& also&




Overexpression& of& Pear1& in& mouse& bone& marrow& cells& reduces& myeloid& progenitor&
proliferation.&Moreover,&the&ectopic&expression&of&Pear1&in&NIH&3T3&fibroblasts&reduced&both&
early&and&late&myeloid&progenitors&in&non3adherent&co3cultured&bone&marrow&cells.3&It&is&not&




by& reducing& its& expression& in& 2& distinct&models,& based& on& expression& depletion.& In& human&
CD34+& cells,& PEAR1& was& reduced& employing& lentiviral& vectors& encoding& different& miRNA3
based&short&hairpins&(LV_miR_PEAR1_1461&and&LV_miR_PEAR1_2938);&in&zebrafish&embryos&
it& was& counteracted& via& injection& of& two& types& of& morpholino.& Both& approaches&
demonstrated& that& PEAR1& negatively& regulates& the& early& steps& of& megakaryopoiesis,&
respectively&thrombopoiesis.&&
&
Several& approaches,& distinguishing& MK& progenitor& proliferation& and& MK& maturation& all&
pointed&towards&a&role&for&PEAR1&in&proliferation&primarily.&This&is&illustrated&by&the&gradual&
expression&of&CD41&in&megakaryoblasts&and&by&the&similar&distribution&of&CD41&over&smaller&
and& larger& differentiating& MK& precursors,& after& control& or& shPEAR1& treatment.& Zebrafish&
CD41& positivity& has& been& demonstrated& as& early& as& 42& hpf& and& it& appears& at& 48& hpf& in&
circulating&hematopoietic&cells.&Since&CD413GFP&zebrafish&allow&the&identification&of&mature&
thrombocytes&with&high&GFP&positivity24&vs.&their&precursors34,&this&model&was&suited&to&study&
Pear1& neutralization& in& thrombopoiesis.& & This& model& also& illustrated& that& the& rapid&
stimulation& of& thrombopoiesis& was& without& effect& on& erythropoiesis.& Whereas& we& cannot&
exclude&that&the&Pear1&knockdown&affects&other&circulating&cells&(excluding&red&blood&cells)&
in& the& zebrafish,& in& human& blood,& PEAR1& is& exclusively& expressed& in& circulating& platelets.&
PEAR1&is&also&expressed&in&human&myeloid&precursors,&the&relevance&of&which&remains&to&be&
elucidated.&&
Both& in&MK&progenitors& and& zebrafish,& a& knockdown&of& PEAR1&affected& the& transcriptional&
regulation& of& several& genes,& including& PTEN.& PTEN& is& a& tumour& suppressor& protein& and&
mutations& in&PTEN& have& been& observed& in& a& variety& of&malignancies,& including& leukaemia.&
Correspondingly,& the& transient& silencing& of& PTEN& in& human& CD34+& cells& enhanced& their&
proliferative&potential&and&ability&to&engraft&mice.35&The&present&study&shows&that&absence&of&
PEAR1&also&causes&a&partial&silencing&of&PTEN,&leading&to&a&new&steady&state&in&proliferating&
CD34+& cells,&with& elevated&baseline& levels& of& Akt3P,& stimulating& cell& proliferation.& Formally,&
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PEAR1& (The& human& protein& atlas& at&
http://www.proteinatlas.org/ENSG00000187800/cancer).&&
&
The& zebrafish& genome& encodes& 2& Pten& genes& Ptena& and& Ptenb.& Both& have& similar& lipid&
phosphatase& activity.25& In& the& Pear1& knockdown,& we& observed& an& association& between&
elevated& thrombocyte& formation& and& downregulated& Ptena,& but& not& Ptenb.& The& MO3








CD34+&cells,&but&not& in&zebrafish.&The&regulation&of&PTEN&expression& is& still&unclear.&Recent&
studies& have& shown& that& PTEN& may& both& be& positively& and& negatively& regulated&
transcriptionally,& as& well& as& post3translationally& by& phosphorylation,& oxidation& and&
acetylation.& Transcription& factors& known& to& be& involved& include& peroxisome& proliferator3
activated&receptor&γ,36&EGR1,37&p5337,&etc.&Several&factors&negatively&regulate&PTEN,&including&





Src& family& tyrosine& kinases& (SFKs)& have& been& identified& as& negative& regulators& of&
thrombopoiesis.& A& reduced& PEAR1& expression& inevitably& interferes& with& PEAR13dependent&
SFK&signalling.&Hence,&our&present&findings&that&the&loss&of&PEAR1&increases&thrombopoiesis&
comply&with& these&observations& that& SFK& inhibitors& and&mice&deficient& in& Lyn&enhance&MK&
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proliferation,& maturation,& polyploidy& and& platelet& release& in& cell& culture.45,& 46& Therefore,&
PEAR1& may& join& other& previously& described& negative& regulators& like& SFKs,& focal& adhesion&
kinase,& platelet& factor& 4,& thrombospondin3147,& and& the&pituitary& adenylyl& cyclase3activating&
peptide.48&
&
In& addition& to& the& role& of& PEAR1& in& platelet& function1,& and& in& megakaryopoiesis& and&
thrombocyte& formation& (this& study),& PEAR1& is& abundantly& present& in& the&neuronal& crest& of&
zebrafish& where& it& appears& to& be& necessary& for& embryo& development.& Progressively&
increasing& Pear1& MO& concentrations& caused& a& variety& of& central& nervous& system& defects.&
Previously,&Wu&et& al.49& identified&PEAR1& in& glial& precursor& cells& as& an&engulfment& receptor,&
implicated& in& the& phagocytosis& of& dead& sensory& neurons.& The& developmental& problem& in&
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Chapter II – Illustration from “Secunda musculorum Tabula – de humanum corporis fabrica libri septem” – 
A. Vesalius, 1543  
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Genome&wide* association* studies* to* identify* loci* responsible* for* platelet* function* and*
cardiovascular* disease* susceptibility* have* repeatedly* identified* polymorphisms* linked* to* a*
gene* encoding* Platelet* endothelium* aggregation* receptor* 1* (PEAR1),* an* “orphan”* cell*
surface*receptor*that*is*activated*to*stabilize*platelet*aggregates.*To*investigate*how*PEAR1*
signalling* is* initiated,* we* sought* to* identify* its* extracellular* ligand* by* creating* a* protein*
microarray*representing*the*secretome*and*receptor*repertoire*of*the*human*platelet.*Using*
an* avid* soluble* recombinant* PEAR1* protein* and* a* systematic* screening* assay* designed* to*
detect* extracellular* interactions,* we* identified* the* high&affinity* immunoglobulin* E* (IgE)&
binding* subunit* FcεR1α,* as* a*PEAR1* ligand.* FcεR1α*and*PEAR1*directly* interacted* through*
their*membrane&proximal*Ig&like*and*13th*EGF*domains*with*a*relatively*strong*affinity*(KD*~*
30nM).* Pre&complexing* FcεR1α* with* IgE* potently* inhibited* the* FcεR1α&PEAR1* interaction*










Platelets* play* a* vital* role* in* preserving* blood* circulation* in* response* to* vessel* injury* by*
detecting*lesions,*aggregating*to*form*a*haemostatic*plug,*and*nucleating*the*formation*of*a*
fibrin&rich,* injury&occluding* clot.* While* necessary* to* prevent* blood* loss* at* sites* of* tissue*




is* the* leading* cause* of* mortality* worldwide.1* With* the* eventual* aim* of* guiding* the*
development* of* new* treatments* and* diagnostic* assays,* genome&wide* association* studies*
using* large* patient* cohorts* have* identified* several* genetic* loci* that* are* associated* with*
cardiovascular*disease*susceptibility*and*platelet* function.2,*3*Amongst*the*candidate*genes*
identified,*polymorphisms*linked*to*PEAR1*have*been*repeatedly*linked*to*natural*variation*
in* response* to* platelet* agonists* in* several* independent* studies.3&7*PEAR1* encodes* platelet*
endothelium*activation*receptor*1*(PEAR1,*also*known*as*Multiple*epidermal*growth*factor&
like* domains* protein* 12* (MEGF12)* or* JEDI&1),* a* platelet* cell* surface* receptor* that* was*
originally* identified* as* a* protein* phosphorylated* in* response* to* platelet* aggregation.8,* 9*
PEAR1* is* expressed* at* low* levels* on* the* surface* of* circulating* platelets* but* is* significantly*
upregulated* during* platelet* activation* when* released* from* cytoplasmic* α&granules.8*
Consistent* with* polymorphisms* linked* to* PEAR1* being* associated* with* cardiovascular*




Identifying* interactions* between* membrane&embedded* receptor* proteins* is* technically*
challenging* and* many* commonly&used* approaches* such* as* biochemical* purifications* are*
generally* not* suitable* to* detect* them.* This* is* largely* due* to* the* amphipathic* nature* of*
membrane&embedded*proteins,*making*them*difficult*to*solubilize*in*detergents*that*retain*
their*native*conformation,*and*the*fact*that*their*extracellular*interactions*are*often*highly*
transient,*having*half&lives*of* just* fractions*of*a* second.10*To*address* these* issues,*we*and*
others* have*developed*assays*based*on*detecting*direct* protein* interactions*between* the*
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entire*ectodomains*of* cell* surface* receptors*expressed*as* soluble* recombinant*proteins* in*
eukaryotic*cells.*11&14*Using*this*approach,*binding*avidity*can*be*increased*by*the*purposeful*
inclusion*of*oligomerising*tags*to*overcome*the*fleeting*nature*of*these*interactions.*In*our*





such* as* disulfide* bonds* are* faithfully* added.* Consequently,* this* method* has* identified*






orange* oval,* and* filled* lollipops* representing* potential* N&linked* glycosylation* sites.* The* design* of* both*
monomeric*biotinylated*“bait”*and*pentameric*β&lactamase&tagged*“prey”*containing*the*entire*ectodomain*of*
the* receptor*are* shown* (prey* is* shown*as*a*monomer* for* clarity);*both* contain* the* rat*Cd4*domain*3*and*4*
(Cd4d3+4)*and*6*His*tags.*The*AVEXIS*assay*is*shown*with*a*biotinylated*bait*captured*on*streptavidin&coated*
slide* interacting* with* a* pentameric* FLAG&tagged* prey* and* interactions* detected* with* an* anti&FLAG* HRP&
conjugated*secondary*antibody*and*fluorescent*tyramide*HRP&substrate*deposition.**
*
In* this* study,*we* have* compiled* a* protein* resource* representing* the* cell* surface* receptor*




for* PEAR1* as* the* high* affinity* IgE* receptor* subunit,* FcεR1α* and* show* that* multimerised*
FcεR1α*potentiated*platelet* aggregation*and* led* to*PEAR1*phosphorylation,* an*effect* that*
was*specifically*inhibited*by*IgE.*
 
MATERIALS AND METHODS 
*
Human platelet protein selection and expression plasmid construction 
After*compiling*a*list*of*platelet*receptor*proteins*and*classifying*them*into*structural*categories,*the*extent*of*
each* ectodomain* was* identified* by* careful* manual* examination* of* its* structural* features* such* as* signal*
peptides,* transmembrane* regions* and* GPI* anchors;* for* secreted* proteins,* the* entire* protein*was* used.* The*
ectodomain* regions* were* codon&optimized* for* human* expression* and* chemically* synthesized* with* unique*
flanking* NotI* (5’)* and* AscI* (3’)* restriction* sites* (GeneArt* AG)* and* subcloned* into* bait* expression* plasmids*
according*to*its*structural*class.*While*we*have*previously*expressed*typeI/GPI&anchored*and*secreted*proteins*
for* interaction* screening,11* we* designed* new* expression* vectors* to* express* the* ectodomains* of* type* II* and*
multi&span* transmembrane* proteins,* in* a*way* that*would*most* appropriately* preserve* their* structure*when*
presented* at* the* cell* surface* in) vivo.* Similarly,* for* multimeric* protein* complexes* such* as* integrins,*
Glycoprotein1bαβ,* and* fibrinogen,* care*was* taken* to*design* the* constructs* that*would*promote* correct* and*
active* complex* formation.* The* truncated* fragments* of* PEAR1* and* FcεR1α* were* designed* based* on* their*
domain* structures,* amplified* by* PCR* from* the* full* length* constructs* and* cloned* into* an* expression* vector*
containing* an* exogenous* signal* peptide* and*C&terminal* 6&His* and* biotinylatable* peptide* sequence.* The* 218&*
and*325&*amino&acid*fragments*encoding*the*Cε3&4*and*Cε2&4*domains*of*the* IgE*constant*heavy*chain*were*
amplified* from* plasmid* pFUSE&CHIg&hE* (Invivogen)* and* cloned* into* a* vector* containing* an* exogenous* signal*
peptide*and*C&terminal*6&His*tag.* IgE* fragments*were*expressed*and*purified*as*described*below.*All*plasmid*
constructs*are*openly*available*from*Addgene.**
Recombinant protein expression 
All* proteins* were* produced* by* transient* transfection* using* HEK293E* cells* as* described11* to* ensure*
posttranslational*modifications*such*as*disulfide*bonds*and*glycans*were*added.*Proteins*were*purified*using*
their* 6His* tag* using* a* bespoke* supernatant* loading* rig* and* 96&well* Ni2+&NTA* filter* plates.15* Heat&labile*
immunoreactivity* to* demonstrate* folding*was* confirmed* by* heat* denaturing* the* proteins* for* 10*minutes* at*
90°C*before*capture*on*a*streptavidin&coated*plate*via*their*biotin*tag*and*determination*of*immunoreactivity*
by*ELISA*as*described.*19'
Construction of the human platelet receptor protein microarray 
Normalized* bait* proteins* were* diluted* in* phosphate&buffered* saline* (PBS)* supplemented*with* 50%* glycerol,*
0.02%* Tween* and* 0.5%* bovine* serum* albumin* (BSA)* prior* to* printing.* Bait* proteins* were* printed* on*
streptavidin&coated* slides* that* also* contained* an* inert* hydrogel* coating* (XanTec)* using* a*Marathon* arrayer*





HRP* antibody* (Sigma,* 1:1000)* for* 1* hour* and* finally* detected* by* TSA* Alexa* 555* substrate* (Invitrogen)* for* 1*
hour.*Between*different*incubation*steps,*slides*were*washed*three*times*in*PBS*buffer*containing*0.1%*Tween*
with* gentle* rocking.* Arraying,* incubations* and*washing* steps* were* performed* at* 22°C.* Positive* interactions*
were*identified*and*quantified*by*scanning*slides*with*a*ScanArray*Express*Microarray*Scanner*(PerkinElmer)*at*
550*nm.**
AVEXIS interaction screening 
To*determine*the*effect*of*IgE/omalizumab*and*map*the*interacting*domains*of*the*FcεR1α&PEAR1*interaction,*
we* used* the* AVEXIS* method* formatted* on* streptavidin&coated* 96&well* microtitre* plates* as* described.* 11,* 17*
Briefly,*bait*and*prey*proteins*were*first*normalized*to*activities*suitable*for*the*AVEXIS*assay.*20*Biotinylated*





Surface plasmon resonance (SPR) studies 
All* SPR* studies* were* performed* on* a* Biacore* T100* instrument* essentially* as* described.17* Purified* analyte*
proteins* were* resolved* by* gel* filtration* just* prior* to* use* in* SPR* experiments.* Increasing* concentrations* of*
proteins*were*injected*at*10*μl/min*for*equilibrium*analysis*or*high*flow*rates*(100*μl/min)*for*kinetic*studies*to*
minimise* the* confounding* effects* of* analyte* rebinding.* Both* kinetic* and* equilibrium* binding* data* were*
analysed*in*the*manufacturer’s*Biacore*T100*evaluation*software*(Biacore).**
 
Platelet aggregometry assays 
Venous*blood*was* collected* from*normal*donors* following* guidelines* from*ethical* committee*of* the* Leuven*
University* Hospital* number* B322201111373/S53239.* Platelet&rich* plasma* (PRP)* was* prepared* and* platelet*
aggregation* monitored* as* described.8* Platelets* (4x105* per* µL)* were* preincubated* with* either* soluble*
recombinant* purified* pentameric* proteins* extensively* dialyzed* into* PBS:* PEAR1* (s5&PEAR1),* FcεR1α* (s5&











Western* blotting*was* performed* essentially* as* described8* using* the* primary* antibodies:* PEAR1&EC* Ab* (R&D*
Systems),*PEAR1&EC*Ab* (Santa*Cruz),* FcεR1α*Ab* (LifeSpan*Biosciences),*anti&PLCγ2* (Sigma),*anti&PLCγ2&P* (Cell*
Signaling),* anti–Akt&P* (Cell* Signaling),* anti&phosphoprotein* (P&Tyr)* 4G10* platinum* (Millipore).* After* adding*
HRP–conjugated* secondary* antibodies* (Dako),* immunoreactive* bands* were* visualized* by* ECL* (Amersham*
Biosciences).* PEAR1* phosphorylation* on* Tyr* residues,* referred* to* as* PEAR1&P,* was* evaluated* after*
immunoprecipitation*with*PEAR1&EC*Ab*and*detection*of*P&Tyr*by*4G10*platinum*as*previously*described.*8*
Platelet immunocytochemistry 








A protein resource representing the secretome and receptor repertoire of the human 
platelet. 
To*identify*an*activating*ligand*for*PEAR1,*we*first*created*a*protein*library*that*represented*
the* cell* surface* receptor* repertoire* and* secretome* of* the* human* platelet* expressed* as*
secreted* recombinant* proteins.*We* and* others* have* previously* only* expressed* typeI/GPI&
anchored*and*secreted*proteins* for* large*scale*extracellular* interaction*screening* 11&14,*but*
because* platelets* also* express* cell* surface* proteins* from* other* structural* classes,* we*
designed*new*expression*plasmids.*We*constructed*these*new*expression*plasmids*with*the*
goal*of*preserving*the*structure*of*the*receptor*when*displayed*at*the*platelet*surface*(Fig.*
2A).* In* the*case*of*multimeric*protein*complexes*such*as* integrins,*Glycoprotein1bαβ,*and*






identifying* functionally* relevant* interactions,* each* protein* was* classified* into* one* of* six*
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structural*categories.*The*entire*extent*of*the*ectodomain*region*was*then*determined,*and*
an* expression* construct* manually* designed* by* pairing* it* with* an* appropriate* expression*
vector.*The*final*library*contained*173*proteins*and*complexes*(76*type*I,*7*GPI&anchored,*14*
type* II,* 57* secreted,* 7* heterodimeric* complexes,* and* 12* multi&span* transmembrane*
proteins)* represented*by*a* total*of*178*plasmids* (not* shown,* see*online*supplement).*The*
proteins*were*expressed*and*purified*as*monomeric*biotinylated*“baits”*in*mammalian*cells*






on* their* expected* size* suggesting* the* presence* of* different* glycoforms* (Fig.* 2B).* The*
recombinant* proteins* were* antigenically* active* as* assessed* by* demonstrating* heat* labile*
immunoreactivity* to* a* panel* of* monoclonal* antibodies* (mAbs)* recognizing* at* least* one*
protein*from*each*structural*category*(Fig.*3A).*The*library*of*biotinylated*bait*proteins*was*
serially*diluted,*and*arrayed*on*streptavidin&coated*glass*slides*(Figure*not*shown).*Proteins*
immobilized* on* the* slides* retained* their* immunoreactivity* to*mAbs* known* to* stain* native*






Figure'2:*Design'and'expression'of'a'human'platelet' receptor' library' for' common'structural' classes'of' cell'
surface' and' secreted' proteins' for' AVEXIS.* A)* Cartoons* schematically* show* the* design* of* ectodomain*
expression*constructs.*Type*II*and*multispan*proteins*contained*an*exogenous*signal*peptide*(Exg.SP)*while*the*














of* selected* recombinant* proteins* representing* each* structural* class* was* confirmed* by* demonstrating* heat&
labile*immunoreactivity*of*monoclonal*antibodies*which*are*known*to*stain*the*native*protein*on*the*platelet*
surface.*The*heat&treated*and*control*proteins*were*probed*with*monoclonal*antibodies*(SELP:*Thromb6;*GP6:*
HY101;* GP1Bαβ:* PAB&5;* α2β1:* P1E6;* αvβ3:* BV3;* CD109:* B&E47;* CD36:* CB38;* CD69:* FN50)* and* detected* by*
ELISA.* Bars* represent* mean* ±* SEM;* n* ≥* 3.* B)* Immunoreactivity* to* mAbs* recognizing* the* individual* named*
platelet* receptors* that* are* known* to* bind* native* proteins* on* platelets* is* preserved* when* arrayed* on*
streptavidin&coated* glass* slides;* note* that* anti&GP1bα* identifies* both* the* GP1bα* monomer* (bait* 75)* and*
GP1bαβ*complex*(bait*77).*
 
Systematic interaction screening of the platelet receptor microarray identified 
FcεR1α as a ligand for PEAR1 
To* identify* an* activating* ligand* for* PEAR1* during* platelet* aggregation,* we* systematically*
screened* the* human* platelet* receptor*microarray* using* the* AVEXIS* assay* which* required*
expressing* the* entire* ectodomain* of* PEAR1* as* a* recombinant* pentameric,* FLAG&tagged*
soluble* “prey”.* Probing* the* array* with* a* control* pentameric* FLAG&tagged* prey* protein*
labelled*the*high*affinity*IgG*receptor*Fcγ2α*(which*directly*bound*the*anti&FLAG*antibody)*
and* P4HB,* a* bait* that* presumably* interacted*with* the* tags* on* the* control* prey* (Fig.* 4A).*
Screening* the* receptor* microarray* with* the* PEAR1* prey* identified* the* high* affinity* IgE&
binding*subunit,*FcεR1α,*as*a*PEAR1*ligand*(Fig.*4B,*Fig.*5).*Since*PEAR1*was*presented*as*a*























Figure' 4:' A' human' platelet' secretome' and' receptor' protein' microarray' identifies' FcεR1α' as' a' ligand' for'
PEAR1.*Soluble*recombinant*biotinylated*proteins*representing*the*secretome*and*receptor*repertoire*of*the*
human*platelet*were*purified*and*arrayed*in*six*three&fold*dilutions*on*streptavidin&coated*slides.*A)*The*array*
was* screened*with*a* control* (rat*Cd200)*pentamerized*FLAG&tagged*prey*which*bound* the*background*baits*
FcγR2α* (red*box)* and*P4HB* (white*box).*B)*PEAR1*prey*additionally* interacted*with* the*FcεR1α*bait* (orange*
box)*when* compared* to* the* control* in*A;* fluorescence* intensities* are*quantified* in* Figure*5.* C)* FcεR1α*prey*
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PEAR1 and FcεR1α directly interact through their membrane-proximal domains. 
To* validate* and* quantify* the* interaction,* we* used* surface* plasmon* resonance* (SPR)* and*
observed* clear* saturable* binding* between* PEAR1* and* FcεR1α*with* an* equilibrium*binding*
constant* (KD)*of*27.4*±*1.3*nM*(Fig.*6A).*The*saturable*binding*behavior*demonstrated*the*
specificity* of* the* interaction* which* had* a* remarkably* high* affinity* when* compared* with*
similar* receptor&ligand* interactions,* which* are* usually* in* the* micromolar* range* when*
measured*using* the*same*approach.10*An* independent*kinetic*analysis*confirmed*this,*and*
revealed* that* the*higher*affinity*was* largely*due* to*a* comparatively* slow*dissociation* rate*
constant*(Fig.*6B).*By*using*the*AVEXIS*assay*and*a*series*of*structure&guided*truncations*in*
both*PEAR1*and* FcεR1α,*we* showed* that* the*minimal* FcεR1α*binding*unit* on*PEAR1*was*
contained* solely* within* the* 45* amino* acids* comprising* the* 13th* EGF* domain* (Fig.* 7A,* C).*
Similarly,*the*PEAR1*binding*site*was*located*within*the*membrane*proximal*Ig&like*domain*
of* the* FcεR1α* ectodomain,* the* same* domain* bound* by* IgE* 27* (Fig.* 7B,* C),* raising* the*
possibility* that* IgE*may*prevent*PEAR1*binding*when*complexed*with* its* receptor.* Indeed,*
IgE,* when* bound* to* FcεR1α,* could* potently* inhibit* the* FcεR1α&PEAR1* interaction* at* low*
concentrations,*consistent*with*the*high*affinity*of*IgE*for*FcεR1α*(Fig.*7D).*To*show*that*this*
inhibitory* effect* was* due* to* blocking* of* the* FcεR1α&PEAR1* interaction,* and* not* steric*
interference* with* the* large* (190* kDa)* IgE* molecule,* we* demonstrated* that* smaller*
subfragments*of* the* IgE*heavy*chain*which*bound*FcεR1α,*and*blocked* the*FcεR1α&PEAR1*
interaction*(Fig.*7E).*To*demonstrate*the*specificity*of*this*effect,*we*showed*that*addition*of*








Figure' 6:' FcεR1α' and' PEAR1' directly' and' specifically' interact' with' a' relatively' high' affinity.' A)* Purified*
monomeric* FcεR1α&Cd4&6His*was* serially* diluted*and* injected*over* immobilized*PEAR1*until* equilibrium*was*
achieved*(inset).*Binding*data*that*had*been*reference*subtracted*were*plotted*as*a*binding*curve*and*a*KD*of*
27.4* ±* 1.3* nM*was* calculated.* B)* Association* and* dissociation* rate* constants* derived* from* an* independent*









the* ability* of* the* fragments* to* bind* the* full&length* (FL)* ectodomain* of* FcεR1α* as* determined* by* AVEXIS;* a*
similar* summary* for* FcεR1α,* but* tested* for* binding* to* PEAR1* is* shown* in* B.* C)* Binding* data* using* AVEXIS*
showing*the*13th*EGF*domain*of*PEAR1*and*the*2nd&Ig&like*domain*of*FcεR1α*are*necessary*and*sufficient* for*
binding.*Bars*represent*means*±*SEM,*n*≥*3.*D)*The*FcεR1α&PEAR1*interaction*detected*by*AVEXIS*using*PEAR1*
as* a* plate&immobilized* bait,* was* completely* inhibited* by* low* (IC50* ~* 0.5* ng/ml)* concentrations* of* IgE* (filled*
circles)*but*not*control*IgG*(open*circles).*A*control*interaction,*rat*Cd200&Cd200R*(squares),*was*not*inhibited*
by*either*antibody.*E)*The* indicated*concentrations*of*purified* full&length* (FL)*and*both*smaller* fragments*of*
the*IgE*constant*heavy*chain*(C2&4)*and*(C2&3)*were*preincubated*with*the*FcεR1α*prey*before*being*added*to*
the*PEAR1*bait*and*the*interaction*detected*using*AVEXIS.*Data*points*are*mean*±*SEM;*n*=*3.*F)*The*FcεR1α&
PEAR1* interaction* was* detected* using* AVEXIS,* and* the* inhibition* by* IgE* (IgE* alone,* filled* circles)* could* be*
relieved*by*the*addition*of*2.5*µg*of*omalizumab*(open*circles).*Data*points*are*mean*±*SEM,*n*≥*3.*
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Oligomerised FcεR1α specifically potentiates platelet aggregation via 
phosphorylation of PEAR1 
To*investigate*the*role*of*the*FcεR1α&PEAR1*interaction*in*platelet*activation,*we*confirmed*
cell*surface*expression*of*PEAR1*8,*9*and*FcεR1α*28,*29*by*platelets*using*both*Western*blotting*
and* immunocytochemistry*(Fig.*8).*Unlike*PEAR1,*8*we*did*not*observe*any* increase* in*the*
cell*surface*expression*of*FcεR1α*after*platelet*activation.*We*next*added*clustered*soluble*
oligomers*(pentamers)*of*PEAR1*and*FcεR1α*to*platelet*aggregation*assays*and*showed*that*
they* did* not,* by* themselves,* trigger* platelet* aggregation* (data* not* shown).* Preincubating*
unactivated* platelets* with* FcεR1α* oligomers* followed* by* collagen* stimulation,* however,*
potentiated*platelet*aggregation*(Fig.*9A).*The*specificity*of*this*effect*was*demonstrated*by*
pre&complexing*the*FcεR1α*pentamers*with*IgE*to*completely*block*FcεR1α&mediated*PEAR1*
signaling,*and*suggested* the*possibility* that* IgE*could*act*as*an*endogenous*plasma&borne*
restrictive* regulator* of* thrombus* formation* (Fig.* 9B).* PEAR1* oligomers*modestly* inhibited*
platelet*aggregation*(Fig.*9A),*and*did*not*trigger*known*FcεR1α*signalling*effectors*such*as*
the* phosphorylation* of* PLCγ* (data* not* shown),* suggesting* that* they* competed* with*
membrane&tethered* PEAR1* for* FcεR1α* binding.* Finally,* oligomerised* FcεR1α,* but* not* a*
control,* was* able* to* trigger* PEAR1* phosphorylation* with* similar* potency* to* an* activating*















































gels* loaded* with* the* indicated* amount* of* recombinant* monomeric* FcεR1α* (A)* and* PEAR1* (B)* and* platelet*
lysate* samples* from* two* individuals* (S1* and* S2,* at* 1.95x107* platelet* equivalents* per* lane)* probed* with*
antibodies* raised* against* the* extracellular* regions* of* human* FcεR1α* and* PEAR1.* Surface* expression* of* both*
PEAR1* and* FcεR1α*was* confirmed* by* immunofluorescence* antibody* staining* on* platelets* (data* not* shown).*
Note* that* the*molecular*mass* difference* between* the* recombinant* FcεR1α* and* PEAR1* proteins* versus* the*
native*proteins*is*due*to*the*tags*present*in*the*recombinant*proteins.*Blots*shown*are*representative*of*three*
independent*experiments.*C*and*F)*Staining*of*platelets*spread*over*a*fibrinogen*matrix*and*stained*with*either*
anti&FcεR1α* (C)*or*anti&PEAR1* (D)* in*green*and*counter&stained*with*phalloidin* (red).*E*and*F)*Platelets*were*
spread*over*a*fibrinogen*matrix*and*stained*with*anti&IgE*(green).*The*IgE*staining*pattern*was*punctate*(E)*and*
shown* to* be* both* specific* and* extracellular* since* it* could* be* abolished* by* incubating* the* platelets* with* an*
excess* of* soluble* recombinant* FcεR1α* (F).* Unlike* PEAR1,* cell* surface* FcεR1α* is* not* increased* upon* platelet*




















Figure' 9:' Oligomerised' FcεR1α' promotes' platelet' aggregation' via' phosphorylation' of' PEAR1.* A)* Soluble*
recombinant*pentamerised* (s5)*PEAR1*ectodomains*modestly* inhibited,*whereas*a* similar* s5&FcεR1α*protein*
strongly* promoted* platelet* aggregation* relative* to* a* control* (rat* s5&Cd200)* when* added* prior* to* collagen&
induced*platelet*aggregation.*B)*Precomplexing*s5&FcεR1α*with*IgE*completely*inhibited*s5&FcεR1α&potentiated*
aggregation* of* collagen&activated* platelets.* C)* Oligomeric* FcεR1α,* but* not* a* control* protein,* triggered* the*
phosphorylation*of*PEAR1*(top*panel)*in*human*platelets*with*similar*potency*to*an*anti&PEAR1*antibody*(lower*
panel);* total* PEAR1* protein* was* detected* as* a* loading* control.* D)* Oligomeric* FcεR1α* induced* tyrosine*
phosphorylation* in* human* platelets* as* shown* by* anti&phosphotyrosine* (P&Tyr)* Western* blotting* of* lysates.*
Phosphorylation*of*PEAR1*and*AKT*but*not*PLCγ2*(a*mediator*of*FcεR1α*signalling)*was*observed.*Total*PLCγ2*












Platelets*perform*a*delicately&balanced* role* in*haemostasis*because* they*must*detect* and*
seal*vascular*breaches*to*restrict*bleeding*whilst*ensuring*a*proportionate*response*to*avoid*
vascular* occlusion* and* maintain* circulation.* Interactions* between* receptor* proteins*
displayed*on* the* surface*of*platelets*are*a*major* class*of* thrombogenic* regulator,* and*we*
report* here* a* large* recombinant* protein* library* representing* the* secretome* and* receptor*
repertoire*of*the*human*platelet*in*a*format*suitable*for*systematic*extracellular*interaction*
screening*using*the*AVEXIS*assay.*Importantly,*we*have*expanded*the*utility*of*this*assay*to*
include* receptor* proteins* from* a* greater* range* of* structural* classes* as* we* work* towards*
achieving*a*cell&type*rather*than*the*protein&family*orientated*screening*approach;*only*the*
latter* has* been* possible* in* the* past.11&14,* 24* Central* to* this* approach* is* the* use* of* a*
mammalian*expression*system*to*promote*the*correct*folding*of*the*receptor*ectodomains*
which*we*have*previously* shown*can* identify* interactions* that*are* functionally* relevant* in)
vivo.)16&18*The*human*platelet*protein*library*will*be*a*useful*resource*in*further*defining*the*
role*of*platelet*receptors*and*their* interactions* in*cardiovascular*disease,*particularly*since*
all* the* expression* plasmids* have* been* made* openly* available* through* the* Addgene*
repository.* 30* We* have* demonstrated* the* usefulness* of* this* resource* by* identifying* the*
ligand*for*PEAR1,*an*“orphan”*platelet*receptor*that*is*of*topical*interest*because*it*has*been*
identified* in* several* recent* independent* genome&wide* association* studies* linking* it* with*
variation* in* patients’* responses* to* thrombogenic* agonists* in* both* health* and* disease.3&7*
Because*both*FcεR1α*and*PEAR1*are*expressed*on*the*same*cell,* this*raises*the*possibility*
that*the*two*proteins*might*interact*either*in*‘cis’*within*the*same*membrane,*or*in*‘trans’,*
between* neighbouring* cells.* Although* these* need* not* be* mutually* exclusive,* PEAR1*
phosphorylation* is* known* to* be* dependent* upon* platelet* contact* 8,* 9* within* forming*
aggregates*suggesting*that*the* interaction* is* likely*to*occur* in*trans.*The*kinetic*analysis*of*
the* interaction* between* the* soluble* monomeric* proteins* suggest* that* the* two* proteins*
interact* with* a* 1:1* stoichiometry,* although* both* proteins* are* likely* to* form* signalling&
competent* clusters*within* the*membrane,* consistent*with* previous* findings* that* bivalent,*
but* not* monovalent,* anti&PEAR1* antibodies* trigger* PEAR1* phosphorylation.8* Soluble*
oligomers*of*FcεR1α,*but*not*PEAR1,*triggered*known*signalling*effectors*which*is*consistent*
with*a*unidirectional*signal*triggered*by*the*FcεR1α*ligand*through*the*PEAR1*receptor.**
! Chapter II !
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The* function* of* the* high* affinity* IgE* receptor* on* platelets* is* poorly* characterized,* but*









be* bound* by* IgE,* and* unable* to* interact* with* PEAR1.*Where* circulating* levels* of* IgE* are*
increased,*for*example*in*atopic*patients*31,*this*would*significantly*decrease*the*amount*of*
IgE&free*FcεR1α*on*the*platelet*surface*available* for*PEAR1*binding.*This* is*consistent*with*
reports* of* a* systemic* lack* of* secondary* platelet* responsiveness* in* atopic* patients,* an*
observation*that,*in*one*study,*was*correlated*with*elevated*IgE*levels.33&36*Others,*however,*
have* not* replicated* these* findings* 37,* 38* suggesting* a*more* complex* relationship* between*
circulating*IgE*levels*and*platelet*function.*
The*controlled* reduction*of* circulating* IgE*can*be*achieved* in*humans* in* the* treatment*of*
allergy* with* a* humanised* anti&IgE* monoclonal* antibody* (omalizumab)* that* is* currently*
licensed* for* the* treatment* of* severe* persistent* allergic* asthma.39* It* is* a* systemic* anti&IgE*
agent*which*prevents*the*interaction*of*IgE*with*its*receptors,*reducing*plasma*IgE*levels*by*
99%*and*downregulating*FcεR1*on*mast*cells*and*basophils.*40,*41*We*have*shown*here*that*
omalizumab* is*able* to* relieve* the* IgE&mediated* inhibition*of* the*FcεR1α&PEAR1* interaction*
suggesting*that*omalizumab*treatment*could*lead*to*alterations*in*the*regulation*of*PEAR1*
signalling.* Indeed,* concerns* have* recently* been* raised* about* an* increased* risk* of* arterial*
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Chapter III – Illustration from “Tertia musculorum Tabula – de humanum corporis fabrica libri septem” – 
A. Vesalius, 1543  
!




Dextran( sulphate( (DxS;(Mr( 500kD)( induces( fibrinogen( receptor( (αIIbβ3)Aactivation( via( CLECA
2/SykAsignalling(and(via(a(SykAindependent(SFK/PI3K/AktAdependent(tyrosine(kinase(pathway(
in(human( and( murine( platelets.( The( platelet( surface( receptor,( responsible( for( the( DxSA
induced( SykAindependent( AktAactivation,( has( hitherto( not( been( identified.(We( found( that(
DxS(elicited(a(concentrationAdependent(aggregation(of(human(platelets(resulting(from(direct(
PEAR1Aactivation(by(DxS.(Blocking(the(PEAR1(receptor,(in(combination(with(a(selective(SykA
inhibitor( completely( abrogated( the( DxSAdriven( platelet( aggregation.( The( DxSAinduced(SykA
phosphorylation(was(not(affected( in(Pear1&/&(platelets,(but(AktAphosphorylation(was( largely(
abolished.(As(a(result,(the(aggregation(of(Pear1&/&(platelets(was(reduced(and(reversible,( i.e.(
aggregates( were( less( stable( compared( to( wildAtype( platelet( aggregates.( Moreover,( DxSA
induced(Pear1&/&( platelet( aggregation(was( fully( abrogated( by( SykAinhibition,( indicating( that(
the( remaining( platelet( aggregation( of( Pear1&/&( platelets( was( SykAdependent.( Hence,( the(
Pear1/cASrc/PI3K/AktA(and(CLECA2/SykAsignalling(pathways(are(independently(and(additively(
activated(during(platelet(aggregation(by(DxS.(
Conclusion) –)The(DxSAinduced(aggregation(of(human(and(murine(platelets( is( the( result(of(









multiple( epidermal( growth( factor( (EGF)–like( domain( protein( family( is(mainly( expressed( in(
platelets( and( endothelial( cells.1,( 2( PEAR1( comprises( an( extracellular( EMI( domain( (proteinA




that( PEAR1,( cASrc( and( Fyn,( and( the( p85/phosphatidylinositol( 3Akinase( (PI3K)( subunit(
constitute( a( signalling( complex( in( platelets( that( sustains( the( activation( of( αIIbβ3( in(





two( different( pathways( in(both( human( and( murine( platelets:( a( SykAdependent( pathway(
(activating(αIIbβ3(via( Syk/PLCγ2( activation)( and( a( SykAindependent( SFK/PI3K/AktAdependent(
tyrosine(kinase(pathway.5,(6(Alshehri(et)al.( recently( identified(CLECA2(as(the(major(receptor(
for(the(Syk/PLCγ2(mediated(αIIbβ3(activation(via(DxS.7(However,(the(receptor(through(which(
DxS( induces(PI3KAmediated(αIIbβ3(platelet(activation,( independent( from(Syk,( still(had( to(be(
identified.   
Since( both( DxS( and( PEAR1( induce( sustained( platelet( aggregation( via( the( SFK/PI3K/Akt(
pathway(in(platelets,(and(since(activation(of(PEAR1(in(human(platelets(is(independent(from(
Syk3,(we(hypothesized(that( the(SykAindependent(DxSAinduced(platelet(aggregation( involves(
















MATERIALS AND METHODS 
(
Reagents 
Watersoluble( dextran( sulphate( sodium( salt( (Mr( 500K),( dimethylsulfoxide( (DMSO)( and( antiAPLCγ2(were( from(
SigmaAAldrich((St.(Louis,(USA).(The(dextran(polymer(is(the(result(of(approximately(95%(alphaADA(166)(linkages.(
For(the(longest(molecules,(branching(up(to(50(glucose(units(has(been(measured((data(sheet(Sigma).(The(human(
and(mouse( SykAinhibitor( BAY( 61A3606( was( from( Santa( Cruz( (Dallas,( USA).( The( PI3K( inhibitor( LY294002( was(
purchased( from( Calbiochem( (California,( USA)( and( the( SFK( inhibitor( PP1( from( Enzo( Life( Sciences( (Antwerp,(
Belgium).(The(αIIbβ3Aantagonist(eptifibatide(was(from(GSK((Integrilin®).(The(4G10/antiAPATyrAantibody(was(from(
Millipore( (Overijse,(Belgium).(Rabbit(monoclonal(antibodies(against( the(phosphorylated( (human(and(murine)(
form(of(Akt((pSerA473),(Syk((pTyrA352)(and(PLCγ2((pTyrA759)(and(polyclonal(antibodies(against(total(Akt,(total(βA
actin( and( total( Syk( were( from( Cell( Signaling( Technology( (Bioké,( The( Netherlands).( The( antiAGAPDH/Gapdh(
antibody( was( from( Fitzgerald( (Acton,( USA).( Horseradish( peroxidaseAconjugated( secondary( antibodies( were(









sFcεR1α, s5FcεR1α, sPEAR1 and s5PEAR1 
Monomeric(recombinant(FcεR1α(protein,(pentameric(recombinant(FcεR1α(protein((s5FcεR1α)(and(pentameric(
recombinant(PEAR1((s5PEAR1)(constructs(were(designed,(produced(and(validated(as(recently(published(by(our(
group.4( A( human( recombinant( extracellular( PEAR1Adomain( was( made( by( cloning( the( corresponding( mRNAA
fragment,(encoding(aminoAacids(residues(Met1ASerA754( into(the(pSecTag2/Hygro(AAvector( (Life(Technologies,(
Ghent,( Belgium).( ( The( resulting( construct( was( transfected( in( COSA7( cells( using( a( jetPRIME( transfection( kit(
(Polyplus,( Leuven,( Belgium)( according( to( the( manufacturer’s( protocol.( Conditioned( medium( containing( the(
extracellular( PEAR1( recombinant( protein( was( collected( after( 48( hours.( ( The( presence( of( homogeneous(
recombinant(PEAR1Aprotein(in(the(medium(was(confirmed(by(western(blot((Mr(125(kDa).((
)





DxS( was( investigated( by( coAincubation( of( PEAR1( with( DxS( during( the( first( binding( step.( Bound( antiAPEAR1(
antibodies(were(detected(via(HRPAconjugated(rabbit(antiAgoat(IgG((1/2000,(in(TBS(+(0.1%(BSA(for(1(hour,(RT).(
Binding(was( visualized(by( the(addition(of( 100(μl( chromogenic( substrate( (TMB)( for(30(min.( The( reaction(was(





the(presence(of(0.1( IU/ml(of(apyrase( (SigmaAAldrich).(Platelet(aggregation(was(monitored(by(measuring( light(
transmission( through( the(stirred(suspension(of(washed(platelets( (3(×(105/μL)(at(37°C(with(a(Chronolog(dualA
beam(aggregometer,( in( the(absence(of( added( fibrinogen.( In( some(experiments,(platelets(were(preincubated(
with(LY294002((5(minutes,(50(μM),(PP1((10(minutes,(10(μM),(DMSO((5(minutes),(eptifibatide((10(minutes,(10(
µg/ml)(or(BAY(61A3606((10(minutes,(10(μM)(at(37°C.(The(DMSO(concentration(never(exceeded(0.2%((vol/vol).(
Platelet( aggregation( was( triggered( by( DxS( after( adding( Ca2+( (2( mM)( and( measured( and( expressed( as( the(
percentage(of(change(in(light(transmission,(with(the(value(for(the(blank(sample((buffer(without(platelets)(set(at(
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Static platelet incubation 
Washed(platelets(were(prepared( as( previously( published.3( In( some(experiments,( platelets( (4( ×( 105/μL)(were(
incubated(under(static(conditions,((i.e.(unstirred)(with(DxS((15(min),(DxS(5K((15(min),(sFcεR1α((15(min;(excess(










Pear1( (1/1000),( antiAAktAP( (1/500),( antiAAkt( (1/1000),( antiASyk( (1/1000),( antiASykAP( (1/1000),( antiAPLCγ2AP(
(1/1000),( antiAPLCγ2( (1/1000),( antiAβAactin( (1/1000),( antiAphosphotyrosine( (PATyr)( 4G10( (1/1000)( and( antiA
GAPDH/Gapdh( (1/10.000).( After( adding( complementary( horseradish( peroxidase–conjugated( secondary(
antibodies,( immunoreactive( bands( were( visualized( by( ECL( (Amersham( Biosciences)( on( a( BioARad( Universal(
Hood( II( Imager( model.( Each( Western( blot( is( the( representative( image( of( at( least( three( independent(
experiments.(
PEAR1/Pear1Aphosphorylation( on( Tyrosine( residues,( referred( to( as( pPEAR1( or( pPear1,( was( evaluated( after(
immunoprecipitation( with( antiAPEAR1/Pear1AAb( and( detection( of( PATyr( by( 4G10,( as( previously( described;(
membranes(were(stripped(and(reprobed(for(total(PEAR1/Pear1(detection.3((
(
Isolation of Pear1-/- platelets 
The( Pear1+/&( mouse( (Pear1tm1a(KOMP)Wtsi;( C57BL/6NAbackground)( was( acquired( through( courtesy( of( the(
International( Mouse( Phenotype( Consortium( (IMPC;( EPD0299_2_C05).( Pear1+/&( mice( were( mated( to( obtain(



















diluted( threefold( in(ACD(and( centrifuged( for( 10(minutes( at( 2000( rpm( to( collect( the(platelet( pellet.( Platelets(




















DxS induces human and murine platelet aggregation 
 
DxS( induced(a( concentrationAdependent( aggregation(of( stirred(washed(human( (Figure(2A)(
and(murine( (Figure( 2B)( platelets( in( the( concentration( range( previously( shown( to( provoke(
platelet(activation(and(ATP(secretion.5(Getz(et)al.(performed(murine(platelet(aggregations(in(
the(presence(of(DxS(5(nM.(We(did(not(observe(substantially(altered(aggregation(of(murine(
platelets( for( DxS( 0.25( nM( compared( to( DxS( 5( nM( (Figure( 2B).( The( DxSAinduced( human(
platelet( aggregation( was( abrogated( in( the( presence( of( the( αIIbβ3Areceptor( blocker(
















DxS induces direct PEAR1 activation 
 
As(previously( published(by( our( group,3( PEAR1(phosphorylation( can( be( the( result( of( direct(
PEAR1Aactivation( via( a( PEAR1Aligand( interaction( or( it( can( be( triggered( indirectly( following(
plateletAplatelet(contact(as(part(of(platelet(amplification(induced(by(various(classical(platelet(






Activation( of( platelets( with( a( specific( PEAR1( ligand( (e.g.( soluble( recombinant( pentameric(
FcεR1α( (s5FcεR1α)( or( antiAPEAR1AextracellularAantibodies,( Figure( 3A)( and( activation( of(
platelets(with( traditional( platelet( agonist( (e.g.( collagen( or( thrombin,( binding( to( their( own(
classical(receptors;(Figure(3B)(result(both(in(platelet(aggregation(and(PEAR1Aphosphorylation(
under(stirring(conditions.(However,(blocking(the(αIIbβ3Areceptor(under(stirring(conditions( in(
the( direct( PEAR1Aactivation( pathway( (Figure( 3C)( preserves( the( phosphorylation( of( PEAR1,(
although( aggregation( is( absent.( In( contrast,( blocking( the( αIIbβ3Areceptor( in( the( indirect(
PEAR1Aactivation(pathway((Figure(3D)(results(in(abrogation(of(the(PEAR1Aphosphorylation.((
Therefore,( to( illustrate( that(DxS( binds( directly( to( PEAR1,(we( analysed(DxSAinduced( PEAR1(
phosphorylation( under( stirring( conditions( in( the( presence( of( an( αIIbβ3Areceptor( blocker(
(Figure( 3C)( or,( alternatively,( under( static( conditions( (Figure( 3E( and( 3F)( to( avoid( indirect(












Figure( 3)( via( a( PEAR1Aligand( (e.g.( soluble( recombinant( pentameric( FcεR1α( (s5FcεR1α)( or( antiAPEAR1A
extracellularAantibodies)( interaction( or( can( be( triggered( indirectly( (#( in( Figure( 3)( as( part( of( platelet(
amplification(with(traditional(platelet(agonists((e.g.(thrombin,(collagen).(This(has(been(schematically(shown(in(
Figure(3(and(confirmed(by(western(blot( for(pPEAR1((PEAR1( immunoprecipitation(and(western(blot( for(PATyr;(
Figure(3G).(Direct(activation(of(platelets(by(a(specific(PEAR1Aligand(under(stirring(conditions((Figure(3A)(results(
in( direct( PEAR1Aphosphorylation( via( a( PEAR1Aligand( interaction( and( indirect( PEAR1Aphosphorylation( via(
plateletAplatelet( contact.( This( is( in( contrast( with( platelet( activation( under( stirring( conditions( with( classical(
platelets(agonists((Figure(3B),(where(only(indirect(PEAR1Aphosphorylation(occurs(via(plateletAplatelet(contact.(
Incubation( of( platelets(with( a( specific( PEAR1Aligand( in( nonAaggregating( conditions( (stirring( conditions( in( the(




















a) Static incubation of washed human platelets with DxS 
(
Static( incubation( of(washed(human(platelets(with(DxS( (0A10( nM)( for( 15(min( resulted( in( a(
doseAdependent( PEAR1( phosphorylation( comparable( to( that( induced( by( antiAPEAR1A
antibodies((PEAR1(immunoprecipitation(and(western(blot(for(PATyr;(Figure(4A).(In(agreement(
with( Figure( 3E( and( 3F,( this( phosphorylation( is( compatible( with( direct( binding( of( DxS( to(
PEAR1.((
(
b) Stirring conditions in the presence of an αIIbβ3-receptor blocker 
(
To( further( investigate( a( direct( interaction( between( DxS( and( PEAR1,( we( investigated( the(
phosphorylation( state( of( PEAR1( in( DxSAinduced( platelet( aggregation( in( the( presence( of(
eptifibatide( (Figure( 4B;( antiAPEAR1AAb( served( as( a( positive( control).( The( phosphorylation(





Next,( we( confirmed( the( direct( binding( of( DxS( to( PEAR1( by( competition( experiments( for(
PEAR1(with( its(physiologic( ligand(FcεR1α.(We(previously( reported( that(phosphorylation(of(
PEAR1( requires( clustering( of( the( PEAR1Areceptor.3,( 4( As( summarized( in( Figure( 4C,( static(
incubation( of( platelets( with( a( (divalent)( antiAPEAR1AextracellularAantibody( or( with(
pentameric( recombinant( FcεR1α( (s5FcεR1α)( resulted( in( PEAR1Aactivation( whereas(
incubation(with( FabAfragments( of( the( antiAPEAR1Aantibody8( or(with( a(monomeric( form( of(




were( preAincubated( with( an( excess( of( recombinant( pentameric( PEAR1( (s5PEAR1),(
compatible(with(the(direct(binding(of(pentameric(s5PEAR1(to(DxS(and(thus(competing(with(
DxS( binding( to( platelet( PEAR1.( Similarly,( DxSAinduced( PEAR1( phosphorylation( is( blocked(
when( platelets( were( preAincubated( with( an( excess( of( monomeric( sFcεR1α,( shielding( the(
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PEAR1Areceptor( from( DxSAmediated( PEAR1Aclustering.( Since( we( were( interested( in( direct(
phosphorylation( of( PEAR1,( these( competition( experiments( were( performed( under( static(
conditions.((
We( also( confirmed( the( direct( interaction( of( DxS( to( PEAR1( through( ELISA;( the( binding( of(




















(A)( Static( incubation( of( human( platelets( with( DxS( resulted( in( concentrationAdependent( phosphorylation( of(





shielding/blocking(monovalent( antiAPEAR1AAb( Fab(or(monomeric( sFcεR1α,( as( previously( shown.3,(4( (D( and( E)(
Static( incubation( of( washed( human( platelets( with( DxS( in( competition( with( an( excess( of( the( PEAR1(
shielding/blocking( monomeric( sFcεR1α( (D)( or( an( excess( of( recombinant( pentameric( PEAR1( (s5PEAR1;( E)(
resulted( in( reduced( PEAR1Aphosphorylation.( These( experiments( were( performed( under( static( conditions( in(
order(to(avoid(indirect(PEAR1Aactivation(as(shown(in(Figure(3.((F)(Competitive(ELISA(for(the(binding(of(soluble(
PEAR1(to(its(coated(ligand((pentameric(s5FcεR1α)(in(the(presence(of(increasing(concentrations(of(DxS((500K;(1A
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which( DxS( induces( PI3K/αIIbβ3( Amediated( platelet( activation.( Therefore,( we( investigated(
whether( Syk/PLCγ2Aactivation( together( with( PEAR1/AktAactivation( is( sufficient( to( explain(
DxSAmediated( platelet( aggregation.( ( Indeed,( we( showed( that( DxSAinduced( platelet(
aggregation( (Figure( 5A;( left( panel)( could( be( completely( blocked( after( preAincubation(with(
sFcεR1α( (shielding(the(PEAR1(receptor)(plus(the(SykAinhibitor(BAY(61A3606,(coinciding(with(
abrogated(Akt(and(SykAphosphorylation((Figure(5A,(right(panel,(western(blot).((
The( PEAR1( antagonist( sFcεR1α( alone( incompletely( blocked( aggregation,( without( affecting(
the(degree(of(Syk(phosphorylation((Figure(5B).(Correspondingly,(inhibition(of(the(Syk/PLCγ2A
pathway( after( preincubation( with( the( selective( SykAinhibitor( BAY( 61A3606( only( partially(
reduced( DxSAmediated( human( platelet( aggregation( (Figure( 5C).( The( phosphorylation( of(
PEAR1(and(Akt(remained(unaffected(in(the(presence(of(BAY(61A3606((Figure(5A;(right(panel),(
because(of(the(lack(of(SykAinvolvement(in(PEAR1Asignalling,(as(previously(reported.3((










(A)( DxSAinduced( human( platelet( aggregation( was( completely( abrogated( by( combined( preincubation( of( the(
PEAR1Ablocking(ligand((sFcεR1αAmonomer)(and(the(selective(SykAinhibitor(BAY(61A3606(((left(panel),(indicating(
that( blocking( PEAR1( together( with( Syk( is( sufficient( to( explain( DxSAinduced( human( platelet( aggregation;(
corresponding( western( blot( for( phosphorylation( of( PEAR1,( Akt( and( Syk( (right( panel)( in( the( presence( of(
monomeric(sFcεR1α(and/or(BAY(61A3606.((B(and(C)(DxSAinduced(platelet(aggregation(was(partially(reduced(by(
preincubation(with(monomeric( sFcεR1α( (B)(or(with( the( selective(SykAinhibitor(BAY(61A3606( (C);( right(panels:(






DxS and Pear1-signalling in murine platelets 
(
This(is(the(first(manuscript(using(Pear1&/&(platelets.(Therefore,(we(firstly(investigated(whether(
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absent( in( washed( Pear1&/&&platelets( (Figure( 6A).( Similar( to( human( platelets,( incubation( of(
washed( murine( WT( platelets( with( a( polyclonal( murine( antiAPear1AAb( resulted( in(
phosphorylation(of( Pear1( and( similar( phosphorylation(was( observed( after( incubation(with(




by( the( PI3KAinhibitor( LY294002( (Figure( 6D;(western( blot).( These( findings( identify( a( similar(
signallingApathway( for( PEAR1( in( human( and( murine( platelets.( In( order( to( avoid( indirect(





(A)(Confirmation(of( absence(of(Pear1Aexpression( in(Pear1&/&)vs.(WT(platelets.( (B)( Static( incubation(of(WT(and(
Pear1&/&)platelets(with(0.25(nM(DxS(resulted(in(Pear1Aphosphorylation(of(WT(platelets((compatible(with(direct(
DxSAinduced(Pear1Aphosphorylation(in(murine(platelets)(and(its(absence(in(Pear1&/&)platelets,(used(as(a(negative(
control.( (Western( blot;( pPear1:( PATyr( after( immunoprecipitation( for( Pear1;( Polyclonal( Pear1AAb( serves( as(
positive( control).( (C)( DxSAinduced( Pear1Aphosphorylation( under( static( conditions( was( abrogated( by(
preincubation(with(PP1((inhibitor(of(SFK;(10(µM).( (D)(Static( incubation(of(two(separate(murine(platelet(pools(
(lane(2(and(3)(with(DxS(resulted(in(phosphorylation(of(Akt,(which(was(abolished(after(preincubation(with(PP1(or(



























Pear1-/-platelets confirm that DxS-induced platelet aggregation is mediated via Pear1 
and CLEC-2/Syk 
The( DxSAinduced( platelet( aggregation( in( Pear1&/&&platelets( was( reduced( and( reversible(
compared( to( WT( platelet( aggregation( (Figure( 7A;( left( panel),( compatible( with( a( weaker(
Pear1Ainduced( αIIbβ3Aintegrin( stabilisation( and( thus( decreased( aggregate( stability.(
Corresponding( western( blots( of( Pear1&/&) platelets( compared( to( WT( platelets( resulted( in(
strongly(reduced(phosphorylation(of(Akt(in(Pear1&/&&platelets(whereas(phosphorylation(of(Syk(
and( PLCγ2(was( not( affected( (Figure( 7A;( right( panel).( Finally,(we( showed( that( the( residual(
DxSAinduced(platelet( aggregation(of(Pear1&/&( platelets( could(be( fully( abrogated(by( the( SykA





























Figure) 7) –) Pear1&/&) platelets) confirmed) that) DxS:induced) platelet) aggregation) is) mediated) via) Pear1) and)
CLEC2/Syk)
(A)( DxSAinduced( platelet( aggregation( in( Pear1&/&( platelets( was( weaker( and( displayed( decreased( platelet(
aggregate( stability( compared( to( WT( platelets,( compatible( with( a( weaker( Pear1Ainduced( αIIbβ3Aintegrin(
stabilisation( (left( panel);( corresponding( western( blot( for( phosphorylation( of( Akt,( Syk( and( PLCγ2( showed( a(
strongly( reduced,( but( not( completely( abrogated,( phosphorylation( of( Akt( in( DxSAinduced( Pear1&/&( platelet(
aggregation,(whereas(the(Syk/PLCγ2Aactivation(remained(unaffected.((B)(DxSAinduced(platelet(aggregation(was(
fully( eliminated( in(Pear1&/&( platelets( after( preincubation(with( a( SykAinhibitor,( indicating( that( Pear1A( and( SykA



















murine( platelet( activation( both( via( a( SykAdependent( 5,(10( and( a( SykAindependent( pathway,(
the( latter( involving( PI3KAmediated( phosphorylation( of( Akt.5( Alsheri(et) al.( recently( showed(
that( the( SykAdependent( pathway( through( which( DxS( induces( platelet( aggregation( is(
predominantly(mediated(via(CLECA2(7,(but(the(platelet(surface(receptor(s)(responsible(for(the(






platelet(aggregation,( compatible(with(our(previous( findings,( showing( that(PEAR1Asignalling(




under( stirring( conditions( in( the( presence( of( an( αIIbβ3Areceptor( blocker,( in( order( to( avoid(
indirect( PEAR1Aphosphorylation( induced( by( PEAR1A( FcεR1α( interactions( during( plateletA
platelet(contacts.(We(also(performed(competition(experiments(with(an(excess(of(the(PEAR1A
blocking(sFcεR1αAmonomer(4((shielding(the(receptor(and(preventing(PEAR1Amultimerisation)(
and(by(an(excess(of( soluble(pentameric(PEAR1( (s5PEAR1),( inhibiting( the(binding(of(DxS( to(
platelet( PEAR1.(All( these( results( identified(DxS(as( a(direct( activating( ligand( for(PEAR1(and(
excluded( indirect( activation(of(PEAR1( through(DxS,( as( seen(during(platelet( aggregation(by(
classical(agonist,(e.g.(collagen(and(thrombin.(((







by( a( selective( SykAinhibitor( 11,( 12( also( mildly( reduced( the( DxSAinduced( human( platelet(
aggregation,( whereas( it( did( not( affect( phosphorylation( of( PEAR1.( Furthermore,( the(
combined( preincubation( with( selective( blockers( of( both( the( PEAR1( and( SykApathway(
completely( abrogated( DxSAinduced( platelet( aggregation( as( well( as( PEAR1A( and( SykA
phosphorylation.( All( these( results( suggested( that( both( receptors( independently( but(
additively( initiate(DxS(αIIbβ3Amediated( human(platelet( aggregation.( To( further( support( our(









reached( with( a( polyclonal( antiAmPear1AAb( (positive( control).( Interestingly,( DxSAinduced(
Pear1&/&&platelet( aggregation( was( reduced( and( reversible,( compared( to( WT( platelet(
aggregation,( compatible(with( a(weaker(Pear1Ainduced(αIIbβ3Aintegrin( stabilisation(and( thus(
decreased( aggregate( stability,( in( line( with( our( findings( in( human( platelets.3( The( Pear1&/&(
platelet( aggregation( by( DxS( was( reduced( compared( to( WT( platelets( but( not( completely(
abrogated,( confirming( that( Pear1( is( not( the( only( surface( receptor( on( mouse( platelets(
activated( by( DxS( during( platelet( aggregation,( in( agreement( with( previous( reports.7,( 10(
Corresponding(western(blots(showed(that(DxS(only(induced(minimal(phosphorylation(of(Akt(
in(Pear1&/&(platelets,(whereas(SykA(and(PLCγ2Aphosphorylation(were(comparable( to( that( for(
WT( platelets( activated( by( DxS.( Ultimately,( we( found( that( the( DxSAinduced( platelet(
aggregation(of(Pear1&/&(platelets(was(abrogated(after(preincubation(with(a(SykAinhibitor.(This(
indicated( that( the( remaining( platelet( aggregation( of( Pear1&/&( platelets( was( fully( SykA
dependent,( confirming( that( Pear1A( and( SykAsignalling( both( are( sufficient( to( explain( DxSA
induced(murine(platelet(aggregation,(as(seen(in(human(DxSAinduced(platelet(aggregation.(
(
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The( major( platelet( receptors( that( employ( SFK( and( Syk( are( the( platelet( receptor( for(
podoplanin( CLECA2,( the( major( collagen( receptor( GPVI( and( the( platelet( receptor( for( von(
Willebrand(GPIb.(As(mentioned(above,(Alsheri(et)al.(recently(found(that(DxS(activates(both(
GPVI(and(CLECA2,(with(a(clear(preference(for(CLECA2(over(the(collagen(receptor.(They(found(
reduced( platelet( aggregation( in( CLECA2Adeficient( and( in( GPVI/CLECA2( double( deficient(
platelets,(whereas(the(response(to(DxS(was(not(altered(in(GPVI(deficient(platelets.7(Although(
the( DxSAinduced( AktAphosphorylation( was( strongly( reduced( during( aggregation( of( Pear1&/&(
platelets,(it(was(not(completely(absent.(This(is(in(agreement(with(the(recent(report(of(Manne(
et)al.(10,(who(showed(that(the(PI3K/AktApathway(is(a(downstream(player(of(CLECA2,(further(
supporting( that( CLECA2( is( the( Syk( coupled( receptor( responsible( for( DxSAinduced( platelet(
aggregation.(However,(our(data(show(that(PEAR1Aactivation(is(the(major(trigger(for(the(DxSA
induced(AktAsignalling( and( that( there( is( only( a(minor( role( for(Akt( in(DxSAactivated(Pear1&/&(
platelets,(downstream(of(CLECA2.(
)
In( conclusion,( DxS( is( a( direct( ligand( of( PEAR1,( causing( αIIbβ3Aactivation( via( the(
PEAR1/PI3K/AktApathway(and(via(the(complementary(activation(of(Syk,(both(in(human(and(
murine( platelets.( The( major( effect( of( DxS( on( AktAactivation( results( from( PEAR1A
phosphorylation(via(cASrc(through(clustering(of(the(receptor(and(direct(activation(of(PEAR1,(
whereas( DxSAinduced( SykAsignalling( occurs( independently( from( PEAR1Apathway( activation.(
The( direct( PEAR1Asignalling( in( human( and(murine( platelets( is( similar( and( Pear1( stabilizes(
murine(platelet(aggregates.((
(
Further( research( will( have( to( define( whether( DxSAinduced( platelet( aggregation( can( be( of(
importance(in(certain((physio)pathologic(processes(and(further(research(in(Pear1&/&(mice(will(
need( to(address( the(contribution(of(Pear1( to( thrombus(stability( in(proper(models(of( flowA
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on& platelets& and& endothelial& cells& (ECs).& PEAR1& sustains& αIIbβ3Bactivation& in& aggregating&
platelets& and& attenuates& megakaryopoiesis& via& controlling& the& degree& of& AktB
phosphorylation.&Its&role&in&EC&biology&is&unknown.&The&aim&of&this&study&was&to&determine&
the& expression& of& PEAR1& in& human& endothelium&of& various& tissues& and& to& investigate& its&
role&in&ECs&in#vitro#and&in&angiogenesis,&using&Pear1,/,&mice.&&
&
PEAR1& is&present&on& the&membrane&and&on& filoB&and& lamellipodia&of&human&cultured&ECs&
and& its&expression&coincides&with&CD31& in&various&tissues.&PEAR1Bexpression& is&variable& in&
ECs& of& different& origin.& Lentiviral& knockdown& of& PEAR1& in& cultured& ECs& doubled& EC&
proliferation& and& significantly& stimulated& EC& migration,& in& turn& enhancing& in# vitro# tube&
formation& on&matrigel& through& the&Akt/PTENBdependent& p21/CDC2Bpathway.& Even&when&













Cardiovascular& disease& is& the& leading& cause& of& death& worldwide2,& in& part& due& to& various&
interactions& between& platelets& and& blood& vessels.& In& response& to& hypoxia,& ischemia,& or&
developmental&cues,&new&capillary&sprouts&are&formed&from&preBexisting&vessels&in&a&process&
called& angiogenesis.& These& newly& formed& blood& vessels& play& an& important& role& in& crucial&




The& formation& of& vessels& is& a& complex& process,& requiring& a& finely& tuned& balance& between&
numerous& stimulatory& and& inhibitory& signals.& Endothelial& growth& factors& (e.g.,& VEGF,& FGFs,&
angiopoietins,…)&are&of&particular&interest&because&of&their&key&role&in&angiogenesis,&wound&
healing,& arteriosclerosis,& and& inflammatory& reactions.3,& 6& A& major& signalling& event&
downstream&of&proBangiogenic& factors& is& the&activation&of&Akt,&which& is& tightly&balanced&by&
phosphatidylinositol&3Bkinase&(PI3K)&and&phosphataseBandBtensinBhomolog&(PTEN).7&
&




Various& genomeBwide& association& and& functional& genomic& studies& have& suggested& a& link&
between& common& single& nucleotide& polymorphisms& in& the& PEAR1Blocus& and& increased&
platelet&responses&to&standard&platelet&activation&agonists,&both&in&control&populations&and&
various&cohorts&of&patients&with&cardiovascular&disease.10B13&We&have&identified&a&functional&
role& for& PEAR1& during& platelet& activation& and& demonstrated& that& PEAR1Bsignaling& sustains&
the&activation&of&αIIbβ3& in&aggregating&platelets,& favouring&the& formation&of&stable&platelet&
aggregates.14&We&also&observed&that&PEAR1&attenuates&megakaryopoiesis&via&controlling&the&
activity& of& the& PI3K/Akt/PTENBpathway& during& megakaryocyte& progenitor& proliferation.15&
Nevertheless,&the&abundance&of&PEAR1Bexpression&in&ECs&and&its&role&in&these&cells&remains&
unknown.&
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&
To& understand& the& contribution& of& PEAR1& to& (neo)angiogenesis,& we& studied& the& effect& of&
PEAR1Bdeficiency& on& EC& proliferation,& migration& and& tube& formation& in# vitro& and& in& two&
revascularization&models#in#vivo#in&Pear1,/,&mice.&We&were&able&to&match&our&in#vitro&and&in#
vivo&data&with&the&phosphorylation&status&of&Akt,&a&central&player&in&vessel&assembly.16&!!
MATERIALS AND METHODS 
!




days),& to& avoid& senescence.& Senescence& was& monitored& by& measuring& eNOSBmRNA& by& qPCR17& in& all& nonB
immortalized&cells.&
All&HUVECs&and&HUAECs&used&in&this&manuscript&were&freshly&isolated&from&human&umbilical&veins&and&arteries&
of&healthy&volunteers,& the&day&after&birth,& following&a&modification&of& the&method&of& Jaffe&et#al.18&Cells&were&
extracted&using&0.2%&collagenase& type&1& (Gibco,& Life&Technologies,&Ghent,&Belgium),&and&seeded&on&gelatineB
coated& (0.1%)& culture& dishes& in& EBMB2& containing& EGMB2& BulletKit& (Lonza,& Walkersville,& USA)& and& cultured&
(37°C,& 5%& CO2)& until& they& reached& confluence.& Each& in# vitro& experiment,& performed& in& this& study,& has& been&
performed&with&HUVECs/HUAECs&isolated&from&at&least&3&different&umbilical&cords&(n=3),&with&each&data&point&
being& the&mean&value&of&3B4& replicates.&Formal&permission&was&given&by& the&ethics&committee&of& the&Leuven&
University& Hospitals& to& use& human& umbilical& cords& (Ref& nr.& ML8663& –& Approval& S54528)& and& an& informed&
consent&was&signed&by&each&mother.&&
BOECs& were& isolated& from& blood& of& healthy& volunteers,& as& previously& reported.19& A& more& detailed& method&





1.5%& sodium& bicarbonate& and& 0.5%& antibiotics& (penicillin,& 100U/ml& and& streptomycin,& 100& µg/mL)& and& was&
purchased& from&the&American&Type&Culture&Collection& (USA).&This& robust&and&stable&cell& line&has&most&of& the&
characteristics&of&primary&cultured&endothelial&cells.20&
Human&microvascular&(µ)ECs&were&freshly&isolated&from&heart&or&liver&biopsies,&as&described.21&For&human&heart&
ECs,& biopsies&were&digested&with&1.5&mg/mL& collagenase& I;& for&human& liver& ECs,& biopsies&were&digested&with&
0.08& Wunsch& U/mL& liberase& and& 39& U/mL& DNAse.& After& a& final& wash& in& PBS,& cells& were& resuspended& in&
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Fluorescence& Activated& Cell& Sorter& (FACS)& buffer,& filtered& with& a& 40& μm&mesh& and& sorted& directly& in& RLT& or&
TRIzol®&(+&1%&βBmercaptoBethanol&[BME])&for&RNA&extraction.&Sorting&was&done&based&on&the&Tie2+podoplaninB
CD45B& fraction&using& a& FACS&Aria& ITM&device.& For&murine&µECBisolation,& tissues& from&8B12&weeksBold&Tie2,GFP&
mice& were& dissected& out,& surrounding& connective& tissue& and& visible& large& vessels& removed& and& tissues&
enzymatically& digested& using& optimized& procedures& for& each& organ& [i.e.,& 1.2& U/mL& dispase& (BD),& followed& by&
Percoll&gradient&centrifugation&for&liver;&1.5&mg/mL&collagenase&I&for&heart],&as&described.21&After&a&final&wash&in&
PBS,& cells& were& resuspended& in& a& FACS& buffer& (PBS/EDTA,& 1& mmol/L/HEPES,& 25& mmol/L& /1%& Bovine& Serum&
Albumin&(BSA),&pH7),&filtered&through&a&40&µm&mesh&and&the&GFPBpositive&fraction&was&sorted&on&a&FACS&Aria&
ITM&(Beckton&Dickinson)&directly&in&RLT&(Qiagen)&or&TRIzol®&(+&1%&BME)&for&RNA&extraction.&Human&biopsies&were&
obtained& under& informed& consent.& Procedures& were& approved& by& the& University& Hospitals& Leuven.& All&
endothelial&cell&studies&were&performed&conform&the&declaration&of&Helsinki.   
 
Isolation of BOECs 
Briefly,&peripheral&blood&samples&were&diluted&twoBfold&in&PBS&and&centrifuged&on&Ficoll&Paque&(GE&Healthcare,&
17B440B02).& Buffy& coats& were& pooled& and& centrifuged& multiple& times& in& PBS.& Pellets& were& resuspended& in&
Endothelial& Basal&MediumB2& (EBMB2;& Lonza)&medium&and& seeded&on& collagen& typeBI& coated&dishes& (37°C,& 5%&
CO2)& for&30&days& (medium&was& changed&daily&during& the& first&week&and&every&2&days& thereafter)& after&which&
outgrowing& colonies&were& pooled& and&passaged.&After& 20B30&days,& typical& cobbleBstoneBlike& colonies& appear,&
showing&a&exceptionally&high&proliferative&phenotype,&so&called&BOECs.&These&cells&are&able&to&perform&deBnovo&
tube& formation& and& are& proBangiogenic.& BOECs& express& a& clear& endothelial& morphology& (cobble& stone& and&
WeibelBPalade&bodies)&and&phenotype&(positive&for&CD31,&VEGR2,&CD34,&VWF,&VEBCadherin,&eNOS),&comparable&
to&HUVECs.19,&22B24&Interestingly,&they&have&higher&expression&of&the&proBangiogenic&gene&Akt&(and&lower&PEAR1B
expression)& compared& to&HUVECs,&which& is& compatible&with& the&controlling& function& for&PEAR1&on&Akt/PTEN.&
BOECs&(Figure&1D)&were&immediately&harvested&for&cDNABsynthesis&after&isolation.!
 
Generation of lentiviral transfer plasmids 
Two& short& hairpin& (sh)Bbased&miRNA& lentiviral& vectors,& previously& designed& and& described& by& our& group,& i.e.,&
shPEAR1B1461& and& shPEAR1B2938,15& were& used& to& suppress& PEAR1Bexpression& in& various& EC& lineages.& Both&
constructs& were& equipotent& in& suppressing& PEAR1# in& various& ECs& (see& supplement)& and& are& designated&
“shPEAR1”& throughout& the&manuscript.&Most& experiments&were& performed&with& the& shPEAR1B1461& lentiviral&
vector,&unless&mentioned&otherwise.&Control&cells&were&transduced&with&a&nonBcoding&dsRed&lentiviral&vector15,&
further& referred& to& as& control& ECs.& PEAR1Bknockdown& was& achieved& by& plating& ECs& (HUVECs,& HUAECs& and&
EAhy926)& at&500& x103& cells& per& well& in& 12Bwell& plates& and& by& double& transduction& with& lentiviral& particles&
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Real-time quantitative PCR (qRT-PCR) 
Total&mRNA&was&extracted&with&the&Qiagen&kit&(RNeasy&mini&kit,&Hilden,&Germany)&from&cultured&cells.&cDNAs&
were& synthesized& using&MBMLV& reverse& transcriptase& (Invitrogen,&Ghent,& Belgium).&Human& and&murine& gene&
expression&was&measured&using&FAMBlabelled&TaqMan&assay&products&(PEAR1,#CIP1/CIP1,#PTEN,#HIF1α,#GAPDH;&
Applied&Biosystems,&Life&Technologies,&Ghent,&Belgium)&or&via&Sybr&Green&PCR&(FLK1,#CDH5,#ENOS#and#GAPDH;&
IDT,& Leuven,& Belgium).& qRTBPCR& reactions& were& analysed& using& an& ABI& 7000& realBtime& PCR& machine& (Life&







Na3VO4,&protease& inhibitor& cocktail).&Proteins&were& subjected& to&SDSBpolyacrylamide&gel&electrophoresis& (SDSB
PAGE)& and& transferred& to& nitrocellulose& membranes& in& a& TransBBlot& Turbo& apparatus& (BioBRad,& Nazareth,&
Belgium).&Membranes&were&incubated&with&various&primary&antibodies&overnight:&antiBPEAR1BEC&(1:1.000;&R&D&
Systems),& antiBHIF1α& (1:1.000;& R&D& Systems),& antiBβBactin& (1:1000;& Cell& Signaling),& antiBAktBP& (1:500;& Cell&
Signaling),& antiBErk1/2BP& (1:1.000;& Cell& Signaling),& antiBVEGF& and& VEGFR2& (1:500;& Cell& Signaling),& antiBp21&
(1:1,000;&Cell&Signaling),&antiBCDC2/BCdc2&(1:1,000;&Cell&Signaling;&membranes&were&stripped&and&reprobed&for&
GAPDH& as& loading& control),& antiBeNOSBS1177& (1:1000;& BD),& antiBGAPDH/BGapdh& (1:10.000;& Fitzgerald),& antiB
PTEN/BPten& (1:500;& Santa& Cruz),& antiBp53& (1:1000;& Santa& Cruz).& The& PI3KBinhibitor& LY294002& was& purchased&
from& Calbiochem.& After& adding& horseradish& peroxidaseBconjugated& secondary& antibodies,& immunoreactive&
bands& were& visualized& by& ECL& (Amersham& Biosciences,& Diegem,& Belgium).& The& band& intensity& was& digitally&
quantified&using&a&BioBRad&molecular&imager&(ChemiDoc&XRS+,&Nazareth,&Belgium).&&








(1:100;& AlexaBPhalloidin& 488),& CD31& (2& mg/L;& Dako);& and& with& the& appropriate& Alexa& 488–& or& 647–labelled&
secondary& antibody& (1:200;& Invitrogen)& for& 45&minutes& at& 37°C.& Coverslips&were&mounted&with&DAPI& Prolong&




Immunohistochemistry& (IHC)& for& tissue& sections& was& performed& using& standard& protocols& with& the& following&
antibody&dilutions:&PreBimmune&Rabbit&Ig&(1:5;&Dako),&human&antiBPEAR1BEC&Antibody&(5&mg/L;&R&D&Systems),&
murine&antiBPEAR1BEC&Ab& (3&mg/L;&R&D&Systems),&human&CD31& (2&mg/L;&Dako),&murine&CD31& (2&mg/L;&Dako)&
and&PCNA&(2&mg/L;&Dako).&Briefly,&sections&were&deparaffinised&using&xylol,&quenched&with&ethanol,&and&antigen&
retrieval&was&performed&using&Dako&Target&Retrieval& Solution& (S169984).& Subsequently,&we& incubated& tissues&
with&primary&antibodies&overnight& followed&by& incubation&with&secondary&antibodies& for&45&minutes&at& room&
temperature,& 30& minutes& of& streptavidinBHRP& (1:100;& Perkin& Elmer)& and& 8& minutes& of& amplification& diluent&
(1:50;&Perkin&Elmer).&Signals&were&detected&using&Diaminobenzidine&(DAB;&Sigma&Aldrich).& Images&were&taken&











cytoskeleton& buffer& pH& 6.9& and& stained& with& DAPI& Prolong& Gold& (Invitrogen,& Ghent,& Belgium).& A& blinded&
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Hind limb ischemia model 
Surgery#and#Isolectin#staining#gastrocnemius#muscle#
This&method&was&adapted&from&Limbourg&et&al.6&Briefly,&elevenBweekBold&C57BL/6NBmice&were&sedated&with&an&













and& temperature,& calculated&perfusion&was&expressed&as&a& ratio&of& the& ischemic& (left)& to&nonBischemic& (right)&




The& vasculature& in& the& gastrocnemius& muscle& was& visualized& 21& days& after& unilateral& (left)& femoral& artery&
ligation& in&Pear1+/+& (WT)&and&Pear1,/,&mice.&Therefore,&mice&were&sedated&with&an& intraperitoneal& injection&of&
ketamine&(125&mg/kg&body&weight)/xylazine&(12,5&mg/kg&body&weight)&and&perfused&with&0.2%&adenosine&for&
vasodilatation,&followed&by&4%&paraformaldehyde&for&fixation,&subsequently&saline&to&wash&out&the&fixative&and&
finally& with& a& preheated& solution& of& 30%& barium& sulphate& (Micropaque,& Guerbet)& as& contrast& agent& in& 2%&
gelatin.&Mice&were&stored&on&ice&at&4°C&overnight&to&solidify&the&gelatin&with&the&contrast&agent&in&the&vessels.&
After&overnight&solidification,&limbs&were&dissected&out,&stored&in&PBS&and&imaged&with&the&SkyScan&1172&microB
CT& system,& using& a& peak& tube& voltage& of& 50& kV,& a& current& of& 200&mA,& a& filter& of& 0.5&mm& aluminium& and& an&
exposure& time& of& 590&ms.& The& FDKBalgorithm&of& the&manufacturer& (NRecon,& SkyScan,& Kontich,& Belgium)&was&
applied& to& reconstruct& the& dataset& into& a& 3DBimage& with& isotropic& voxel& size& of& 8& µm.& The& dataset& was&





The& methods& used& to& harvest& muscles& tissues& and& the& methods& to& extract& protein& and& mRNA& in& order& to&
determine&the&concentration&of&HIF1α,&VEGF&and&VEGFR2&are&described&in&the&online&data&supplement.&&
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Ligated#muscle#tissue#harvest#and#protein/cDNA#extraction:#
Tissues& were& prepared& as& previously& described;28& after& an& intraperitoneal& injection& of& ketamine& (125&mg/kg&
body&weight)/xylazine&(12,5&mg/kg&body&weight),&the&left&proximal&femoral&artery&was&twice&ligated&and&cut&in&
the& middle& as& previously& described.& At& day& 4,& mice& were& sacrificed& using& an& overdose& of& intraperitoneal&
pentobarbital&(70&mg/kg).&The&gastrocnemius&muscles&(both&at&the&ligated&and&nonBligated&limb)&were&surgically&




4°C,& the& RNABcontaining& & colourless& upper& aqueous& phase& of& the& mixture& was& collected,& precipitated,& and&
washed&with& isopropyl& alcohol& and&75%&ethanol.&RNA&concentration&was&determined&by& spectrophotometry.&
For&protein&extraction,&middle&and&distal&parts&of& the&gastrocnemius&muscle&samples&were&weighed& (300B400&







Skin wound healing model 
Mice&were& sedated&with& an& intraperitoneal& injection& of& ketamine& (125&mg/kg& body& weight)& /& xylazine& (12,5&
mg/kg&body&weight).&FullBthickness&skin&wounds&(29&mm2)&were&made&on&the&back&of&Pear1,/,&mice&(C57BL/6N)&
and& their& littermates,& using& a& dermal& biopsy& puncher.&Wounds&were& splinted&with& a& silicone& ring& (Fig.& 15A),&
moistened&with&saline&and&covered&with&a&Tegaderm&dressing.&Every&other&day,&a&digital&picture&of&the&wounds&
was&taken&(Canon&digital&Camera)&and&wound&dimensions&were&measured&under&Isoflurane&anaesthesia&and&the&
dressing& was& renewed.& Mice& were& sacrificed& at& day& 4& or& day& 8& using& an& overdose& of& intraperitoneal&






replicates& represents& 3x6&measurements,& for&which& 3& averages& are& calculated,& reported& as&n=3).& Results& are&
expressed&as&mean&values&plus&or&minus&SEM.&Statistical&significance&was&evaluated&with&unpaired&Student’s&tB







PEAR1-expression in human ECs 
In&this&first&study&addressing&the&role&of&PEAR1&in&ECs,&we&performed&a&detailed&analysis&of&its&
expression& in& various& human& tissues& (Fig.& 1).& IHCBstaining& for& PEAR1& and& the& specific& EC&
marker& CD31& confirmed& comparable& expression&of& both& proteins& in& human& liver,& lung& and&
kidney,&substantiating&expression&of&PEAR1&in&ECs&primarily&(Fig.&1A).&Double&IF&staining&for&
CD31& and& PEAR1& coBlocalized& both& proteins& in& the& endothelium& of& the& human& renal&
glomerulus&(Fig.&1B).&IF&staining&for&PEAR1&in&freshly&isolated&HUVECs&(Fig.&1C;&upper&panel)&
and&confluent&immortalized&HUVECs&(EAhy926&cells;&Fig.&1C,&lower&panel)&revealed&PEAR1&in&
the& cell&membrane&and& in& the& filoB& and& lamellipodia&of&ECs.# PEAR1&mRNA&was&detected& in&
blood& outgrowth& endothelial& cells& (BOECs),& in& ECs& from& human& umbilical& cord& (EAhy926,&
HUAECs& and& HUVECs)& and& in&microvascular& ECs& (µECs)& isolated& from& the& vascular& beds& of&
human&liver&and&heart&and&lysed&immediately&after&isolation.&The&mRNA&expression&of&PEAR1&
was& heterogeneous&with& the& lowest& expression& in& less& differentiated& ECs& (BOECs)& and& the&
highest& in& freshly& isolated&µECs& from&heart&and& liver& tissue.&mRNA&of&HUAECs&and&HUVECs&
(lysed&immediately&after&isolation&from&umbilical&cords)&and&cultured&EAhy926&ECs&revealed&
intermediate& levels& of&PEAR1&mRNA& (Fig.& 1D).& Protein& levels& (WB)&were& low& in& BOECs& and&
comparable& for& HUAECs,& EAhy926& and& HUVECs.& Protein& levels& of& µECs& could& not& be&
determined,&due& to& the&small&amount&of&ECs& that&could&be& isolated& from&the&human& liverB&
and&heart&biopsies&only.&&
 
PEAR1-knockdown enhances EC proliferation 
To&investigate&the&role&of&PEAR1&in&ECs,&we&first&performed&a&knockdown&of&PEAR1#by&double&
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Knockdown of PEAR1 modulates EC proliferation via Akt/p21/CDC2 
Our& previous& work& demonstrated& a& tight& link& between& PEAR1& and& PI3K/AktBactivation& in&
platelets& and& megakaryocytes.14,& 15& To& unravel& the& mode& of& action& of& PEAR1& in& ECs,& we&
selected&the&immortalized&EAhy926&cells&to&avoid&effects&of&senescence&throughout&different&
cell& passage& numbers.&Western& blots& revealed& constitutively& increased& phosphorylation& of&
Akt& (Ser473)& in& shPEAR1& vs.& control& ECs& (Fig.& 5A;& 5.1Bfold& increase)& both& in& confluent& and&
nonBconfluent& cells,& indicating& a& confluenceBindependent& enhanced& AktBphosphorylation&
state.&The&MAPKBpathway&(Erk1/2)&was&not&affected&by&PEAR1Bknockdown&(Fig.&14).&At& the&
same&time,&we&found&a&decrease&of&PTENBexpression&(HUVECs&and&EAhy926)&and&p21/CIP1&




in& shPEAR1& ECs& was& reversed& to& basal& CDC2Blevels& in& the& presence& of& the& PI3KBinhibitor&
LY294002& (Fig.&5B),& indicating&a&direct& link&between& the&phosphorylation&of&Akt&and&CDC2B
expression,& explaining& the& association& between& increased& AktBP& and& the& upregulation& of&
CDC2& in& shPEAR1& ECs.& IFBstaining& of& EAhy926& cells& (shPEAR1# vs.& control& ECs)& for& p21& and&
nuclear&DAPI&showed&a&nuclear& localization&of&p21& in&control&ECs&and&a&strong&shift&of&p21&
towards&the&cytoplasm&in&shPEAR1&ECs,&consistent&with& increased&mitosis& (Fig.&6).&A&critical&







that& PEAR1& controls& the& expression&of& PTEN&and& that& the&drop&of& PTEN& in& shPEAR1& ECs& is&
associated&with&the&increased&phosphorylation&status&of&Akt,&leading&to&enhanced&cell&cycle&







Knockdown of PEAR1 enhances EC migration in vitro 
Migration&of&ECs&is&an&essential&process&in&(neo)angiogenesis30&and&is&known&to&be&mediated&
via& phosphorylation& of& Akt.30& Since& PEAR1& was& found& to& be& highly& expressed& at& filoB& and&
lamellipodia&of&ECs,&in&ECBruffles&and&at&the&migratory&border&of&low&confluent&ECs&(Fig.&8A),&
suggesting& a& role& for& PEAR1& in& EC&migration,& we& performed& in# vitro& migration& assays& and&
demonstrated& enhanced& cellular&migration& of& shPEAR1& HUVECs& vs.& control& ECs.&Migration&
was&analysed&within&a&12&hours&time&window&to&avoid&confounding&interference&of&effects&on&
EC&proliferation.&Analysis&of&the&migration&distance&in&a&cell&migration&assay&revealed&up&to&3B





PEAR1 controls in vitro tube formation 
Since&both&EC&proliferation&and&migration&are& important&players& in&blood&vessel& formation,&
we& further& investigated&whether& the& PEAR1Bknockdown&would& affect& tube& formation& in& a&
matrigel&assay,&using&control&and&shPEAR1&HUVECs&and&HUAECs.&Tubes&were&evaluated&16&
hours& after& EC& seeding& (Fig.& 9A).& We& observed& a& significant& increase& in& the& number& of&
branching& points,& number& of& tubes& and& of& the& total& tube& length& in& shPEAR1& HUVECs,&
compared& to& control& HUVECs& (Fig.& 9B).& Similar& results& were& found& for& both& shPEAR1&
constructs&(Fig.&9C)&and&for&lentiviral&transduced&HUAECs&(not&shown).&The&mRNA&levels&of&3&
typical& EC& markers& (KDR/VEGFR2,& CD31/PECAM1& and& VE,cadherin/CDH5)& were& mildly&
upregulated& during& tubulogenesis& but& no& significant& differences& between& control& and&
shPEAR1#ECs&were&observed&(Fig.&10),&suggesting&that&endothelial& identity&was&not&affected&
by& PEAR1Bknockdown.& The& expression& of& PEAR1& and& PTEN& was& measured& in& control& and&
shPEAR1&HUVECs&by&qRTBPCR&at&the&beginning&and&at&the&end&of&the&tube&formation&process&
(Fig.&9D).&PEAR1&was&upregulated&in&control&ECs&during&tubulogenesis&(left&panel),&in&parallel&
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Pear1 controls neoangiogenesis in vivo  






Hind& limb& ischemia& is& a& preBclinical& model& for& peripheral& arterial& disease,& where& both&
arteriogenesis&and&angiogenesis&are&induced&upon&femoral&artery&ligation.&After&the&ligation&
of& the&femoral&artery,& increased&shear&stress&triggers&outward&collateral& remodelling& in&the&
adductor& muscle,& while& the& more& distal& gastrocnemius& becomes& hypoxic,& triggering& an&
angiogenic& response& in& the& lower& leg.6,& 31& Therefore,& we& adopted& this& hypoxia& model& to&
investigate&angiogenesis&in&the&gastrocnemius&muscle&after&ligation&of&the&femoral&artery&in&
Pear1,/,&mice&vs.& littermates.&We&nonBinvasively&monitored&blood&flow&recovery&in&the&paws&
by& means& of& a& Laser& Doppler& system& over& a& period& of& 21& days& (Fig.& 12A;& left& panel;&





the& gastrocnemius&muscle& by& IF& staining& for& the& endothelial&marker& isolectin&GSBIB4& three&
weeks& after& the& induction& of& ischemia.6,& 31& The& density& of& isolectinBpositive& capillaries&was&
2.4Bfold&higher&in&Pear1,/,&compared&to&WTBmice,&which&supports&the&enhanced&angiogenesis&
in& the& gastrocnemius& muscle& in& Pear1,/,#mice& after& chronic& hind& limb& ischemia& (Fig.& 12B).&
Capillary& density& in& nonBligated& limbs& of& Pear1,/,& was& comparable& with& that& in& WTBmice;&
supporting&our&findings&that&PEAR1&does&not&affect&embryological&vascular&development&(Fig.&
12B).& A& 3D& reconstruction& by& microBCT& (CTBangiography& after& bariumBinstillation)& of& the&
gastrocnemius& at& the& ligated& side& (day& 21)& confirmed& a& stronger& angiogenic& response& and&
hence& denser& vascular& network& in& the& Pear1,/,& mice,& compared& to& WTBlittermates&
(representative& images& in&Fig.&12C).&MicroBCT& images&of&nonBligated&hind&limbs&revealed&no&
differences&in&vessel&density&between&Pear1,/,&mice&and&WTBmice&(Fig.&13);&in&agreement&with&
our& histological& analysis.& Various& reports& have& shown& a& role& for& PTEN& in& modulating&
angiogenesis.32B36&E.g.&in&pancreatic&cancer&cells,&PTEN&knockdown&increases&VEGF&secretion,&




Since& enhanced& AktBphosphorylation& can& result& in& enhanced& VEGFBactivity& (Fig.& 14A),& we&
assessed& the& concentration& of& these& major& proBangiogenic& molecules& VEGF/VEGFR& in&
enhanced& neoBangiogenesis& upon& knockout& of& Pear1.& We& performed& analyses& for& HIF1α,&
VEGFR2& (considered& the&major& receptor& that& transduces& the& effects& of& VEGF& in& ECs)39& and&
totalBVEGF& on& homogenized& tissues& of& ischemic& and& nonBischemic& gastrocnemius& muscles&
since& muscle& specific& VEGF/VEGFR2& levels& play& a& crucial& role& in& EC& proliferation& and&
angiogenesis.40&Tissue&levels&of&HIF1α&provide&a&marker&of&hypoxia/ischemia&and&are&known&
to&be&elevated&in&the&gastrocnemius&muscle&until&3B4&days&after&femoral&ligation.41&Therefore,&
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HIF1α&levels&and&VEGF/VEGFR2&levels&were&measured&at&day&4&postBligation,&since&this&is&also&




protein& expression& levels& for& VEGFR2& were& significantly& upregulated& after& ligation,&
compatible& with& previous& reports28,& but& again& no& significant& differences& in& VEGFR2B
expression&between&WT&and&Pear1,/,#mice&were&observed&(Fig.&14E).&&
Since&VEGF&is&a&strong&activator&of&Erk1/2&via&VEGFR242&and&since&Erk1/2&can&potentiate&the&
activity& of& HIF1α1,& we& investigated& the& phosphorylation& status& of& p42/p44& in& cultured&
EAhy926&ECs& in&the&absence&of&VEGF& in&the&EC&medium.&No&differences& in&phosphorylation&
state&of&p42/p44&were&observed&when&WT&ECs&were&compared& to&shPEAR1&ECs& (Fig.&14D),&
again&confirming&that&VEGFBproduction&by&ECs& is&not&affected&upon&PEAR1BKD.& & It&has&been&
reported& that& the& tumour& suppressor& gene& p53&suppresses& cell& proliferation& and&tube&
formation/angiogenesis&through& inhibition& of& the& PI3K/AKT/mTOR& pathway& and& through&
inhibition&of&HIF1α,&although&its&role&in&angiogenesis&is&not&clear&at&this&moment.43&In&view&of&








the& only& Pear1Bpositive& cells& in& murine& skin& tissues& (Fig.& 16;& left& panel)& vs.& the& expected&
absence&of&Pear1& in&skin&of&Pear1,/,&mice& (Fig.&16;& right&panel).&Fig.&15A&(left&panel)& reports&
wound&healing&up&to&day&8.&At&day&2,&we&observed&a&significantly&decreased&wound&size& in&





IHC& at& day& 8& (CD31& staining;& Fig.& 15B),& quantification& in& Pear1,/,& mice& vs.& WT& littermates&




number& of& blood& vessels& coincided&with& an& increased& proliferative& response,& as& shown& by&
PCNABstaining& in& the& wound& bed& of& Pear1,/,& mice& vs.& their& WTBlittermates;& Fig.& 17).& To&
correlate&the&underlying&mechanistic&pathway&responsible&for&this&enhanced&vascularization&














































































































































































































































































































































































































































































































PEAR1& is& a& transmembrane& protein& expressed& on& the& cellular& border& and& on& filoB& and&
lamellipodia&of&ECs.&So&far,& the&role&of&PEAR1Bsignalling& in&the&vascular&endothelium&during&




In& various&human& tissues,& the&presence&of&PEAR1& in&ECs&was&demonstrated&both&at&mRNA&
and&protein& level.&We&observed&a& lower&PEAR1Bexpression& in& rapidly&proliferating& cultured&
ECs& (BOECs,& HUVECs& and& HUAECs)& and& a& higher& expression& in& slowBproliferating& µECs& of&
heart& and& liver.& Also& in& rapidly& proliferating& ECs& of& a& pyogenic& granuloma,& a&





shPEAR1#CD34+& cells.15& This& hypothesis&was& confirmed& by& lentiviral& knockdown& of& PEAR1;&






Next,& we& unravelled& the& underlying& mechanistic& pathway& responsible& for& enhanced& EC&




of& the& expression& of& the& phosphatase& PTEN,& priming& ECs& to& adopt& a& more& proliferative&
phenotype.&This&is&in&line&with&our&previous&report&showing&that&a&similar&PEAR1Bdependent&
AktBdriven&mechanism&is&operative&during&megakaryopoiesis.15&Cell&cycle&progression&in&ECs&
is& tightly& regulated&by& the& family&of& cyclinBdependent& kinase& inhibitors.& The& increased&AktB
activity&upon&PEAR1Bknockdown#was&associated&with&a&decrease&of&nuclear&p21CIP1/WAF1&and&
elevated& the& cytosolic& localization& of& p21CIP1/WAF1,& an& important& regulatory& mechanism& of&
mitosis.49& These& findings& provided& a& molecular& basis& for& the& enhanced& CDC2Bdriven& EC&
proliferation.&Indeed,&p21CIP1/WAF1&inhibits&the&activity&of&CDC2,&a&cyclin&that&regulates&G2BtoB
M&transition&during&cell&division.50&In&HERB2/neuBoverexpressing&cells,&it&was&established&that&
growth& inhibition& is& coupled& to& nuclear& localization& of& p21CIP1/WAF1.& PI3K/AktBdriven&









VEGFBcontaining& basement& membrane& extracellular& matrix& (Matrigel).& This& differentiation&
process,& used& as& an& in# vitro& assay& of& angiogenesis,& involves& several& steps& in& blood& vessel&
formation,& including& cell& adhesion,& migration,& alignment& and& tubule& formation.54,& 55& We&
observed& an&upregulation&of&PEAR1& during& tube& formation& in# vitro& and&we& illustrated& that&
endothelial& PEAR1Bknockdown# boosted& the& in# vitro& tube& formation,& underpinning& a&







a& lack& of& the& physiological& PTENBenrichment& during& tubulogenesis,42,& 59& indicating& a&
permanent& lack& of& dephosphorylation& of& Akt& during& shPEAR1& tube& formation.& Expression&
levels& of& other& important&markers& of& terminal& EC& differentiation& (VE,cadherin,&VEGFR2& or&
PECAM1)&were&not&significantly&affected&during&tube&formation&upon&PEAR1Bknockdown.& It&
has& been& reported& that& critical& roles& of& Akt& in& angiogenesis& can& be& regulated& by& the& AktB
downstream& effector& eNOS.60,& 61& Enhanced& nitric& oxide& (NO)& synthesis& could& be& the&
explanation& for& the& increased& EC& proliferation& and& angiogenesis,& observed& upon& PEAR1B
knockdown.&However&we&observed&no&differences&in&eNOSBphosphorylation&(activating&site,&
S1177)&upon&PEAR1Bknockdown,&could&not&detect&any&differences&in&NOBproduction&(DAFBFM&




Vascular& assembly& is& a& complex& interaction& between& EC& proliferation,& migration& and&
sprouting.30&PEAR1&was&strongly&positive&at&the&tips&of&endothelial&filoB&and&lamellipodia&and&
was&found&to&be&expressed&in&endothelial&ruffles.&Since&we&found&enhanced&tube&formation&
at& early& timeBpoints& on& matrigel& assays& upon& PEAR1Bknockdown& and& since& it& has& been&
previously& reported& that& constitutively& enhanced& phosphorylation& levels& of& Akt& strongly&




constitutively& enhanced& phosphorylation& levels& of& Akt& upon& PEAR1Bknockdown.& Several&
downstream& mediators& of& Akt,& responsible& for& enhanced& migration& have& been& suggested&





mice& showed& no& overt& vascular& phenotype& and& detailed& IHC& and& angiographic& analyses& of&
various&murine&tissues&did&not&detect&abnormalities&in&blood&vessels&in&the&absence&of&Pear1.&
However,& after& femoral& artery& occlusion& in& Pear1,/,& mice,& we& observed& a& faster&
neoangiogenesis&in&the&gastrocnemius&muscle.&Angiogenesis,&i.e.,&the&sprouting&of&capillaries&
and&proliferation&of&ECs& from&the&preBexisting&vasculature,& is&mainly& initiated&by&hypoxia& in&
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ischemic& tissue& and& is& different& from& vasculogenesis& (i.e.,& de# novo& vessel& growth&
processes).31,& 41,& 64,& 65& Various& reports& show& evidence& that& surgical& ligation& of& the& femoral&
artery& leads& to& an& angiogenic& response& in& distal& ischemic& muscles.6,& 31,& 64& Therefore,& we&
focused& on& neoangiogenesis& in& the& gastrocnemius& muscle& at& day& 21& and& used& isolectin&





tissue.& Wound& healing& is& the& result& of& a& complex& interaction& between& keratinocytes,&
fibroblasts&and&neoangiogenesis,&resulting&from&growth&factorBinduced&(FGF,&VEGF,&TGFBβ,…)&
EC& proliferation& and&migration.44,&45,&66& The& expression& of&Pear1& in& the& endothelium&of& skin&
tissue&was&documented&and&we&showed&ECs& to&be& the&only&Pear1Bpositive&cells&via& IHC.&At&
day& 4& of& wound& healing,& there& was& an& approximately& twoBfold& increase& in& the& speed& of&
wound&closure&(t1/2&of&full&recovery&was&4&days&in&KOBmice&and&7&days&in&WTBmice)&in&Pear1,/,&
mice,& compared& to& their& WT& littermates.& This& was& accompanied& by& increased& cell&






Angiogenesis& constitutes& an& important& aspect& of& EC& function& and& PI3K/AktBsignalling& is&
critical&in&these&processes.16,&56,&67&We&were&able&to&demonstrate,&in&parallel&with&our&in#vitro#
findings,& an& enhanced& AktBPBdriven& Cdc2Bupregulation& in& the& pooled& granuloma& tissues& of&
the& Pear1,/,& mice& compared& to& littermates& at& day& 4& of& wound& healing.& This& allowed& us& to&
extrapolate& our& in# vitro& signalling& data& to& that& of& the& in# vivo& wound& healing& assay& and&
supported& the& controlling& role& for& PEAR1& in& AktBdriven& proliferation/migration& of& ECs& and&
angiogenesis& via& the& PI3K/AktBpathway.& It& remains& to& be& shown& how& PEAR1& controls&
PI3K/PTEN,&but&an& inverse& relation&between&AktBP&and&PTEN&has&been&shown& in&many&cell&
types.30& We& showed& that& the& enhanced& neoBangiogenesis,& observed& upon& ligation& of& the&
femoral&artery&in&Pear1,/,#mice&is&not&the&result&of&increased&VEGFBsignalling.&Several&reports&
have&shown&that&sustained&endothelial&AktBactivation&and/or&AktBoverexpression&in&hind&limb&














In& conclusion,&we& identified&PEAR1&as& a&novel&modifier&of&neoangiogenesis.& This& study&will&
trigger&further&research&on&the&role&of&PEAR1&in&pathological&endothelial&hyperproliferation&
(as& seen& in& e.g.& neoBintima& formation& after& stent& implantation74& or& in& pulmonary&
hypertension75)& and& on& the& interaction& between& platelets& and& ECs,& two& major& players& in&
cardiovascular&disease.&Further&research&will&also&need&to&identify&how&various&SNPs&regulate&
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GENERAL DISCUSSION  
INTRODUCTION 
Platelet Endothelial Aggregation Receptor 1 (PEAR1) was first described by Nanda et al. in 2005.1 
They identified PEAR1 as a platelet-platelet contact receptor, responsible for the stabilisation of 
both platelet aggregates and fully-formed thrombi. Our group has previously studied the 
underlying PEAR1 signalling pathway and described a role for PEAR1 in the sustained activation of 
αIIbβ3, hence a role in stabilising platelet aggregates.5 The principal aim of this thesis was to 
further elucidate the role of PEAR1 in platelet signalling and megakaryopoiesis in addition to 
studying the expression profile and function of PEAR1 in ECs, a so far untouched field in EC 
biology.  
 
In the previous four chapters I provided answers to some important questions regarding this 
novel receptor. We have identified a physiological and non-physiological ligand for PEAR1, 
described a role for PEAR1 in haematopoiesis and discovered PEAR1 as a novel modifier of neo-
angiogenesis. This section of the thesis will go into more detail on some interesting overarching 
topics concerning PEAR1. 
 
 
PEAR1: A CONTROLLER OF CELL QUIESCENCE 
In 2007 Krivtsov et al. described a role for PEAR1 in hematopoietic cell regulation. They reported 
that the overexpression of PEAR1 in murine bone marrow cells led to a decrease in the total 
number of progenitor cells6 and thus suggested that PEAR1 negatively regulates hematopoietic 
cell proliferation and differentiation in the early stages. These preliminary findings prompted us 
to study whether PEAR1 was also a regulator of platelet production and EC proliferation.  
 
As discussed in Chapter I and compatible with the data provided by Krivtsov et al. in murine bone 
marrow cells, we found the expression of PEAR1 to be very low at day 0 in cultured human 
CD34(+) cells and found that PEAR1 expression is progressively upregulated during the process 
of megakaryopoiesis up to day 12.4 Indeed, PEAR1 knockdown in CD34(+) cells via lentiviral 
transduction of a short hairpin PEAR1 construct (shPEAR1) strongly enhanced megakaryocyte 
progenitor proliferation and thrombopoiesis in vitro. These observations were confirmed in an in 
vivo zebrafish model where again Pear1 mRNA was low at 24 hours post-fertilisation and 
progressively increased up to day 4. Early knockdown of Pear1 (via a morpholino knockdown 
strategy) enhanced thrombopoiesis in zebrafish at day 2.4  
 
Both of these approaches demonstrated that PEAR1 negatively regulates the early stages of 
megakaryopoiesis and thrombopoiesis.  
 
Similar to these findings of enhanced proliferation in shPEAR1-transduced CD34(+) cells (Chapter 
I), comparable results were seen in ECs (Chapter IV). Knockdown of PEAR1 in cultured ECs 
(shPEAR1 ECs) also resulted in a proliferative phenotype and, in line with our findings in 
megakaryocytes (MKs), we observed low PEAR1 expression in rapidly-proliferating cultured ECs 
(BOECs, HUVECs and HUAECs) compared to a higher level of expression in the slowly-
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proliferating microvascular ECs of the heart and liver.7 This was also the case in the rapidly-
proliferating ECs of pyogenic granuloma, a hypervascularised skin tumour where an inverse 
association between PEAR1 expression and EC proliferation was observed.7 All of these results 
suggested that PEAR1 can modify endothelial angiogenic behaviour leading to an increased 
proliferation rate and tube-forming capacity in its absence (Chapter IV).7  
 
Our results also show that specific triggers such as hypoxia or skin injury resulted in enhanced 
neo-angiogenesis in a Pear1-/- mouse model, although Pear1-/- pups showed no overt vascular 
phenotype at birth and detailed IHC and angiographic analyses of various murine tissues at the 
age of 13 weeks did not detect abnormalities in blood vessels in the absence of Pear1.7 We 
therefore concluded that knocking out Pear1 does not affect embryological angiogenesis but 
does affect sprouting from mature ECs (neo-angiogenesis). This hypothesis was supported by our 
findings in the ECs of zebrafish. Similar to human ECs, very low Pear1 expression was found in 
the zebrafish ECs during embryonic development (Figure 1), in agreement with the low PEAR1 
expression that was observed in ECs with a highly proliferative and migratory state. Knockdown 
of Pear1 in zebrafish using a morpholino strategy did not affect vasculogenesis in the early 
stages of development (Figure 2), further suggesting that PEAR1 does not play an important role 
during early vascular development and supporting a selective role for it in mature blood vessels. 
To further establish this hypothesis, in a future research project it would be of great value to 
study the expression of Pear1 during the different stages of murine embryogenesis to verify 














Through these results we have identified that PEAR1 controls the proliferation of MKs and ECs 
and modifies neo-angiogenesis. These findings could form a basis for further (clinical) research 
seeking to clarify a potential role for PEAR1 in platelet disorders (e.g. congenital platelet 
production disorders, leukaemia, essential thrombocytosis, etc), in diseases associated with 
enhanced or diminished neo-angiogenesis (haemangiomata, tumour angiogenesis, collateral 
vessel formation, etc) or in diseases where platelets and ECs meet (e.g. pulmonary hypertension, 
stent re-endothelialisation, vasculitis, etc). Some of these topics will be more thoroughly 
discussed in the section entitled “Future Perspectives”.  
Figure 1 – Relative Pear1 expression in isolated Fli1:eGFP zebrafish ECs at 24 and 48 hours post-fertilisation 
(hpf) was extremely low (Ct values ≈ 33; ΔΔCt normalised to the Elfa housekeeping gene ≈ 6; values were 
comparable to PEAR1 mRNA levels in human BOECs). Total Pear1 expression in the zebrafish progressively rose 

































































Figure 2 – Confocal microscopy analyses of Fli1:eGFP zebrafish embryos, injected with control MO (upper 
panel), PEAR1-ATG MO (middle panel) and PEAR1-splice MO (lower panel). Embryos were screened at 1, 2, 3 and 





PEAR1 AND THE PTEN/PI3K/AKT AXIS 
In both platelets and ECs we identified the PTEN/PI3K/Akt pathway as a crucial axis downstream 
of PEAR1. Moreover, we were able to restore the hyperproliferative phenotype in shPEAR1 ECs via 
restoring the PEAR1-driven imbalance between PTEN and PI3K activity. Our results highlight a 
role for PEAR1 in modifying the expression levels of PTEN, resulting in enhanced activity of PI3K 
and enhanced phosphorylation levels of Akt, highlighting PEAR1 as a central orchestrator of 
important cell functions in both platelets and ECs. The mechanism by which PEAR1 regulates the 
PTEN/PI3K/Akt pathway in ECs is still unknown. In shPEAR1 CD34(+) cells, however, we found 
that HES1, a direct target of the Notch receptor pathway, was upregulated without any 
modification of expression of the Notch receptors. As discussed in Chapter I, HES1 is reported to 
be a negative regulator of PTEN transcription during megakaryopoiesis.8,# 9# Therefore we 
concluded that PEAR1 signalling in CD34(+) cells controls PTEN expression via the NOTCH 
pathway, although other signalling pathways might also be involved. The role of integrins in 
platelet PEAR1 signalling is a topic of ongoing research in our laboratory. 
 
In ECs, the mechanism of PEAR1-mediated regulation of the PTEN/PI3K/Akt pathway is less clear. 
As discussed in Chapter IV, The PTEN/PI3K/Akt pathway is a central player in EC biology in 
normal vascular development and tumour angiogenesis through regulation of EC migration, 
proliferation, cell survival and vascular tone10. Given that PEAR1 deletion did not affect 
embryogenesis, we then focussed our investigations on post-natal neovascularisation. Post-natal 
neovascularisation is a complex process that depends on the coordinated interactions between 
endothelial shear stress, endothelial vascular growth factors (VGFs; e.g. VEGF, Ang-1, Ang-2, 
bFGF [basic fibroblast growth factor], PDGF-B [platelet-derived growth factor-B], Ephrins, and 
TGF-β [transforming growth factor β] superfamily members), intracellular signalling proteins (e.g. 
Notch signalling) and cell-cell adhesion molecules (e.g. connexions and VCAM-1 [vascular cell 
adhesion molecule-1]). All of these activate or modulate the PI3K/Akt pathway, highlighting the 
importance of this axis.10, 11  
 
PTEN regulates EC function at various levels and many signalling pathways in turn regulate the 
expression and function of this tumour suppressor gene.12 PTEN is important for the homeostasis 
of the cardiovascular system and it is well known that Pten/PTEN overexpression or the 
administration of PI3K inhibitors blocks vascular sprouting and EC tube formation in vitro and 
blocks tumour angiogenesis and tumour growth in vivo.12 This is probably mediated via 
hypersensitisation to VGFs upon the loss of Pten and via dysregulation of the downstream 
mediators of PI3K/Akt signalling.12-14 In parallel, heterozygous knockout mutations of PTEN in 
ECs have been shown to promote post-natal tumour angiogenesis and neovascularisation 
whereas (floxed) homozygous deletion of Pten in murine ECs was shown to impair cardiovascular 
morphogenesis.11 
 
Homozygous null mutations for Pten in mice are embryonic lethal.11 However, zebrafish embryos 
lacking Pten show an enhanced EC proliferation and hyperbranching of blood vessels.15 This is in 
sharp contrast with the normal embryogenic (vascular) development of Pear1-/- mice, as 
discussed in Chapter IV, again underpinning the fact that PEAR1 does not play a role in 
embryological biology and again suggesting that PEAR1 expression is low/absent during 
embryological development. 
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In the next part of the discussion I will further review the known roles of some of the PTEN/PI3K-
modulating players in post-natal angiogenesis and put them into perspective relative to PEAR1.  
 
 
I. HIF1Α AND VEGF 
It has been thoroughly established that high levels of PTEN inhibit VEGF-induced 
sprouting and capillary formation. Impaired PTEN levels led to an increase in EC 
proliferation, migration and vascular sprouting.12, 14 Moreover, it was shown that PTEN 
deficiency directly leads to an altered VGF profile (decreased expression of Ang-1, 
EphrinB2 and VCAM, and increased levels of Ang-2, VEGF-A, VEGFR 1 and 2)11, 14, 
which likely explains the changes induced in cardiovascular development in Pten-/- 
mice. However, as was discussed in Chapter IV, a lack of PEAR1 did not affect any of 
the important players in the p53-Hif1α-VEGF-VEGFR2 pathway.  
 
II. ANGIOPOIETINS  
Ang-1 (angiopoietin 1) and its receptor Tie2 are important in PI3K-mediated EC 
survival and migration as well as in vessel permeability and in the recruitment of 
smooth muscle cells.16 Tie2 is mainly expressed on ECs and its ligand (Ang-1) is 
antagonised by Ang-2.17 Hamada et al. showed that heterozygous Pten-floxed ECs 
have a more proliferative and faster migratory phenotype and an altered Ang-1/Ang-
2 ratio.11 Since angiopoietins regulate both EC proliferation and migration, it will be of 
interest to unravel their involvement in PEAR1 signalling.  
 
III. NOTCH SIGNALLING 
HES1 is a negative regulator of PTEN transcription during megakaryopoiesis.8,#9#As 
previously discussed, we found an upregulation of HES1 expression in shPEAR1 
CD34(+) cells, linking the decreased PTEN expression in shPEAR1 CD34(+) cells with 
the NOTCH pathway. In ECs however, a link between HES1 and PTEN has not been 
clearly established. As explained in the Introduction chapter of this thesis, NOTCH 
plays an important role in blood vessel growth. Briefly, guiding tip cells are associated 
with high levels of Dll4, which activates the NOTCH pathway in neighbouring stalk 
cells, preventing them from becoming a tip cell. Dll4-induced activation of NOTCH in 
ECs leads to cell cycle arrest and thus the arrest of EC proliferation both in vitro18 and 
in vivo19. Very recently, it was found that NOTCH exerts its negative effects on EC 
proliferation via PTEN.2 Sera et al. reported that NOTCH signalling fails to arrest early 
stalk cell proliferation upon PTEN deletion (or that PTEN negatively regulates stalk cell 
proliferation), resulting in defective sprout length and patterning.2 They showed that 
NOTCH regulates stalk cell proliferation via stimulation of PTEN transcription. This is 
summarised in Figure 3. 
 
Although endothelial PTEN is essential for regulating NOTCH-induced stalk cell 
proliferation and thus sprouting, it is dispensable for the regulation of the sprouting 
activity of tip cells.2 This is illustrated well by the fact that NOTCH mutants show both 
proliferative and (VEGFR3-driven) sprouting defects,20, 21 whereas PTEN mutants only 
show proliferative effects. Although we found an enhanced proliferation of ECs and 
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increased vessel formation in our Pear1-/- hindlimb ischemia model, these newly 
formed vessels were apparently functional since they resulted in a faster blood flow 
recovery. Therefore, we argue that they cannot be compared with the dysfunctional 
vascular density defects reported in PTEN mutants (Figure 3B). This inconsistency 
might be explained by the fact that knockdown of PEAR1 reduced but did not 
completely abrogate PTEN expression in ECs (Chapter IV). These findings suggest that 
PEAR1 might help to regulate NOTCH-driven sprouting and neo-angiogenesis, via the 
modulation of PTEN in stalk cells and via the control of tip cell formation and EC 












IV. SHEAR STRESS 
Shear stress is a complex, haemodynamic force that is applied across the endothelial 
surface and modulates essential EC functions such as vascular tone, inflammatory 
processes, EC remodelling and angiogenesis22-24, and activates a broad variety of 
important EC signalling pathways such as those involving MAPK, protein kinase C 
(PKC), c-Src, Rho family GTPases and PTEN/PI3K/Akt.25, 26 An important mediator in 
shear stress-induced angiogenesis is nitric oxide (NO), whose production via the 
subcellular localisation of endothelial NO synthase (eNOS) is mainly orchestrated via 
KLF-2 (Krüppel-like factor 2), protein kinase A (PKA) and the PI3K/Akt pathway.27 NO 
modulates essential EC processes such as EC survival, proliferation, migration and 
interaction with the ECM. VEGF-induced angiogenesis is blocked in the presence of an 
NO inhibitor (L-NAME)28 and NO production is impaired in a variety of 
pathophysiological conditions such as atherosclerosis, smoking, 
hypercholesterolemia, etc.29 Although NO is essential for shear stress-induced 
angiogenesis, the mechanistic link between shear stress, NO production and 
angiogenesis is poorly understood.  
 
In Chapter IV we showed that knockdown of PEAR1 in ECs did not result in enhanced 
NO production. Nevertheless, additional research has shown (unpublished results; 
Figure 4) that the incubation of ECs with an anti-PEAR1 antibody results in the 
transient phosphorylation of PEAR1 and Akt (as seen in platelets)5 and the transient 
Figure 3 – A) Activation of NOTCH by Dll4 induces the expression of PTEN, which blocks stalk cell 
proliferation.   B) Upon a loss of PTEN, NOTCH signalling fails to arrest stalk cells resulting in defective sprout 
length and patterning. – adapted from Serra et al.2   
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(peaking at 15 minutes) phosphorylation of eNOS (at activation site S1177), leading to 
a transient rise in NO production in vitro (see Chapter IV).  
 
Based on these findings, ongoing research will try to elucidate whether shear stress 
can induce PEAR1 phosphorylation in vitro and in vivo and whether PEAR1 might 
function as a mechanoreceptor on ECs, ultimately inducing shear stress-mediated NO 
production and Akt/NO-induced angiogenesis (Figure 5 shows a hypothetical scheme; 
further discussed in the Future Perspectives paragraph). These findings have very 
recently been further supported by Adam et al., who showed that the minor allele of 
the rs12041331 SNP in PEAR1 is significantly associated with a greater brachial artery 
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Figure 4 – (A) Phosphorylation of Akt and eNOS 
(S1177) following stimulation of EAhy926 ECs with a 
polyclonal PEAR1-Ab (3mg/L) (left panel). Middle and 
right panels show time-dependent, transient 
phosphorylation of Akt upon anti-PEAR1 Ab stimulation 
of EAhy926 ECs, maximal at 15 minutes, vs. that of 
eNOS, which was activated more slowly. (B) Increased 
production of NO in EAhy926 ECs upon eNOS activation 
by anti-PEAR1 Ab, analysed using the DAF-FM dye; L-
NAME is an inhibitor for NO-production. *P<0.05. Error 
bars indicate mean values ± SEM. 
 
Figure 5 – Hypothetical scheme for PEAR1 as a mechanoreceptor for EC shear stress. Undefined negatively 
charged proteins of the glycocalyx (e.g. chondroitin sulphate, heparan sulphate, etc), lead to shear stress-
mediated PEAR1 activation and subsequent Akt and eNOS phosphorylation. 
Endothelial Cell Lumen 
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V. UPAR SIGNALLING 
The urokinase receptor (uPAR, CD87) has been shown to play an essential role in 
growth factor-induced EC activation and EC migration/invasion. In a very recent 
report, Unseld et al. reported an inverse correlation between uPAR and PTEN 
expression.32 They showed that overexpression of uPAR downregulated PTEN 
transcription, leading to enhanced Akt-driven EC motility and EC survival in vitro and 
the promotion of Akt-driven EC invasion in vivo. Although uPAR deficiency in ECs led 
to a remarkable enhanced migratory phenotype and survival rate, EC proliferation was 
not affected.32 In future research it will be of interest to measure the uPAR expression 
profile in PEAR1 knockdown ECs as a possible explanation for the enhanced migratory 
phenotype seen in these cells. 
  
VI. INTEGRINS  
Angiogenesis is a complex process, not only necessitating EC migration and 
proliferation but also their attachment to the extracellular matrix (ECM) and 
proteolysis of this ECM via the activation of specific matrix metalloproteases (see next 
paragraph).33 In order to cross tissue boundaries during EC migration, various 
adhesion receptors (integrins) play a crucial role.34 Integrins are characterised by their 
bidirectional signalling and PI3K plays an important role in both of these processes35. 
Firstly, “inside-out signalling” causes integrins to adopt an active conformation and 
organise adhesion to ECM molecules, a process which is required for adequate cell 
movement.35 Then, through “outside-in signalling” they regulate intracellular 
signalling pathways that control the organisation of the cytoskeleton and mediate cell 
survival. Various integrins play a role in angiogenesis, for example, the deletion of α5 
reduces capillary plexus formation36, and αvβ3 integrins are known to be upregulated 
during angiogenesis37. However, β1 integrins are reported to be particularly important 
during vasculogenesis.38, 39 In vitro, β1-integrin-/- ECs show reduced migration and 
elongation despite an increase in proliferation and apoptosis, ultimately leading to a 
reduced cell number. These effects are also observed in vivo, where a reduction in EC 
maturation, migration and sprouting has been reported.38, 39 Interestingly, the 
enhanced EC proliferative phenotype observed in β1-integrin-/- ECs was found to be 
mediated via the PI3K/Akt pathway.38 
 
We previously reported (Chapter IV) a high expression of human PEAR1 in EC ruffles 
and lamellipodia, suggesting a role for PEAR1 in EC migration and the involvement of 
PEAR1 in the bidirectional cell-ECM contacts, as seen for integrins. We confirmed an 
enhanced migratory phenotype in shPEAR1 ECs and confirmed an enhanced neo-
angiogenesis in Pear1-/- models of hypoxia. Therefore it will be of interest to 
investigate whether the integrin expression profile in shPEAR1 ECs becomes altered 
(e.g. to a more “metastatic” profile) or whether PEAR1 knockdown affects the affinity 
of certain integrins for their ligands.  
 
VII. MODULATORS OF THE ECM 
The ECM is an important source of angiogenic signals. It is not only an important 
extracellular source of VGFs, such as VEGF, but degradation of ECM compounds also 
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leads to the production of strong pro- or anti-angiogenic factors. The most relevant 
proteases involved in this process are matrix metalloproteases (MMPs), with MMP-2 
and MMP-9 being the key players.40, 41 MMPs are reported to be primarily involved in 
EC migration by interference with EC-EC and EC-ECM interactions.19 PTEN 
overexpression in a multiple myeloma cell line results in decreased protein levels of 
MMP-2 and MMP-942, illustrating a negative correlation between PTEN and MMP 
expression.19 Interestingly, this decreased MMP expression in PTEN-overexpressing 
cells was reversed by the addition of a PI3K inhibitor.43 Therefore, it would be 




Eph-receptors belong to the receptor tyrosine kinase (RTK) superfamily and are 
known to play a role in embryogenesis, angiogenesis and axonal guidance.44-46 They 
are divided in the A and B subfamilies and their respective ligands are ephrin A and 
ephrin B. Eph-receptors and ephrins are frequently overexpressed by tumours and 
tumour ECs, leading to the promotion of tumour angiogenesis.19 Various groups have 
reported that Eph-receptors activate PI3K and are regulated via the PTEN/PI3K 
pathway.47-49 Eph-receptor/ephrin interactions are crucial for a broad spectrum of cell 
regulatory processes such as the modulation of cell adhesion, cell repulsion, cell 
motility and cell positioning.47 Since ephrins are particularly crucial for embryological 
vascular development, it is less likely that they are coupled to PEAR1 signalling. 
 
IX. TGFβ   
TGFβ is an important signalling molecule in the complex process of angiogenesis, and 
is involved mainly in EC proliferation and migration.50-52 The crucial roles for TGFβ 
were elucidated using human and murine genetic studies, where mutations in 
important TGFβ signalling pathway components (e.g. endoglin [ENG], Alk1, Smad4) 
were found to result in diseases such as pulmonary arterial hypertension, hereditary 
haemorrhagic telangiectasias (HHT) and vascular malformations (see below).52 It has 
also been reported that the TGFβ/Smad4 complex regulates angiogenesis via 
regulation of the expression of certain pro-angiogenic micro RNAs (miRNAs) such as 
miR-21 and miR-29a, which exercise their effects via the direct downregulation of 
PTEN (miR-29a)50 or upregulation of Akt activity (miR-21)53, promoting EC migration, 
proliferation and ultimately tube formation.50 Interestingly, the effect of miR-29a in 
stimulating tube formation via TGFβ was completely blocked by an PI3K inhibitor 
(LY294002).50 The link between TGFβ and PTEN has been well-established (PTEN is 
also known as TEP1: TGFβ-regulated and epithelial cell-enriched phosphatase) and 
very recently, Adam et al. conducted meta-analyses of 75000 publicly available 
microarrays which revealed that PEAR1 expression is highly correlated with the 
expression of ANG-2, ACVRL1/ALK1 and ENG, which are important genes in the TGFβ 
signalling cascade.30  This makes TGFβ and its associated genes (ENG, ALK1, etc) of 
particular interest when further investigating the effect of PEAR1 knockdown on this 





Further studies investigating the expression and signalling of these important players in blood 
vessel formation will be needed to find out the underlying mechanisms of the enhanced neo-
angiogenesis observed upon PEAR1-knockdown/Pear1-knockout. Since ECs lacking PEAR1 
showed both a proliferative and migratory phenotype, it would not be surprising to find that 
PEAR1 affects both tip and stalk cell formation and/or ECM modification during neo-angiogenesis 
and modulates several of the previously discussed crucial signalling pathways. It will be of 
particular interest to investigate the involvement of PEAR1 in PTEN-modulated tumour 
angiogenesis (which is discussed below) and to analyse patients with PEAR1 mutations to see if 
they result in, e.g. Cowden-like disease (Cowden disease is a disorder in which hereditary PTEN 
mutations lead to tumour susceptibility disorders54). This will be discussed in more detail in the 
Future Perspectives section below. 
 
 
PEAR1 AND ITS LIGANDS 
I. THE IGE-RECEPTOR FCεR1α, A PHYSIOLOGICAL LIGAND FOR PEAR1 ON PLATELETS 
As discussed in Chapter II, we identified human FcεR1α as a physiological ligand for PEAR1 in 
platelets. PEAR1 is in competition (albeit with a lower affinity) with IgE for FcεR1α, suggesting a 
interaction between IgE-mediated diseases and platelet aggregate stability (Figure 6). This 
interaction was surprising to us, even though we found there to be a high affinity between PEAR1 
and FcεR1α and we confirmed, in line with previous reports55, 56, the expression of FcεR1α on the 
platelet surface. Various reports have suggested that patients with an atopic constitution have 
decreased platelet aggregate responses to various classical platelet agonists.57, 58 These 
responses are even cyclic, depending on the allergy season.59 Nevertheless, the underlying 




In healthy individuals, the concentration of circulating IgE is very low, at approximately 0.5 nM.60 
Where circulating levels of IgE are increased, for example in atopic patients,60 this would 
significantly decrease the amount of IgE-free FcεR1α on the platelet surface that is available for 
PEAR1 binding, reducing PEAR1-induced platelet-platelet activation. This is consistent with 
reports of a systemic lack of secondary platelet responsiveness in atopic patients, an observation 
Figure 6 – Schematic reproduction of platelet-platelet contact between PEAR1 and FcεR1α (left and middle 
part). PEAR1 and IgE are in competition for FcεR1α, the latter having the highest affinity for FcεR1α (right part).  
! General Discussion !
! 151!
that has also been correlated with elevated IgE levels.59, 61-63  
To further investigate the FcεR1α-PEAR1-mediated link between platelet function and allergy, we 
added exogenous IgE to collagen-induced platelet aggregation assays using multiple atopic 
donors, and observed a consistent inhibition of platelet aggregation (Figure 7, unpublished 
results). These results might open the door for a prospective randomised trial, linking atopic 
patients to decreased platelet responsiveness, and eventually revealing allergy to be a (minor) 
protective phenotype for cardiovascular disease. In addition, this would further underpin the 
importance of the impact of the environment on the heart and blood vessels.  
  
 
FcεR1α is reported to be expressed on mast cells, eosinophils, basophils, monocytes, epidermal 
Langerhans cells and dendritic cells.55 In addition to this, I also confirmed the presence of FcεR1α 
on the membrane of human ECs (through immunofluorescence and western blotting – 
unpublished results) and that sFcεR1α activates the PEAR1/Akt pathway in ECs, identifying 
FcεR1α as a ligand for PEAR1 in ECs as well as platelets (unpublished results).  
The presence of PEAR1 on both platelets and ECs and the expression of FcεR1α on the surface of 
platelets, ECs and eosinophils raises the question of whether the PEAR1- FcεR1α interaction 
could play a role in the broad disease spectrum of vasculitis. The spectrum of this disease, in 
which inflammation and eosinophilia meet each other, is broad and ranges from granulomatosis 
with polyangiitis (GPA; Wegener’s disease), microscopic polyangiitis (MPA) and rheumatoid 
arthritis to systemic sclerosis and systemic lupus erythematosus (SLE).64 Although inflammation 
and eosinophilia are central to all of these disease entities, the most typical one that brings 
hypereosinophilia and inflammation/vasculitis together is eosinophilic granulomatosis with 
polyangiitis (EGPA; Churg-Strauss syndrome).64  
Churg-Straus has a broad variety of symptoms. Briefly, it is associated with asthma, parenchymal 
lung disease, vasculitis (most commonly involving the peripheral nerves or skin, leading to 
purpura, nodules, ulcerating lesions, livedo reticularis), renal failure (glomerulonephritis), 
gastrointestinal disease (related to eosinophilic infiltration and/or vasculitis) and cardiac 
involvement (cardiomyopathy from myocarditis, pericarditis, endocarditis, valvulitis, coronary 
vasculitis).65, 66 It is well known that eosinophils, activated platelets and activated ECs play a 
central role in the pathogenesis of Churg-Strauss.67 Nevertheless, the underlying mechanism of 
Figure 7 – Exogenously added IgE inhibited platelet 
aggregation triggered by donor-specific concentrations of 
collagen that elicited 40-70% aggregation. Aggregation traces 
from six representative atopic donors are shown.  
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this disease remains unknown. Therefore, it might be interesting to study whether the FcεR1α-
PEAR1 interaction in platelet-platelet, platelet-EC, eosinophil-platelet and/or eosinophil-EC 
contacts contributes to this disease spectrum since it is characterised by vascular occlusion. !!
II. DEXTRAN SULPHATE: A NON-PHYSIOLOGICAL LIGAND FOR PEAR1 IN PLATELETS 
In Chapter III we identified PEAR1 as the major platelet receptor responsible for the dextran 
sulphate (DxS)-induced platelet aggregation that was recently reported by Getz et al.68 Although 
oral administration of (high molecular weight) DxS is a well-established model for the induction 
of murine colitis,69 its physiological role in platelet activation and aggregation remains unclear.  
 
In addition to its activation of PEAR1 in platelets, we also found that DxS is able to induce the 
phosphorylation of PEAR1 in ECs (unpublished results), leading to the phosphorylation of both 
Akt and downstream eNOS. Based on our knowledge, discussed previously in the paragraph on 
shear stress, this is a very interesting finding. It was surprising that a very negatively-charged 
molecule such as DxS was able to bind to an EC surface receptor in the environment of the 
negatively-charged glycocalyx, but we think that this is due to the well-described fast 
degeneration of the EC glycocalyx in cultured ECs.70 DxS shows strong structural similarities with 
heparan sulphate (HS), a major component of the EC glycocalyx, therefore we hypothesised that 
DxS is a non-physiological ligand for PEAR1 and is involved in EC mechanotransduction.  
 
The main components of the EC glycocalyx are hyaluronic acid, heparan sulphate (HS) and 
chondroitin sulphate. Excellent work from the group of Tarbell et al. has shown that during the 
first 30 minutes of shear stress, HS (and its anchoring protein glypican-1) shifts to align with the 
direction of the flow, whereas other components of the glycocalyx do not move.71 In addition, 
dissolving HS on the EC surface using heparanase completely blocks shear stress-induced 
phosphorylation of eNOS and NO production.72 These results demonstrate that HS proteoglycans 
play a role in the mechanotransduction of fluid shear stress in ECs. This has led to the HS-
glypican-eNOS hypothesis: that the HS-glypican complex transmits mechanical forces to the 
caveolae of ECs, where eNOS is phosphorylated, leading to NO production.73 Although it has been 
established that this involves intermediate signalling through c-Src and its downstream signalling 
cascades, the underlying mechanoreceptors responsible for this c-Src-mediated eNOS 
phosphorylation are poorly understood.74  
 
Many components of the glycocalyx disappear from ECs in culture, although immunohistology 
has demonstrated the sustained presence of HS, the main constituent of the glycocalyx, both ex 
vivo and in vitro.70 The presence of HSs on cultured cells may explain why mechanotransduction 
phenomena can be observed in vitro, even with an immature glycocalyx.70  
 
Therefore, we now know that PEAR1 phosphorylation is mediated via c-Src and activates Akt-
eNOS pathways in ECs, and that HS resembles DxS structurally. Since DxS is a ligand for PEAR1 on 
both platelets and ECs, our future work will use an in vitro shear stress technique to investigate 
whether PEAR1 acts as a mechanoreceptor on ECs, ultimately leading to shear stress-induced NO 
production (see Figure 5). This might create new insights into the described intervariability in 
responses to stent endothelialisation where an inverse correlation exists between shear stress 
and neo-intimal hyperplasia, a process that is mainly driven by EC migration and the proliferation 
of stent-adjacent ECs.75    
FUTURE PERSPECTIVES 
 
In the following paragraphs I will give an overview of some important planned experiments for 
the future, which concern the mechanism of PEAR1 signalling. I will also discuss some important 
clinical pathologies in which I hypothesize PEAR1 might be involved.   
 
OVEREXPRESSION STUDIES OF PEAR1 
 
So far I discussed: the effect of lentiviral-mediated PEAR1 knockdown in CD34(+) cells (Chapter I) 
and ECs in vitro (Chapter IV); the effect of morpholino-driven Pear1 knockdown in zebrafish in 
vivo (Chapter I); the effect of Pear1 knockout in murine platelets ex vivo (Chapter III); and the 
effect of (non-conditional) Pear1 knockout in murine ECs in vivo (Chapter IV). 
 
A burning question concerns the effect of PEAR1 overexpression on the phenotype of platelet 
production and neo-angiogenesis. Of particular interest will be whether the overexpression of 
PEAR1 in megakaryocytes and ECs results in enhanced levels of PTEN expression, leading to a 
decreased activity of the PI3K/Akt axis. Several studies have shown that PTEN overexpression, or 
gain-of-function mutations in PTEN, significantly inhibit Akt-driven cell proliferation and/or 
enhanced cell apoptosis.76-79 Interestingly, constitutively active forms of PI3K and Akt can rescue 
PTEN-induced suppression of cell proliferation.80 In megakaryopoiesis, Pten overexpression 
inhibits megakaryocyte development in vivo and ex vivo,8 and in angiogenesis it was recently 
shown that overexpression of PTEN in stalk cells reduces vascular density and abrogates the 
increased EC proliferation induced by blocking NOTCH (as described above).2  
 
To address this, our group recently designed a floxed PEAR1-GFP cassette-based PEAR1 
overexpression vector (CMV-eGFP ON-PEAR1 OFF IRES BSdR) which can be transduced into 
CD34(+) cells or ECs to induce PEAR1 overexpression at certain time points by adding lentiviral-
transduced Cre (Virus Like Particle Carrying Cre (VLP-Cre). This will flox the cassette to a CMV-
PEAR1 ON-eGFP OFF IRES BsdR PEAR1 overexpressing vector and will allow us to study the effect 
of PEAR1 overexpression on the phenotype of both megakaryocytes (for example, will it reduce 
platelet production and megakaryocyte proliferation?) and ECs (will they have reduced 
proliferation and increased apoptosis?) and will allow us to study the downstream cellular 
signalling effects of PEAR1 overexpression.  
 
 
PEAR1 AND PULMONARY ARTERIAL HYPERTENSION 
 
Pulmonary arterial hypertension (PAHT) is a complex disease. It comprises a collective group of 
pathophysiological processes that lead to similar symptoms but result from a variety of 
underlying causes. The main entities in the PAHT disease spectrum are vasoconstriction, smooth 
muscle cell and EC proliferation, and thrombosis. PAHT arises due to imbalances in the 
homeostasis of these entities, probably due to pulmonary EC dysfunction or injury.3 
 
An overview of the most important mediators of pulmonary vascular responses in PATH is given 
in Table 1 An imbalance between those mediators is believed to be the main reason for impaired 
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vasoconstriction, EC proliferation and thrombosis in PAHT, forming the basis for the development 
of a whole range of medicines for the treatment of PAHT.81-85  
 
VASOCONSTRICTION CELL PROLIFERATION THROMBOSIS 
Increased#TXA2 Increased#VEGF Increased#TXA2 
Decreased#PGI2 Decreased#PGI2 Decreased#PGI2 
Decreased#NO Decreased#NO Decreased#NO 
Increased#ET91 Increased#ET91  
Increased#59HT Increased#59HT Increased#59HT 
Decreased#VIP Decreased#VIP Decreased#VIP 
Interestingly, the VEGF-driven disordered angiogenic responses in ECs in PAHT have been shown 
to be c-Src/PI3K/Akt-driven.86, 87 Our interest is mainly focussed on the familial and idiopathic 
(primary) form of PAHT. The familial form of PAHT accounts for 6% of all cases of PAHT and can 
be related to mutations in Ang-1/Tie 2, to mutations in the TGFβ–receptor pathway or the 
serotoninergic pathway.88 Two genes that have been strongly linked to familial PAHT are the bone 
morphogenetic protein receptor type 2 (BMPR2: controlling EC proliferation via Smad) and the 
TGFβ–receptor ALK1 (Activin receptor-like kinase 1; also known as ACVRL1; controlling Smad-
mediated EC proliferation).88 Interestingly, in approximately 15% of patients with hereditary 
haemorrhagic telangiectasia (HHT; The Rendu-Osler-Weber syndrome), patients also present with 
an idiopathic form of PAHT.89 HHT is a rare genetic disorder that is characterised by 
mucocutaneous telangiectasia and recurrent bleeding due to nasal, cerebral, pulmonary and 
gastro-intestinal arteriovenous malformations. HHT is caused by mutations in the ENG gene (HHT 
type 1) or by mutations in the ALK1/ACVRL1-gene (HHT type 2) and it has been shown that the 
association of HHT with PAHT is also related to mutations in these genes.90 Because clinically-
apparent disease occurs only in a small percentage of BMPR2, ALK1 and/or ENG mutations and 
because not all patients with ENG- and/or ALK1-induced HHT also present with PAHT, it is 
believed that there must exist some modifier genes and/or environmental triggers being 
important to the pathogenesis of PAHT. Therefore, a multiple-hit theory has been suggested.3, 88  
 
It was of particular interest to us to translate these data to our PEAR1 results.  Indeed, we showed 
that PEAR1 is involved in the NO metabolism of ECs and that PEAR1 knockdown results in an 
enhanced EC proliferation and increased platelet formation; three cornerstones of idiopathic 
PAHT.91 We also showed that PEAR1 expression is low in rapidly-proliferating vascular 
abnormalities (pyogenic granuloma; see Chapter IV), suggesting that it might be involved in the 
discontinuation of the angiogenic control, as is also seen in HHT. We have previously suggested 
that it would be of high interest to investigate the gene profile for the angiopoietins Ang1 and 
Ang2 as well as for the TGFβ receptor pathway in shPEAR1 ECs, since these genes appear to be 
central to the disease mechanism of both PAHT and HHT. Some very preliminary (unpublished) 
results from our group have indeed shown that the knockdown of PEAR1 in ECs affects the 
expression profile of ENG and ALK1, results that are in line with the recent publication of Adam et 
al.30 Therefore, we believe that patients with PAHT/HHT should be analysed for the occurrence of 
certain single nucleotide polymorphisms (SNPs) in PEAR1 and that a possible role for PEAR1 as a 
modifier gene in the development of PAHT/HHT should be investigated.  
Table 1 – Mediators of pulmonary vascular responses in pulmonary arterial hypertension. TxA2, thromboxane A2; 
PGI2, prostaglandin I2 (prostacyclin); NO, nitric oxide; ET-1, endothelin-1; 5-HT, 5-hydroxytryptamine (serotonin); 
VEGF, vascular endothelial growth factor; VIP, vasoactive intestinal peptide. Adapted from Farber et al.3 
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PEAR1: A ROLE IN TUMOUR ANGIOGENESIS?  
 
As I discussed in Chapter IV, PEAR1 knockdown and murine Pear1 knockout resulted in enhanced 
tube formation in vitro, and enhanced vascular density in vivo.92 This raises the question as to 
whether PEAR1 could also be a player in tumour angiogenesis. Since PEAR1 has been linked to 
PTEN, I would like to start this part of the discussion by an explanation of the autosomal 
dominant Cowden syndrome, which is associated with PTEN mutations, as briefly mentioned 
before.  
 
Patients with Cowden disease (≈ 1/200,000) carry hereditary mutations of PTEN and as a result 
are at high risk for the development of a broad spectrum of benign and malignant tumours. They 
may also experience accelerated tumour growth due to the loss of PTEN in ECs, resulting in 
enhanced angiogenesis.11, 93 Excellent work by Suzuki et al. showed that the loss of PTEN in 
murine ECs makes these cells hypersensitive to VGFs, resulting in enhanced angiogenesis and 
accelerated tumour growth.11 Although the loss of PTEN results in a very strong phenotype, an 
important question is whether loss-of-function mutations in PEAR1 could contribute to an 
imbalance of the PTEN/PI3K/Alt pathway, thus resulting in a Cowden-like syndrome, or whether 
PEAR1 might function as a modifier gene in patients with Cowden syndrome, explaining the 
phenotypic heterogeneity in these patients. 
 
A possible role for PEAR1 in benign vascular malformations (e.g. as seen in HHT, pyogenic 
granuloma, PHT) has been discussed above. A major question of interest is whether PEAR1 is also 
involved in the angiogenesis of malignant tumours and/or in tumour metastasis. Tumour vessels 
are structurally and functionally different from normal vessels.94, 95 They are characterised by 
chaotic, heterogeneous and tortuous vessels, most of which do not succeed in delivering 
sufficient oxygen (or drugs) to the organising tumour,95, 96 resulting in the overproduction of pro-
angiogenic factors and creating a self-reinforcing vicious circle. Tumour ECs are no longer 
quiescent, instead they are organised in a non-polarised way and lack proper tight junctions, 
making them leaky and fenestrated which forms an ideal substrate for bleeding and tumour 
metastasis.95, 97, 98 Their EC gene expression profile is also very heterogeneous, resulting in a 
chaotic underlying signalling substrate.99 
 
Various antibodies against VEGF (bevacizumab, Avastin®) or against the VEGFR tyrosine kinases 
(sorafenib, Nexavar®; sunitinib, Sutent®; pazopanib, Votrient® and vandetanib, Zactima®) have 
been developed for clinical use. Although initially they provided promising results, their success 
was limited and often the problem of tumour resistance arose, resulting in the promotion of 
metastasis.100 Therefore, increasing evidence indicates that shifting anti-tumour therapy targets 
from anti-angiogenic towards vessel normalisation should be considered.100 Recent murine 
genetic and pharmacological studies have identified some groups of molecules that directly 
induce vessel normalisation.100 In tumours, there is a persistant imbalance between angiogenic 
activators and inhibitors, in favour of the activators. Therefore it is reasonable to suggest that 
removing the excess pro-angiogenic signals (e.g. via VEGF inhibitors, upregulating ANG-1, 
blocking ANG-2, enhancing eNOS-activity or blocking the oxygen sensor prolyl hydroxylase 
domain-containing protein 2 [PHD2 or EGLN1]) could result in a shift of tumour vessel 
disorganisation towards vessel normalisation, an important step in blocking the previously 
discussed vicious circle. This type of therapy could result in less aggressive and less 
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malignant/metastatic tumours and might increase the responsiveness to chemotherapy and 
immunotherapy. Although highly speculative, it would be of great interest to study the 
contribution of PEAR1 to tumour vessel growth. As previously discussed, the knockdown of 
PEAR1 resulted in enhanced tubulogenesis, but the maturation of ECs by PEAR1 knockdown was 
not affected (Chapter IV). This was also true for the maturation of CD34(+) cells after PEAR1 
knockdown (Chapter I), indicating that PEAR1 affects proliferation but not maturation. In addition, 
PEAR1 expression is low or non-existing in rapidly-proliferating ECs, as seen in pyogenic 
granuloma or in cells with a high proliferating phenotype (e.g. BOECs). Based on these findings, 
we assume that PEAR1 expression is also low in the ECs of tumour vessels and probably stays low 
during the process of tumour angiogenesis since this process is characterised by immaturity. 
Therefore, in line with the hypothesis discussed above, the induction of PEAR1 overexpression in 




GENETIC VARIATION IN PEAR1 
 
As discussed in the Introduction chapter, genetic variants in both the coding and non-coding 
regions of PEAR1 are associated with increased or impaired responses to various platelet agonists 
and are associated with inter-individual variability to antiplatelet drugs. Williams et al. identified 
PEAR1 as a candidate gene that may be linked to kidney injury in the salt-sensitive Dahl rat101 
(see Introduction), suggesting a possible link between PEAR1 and the development of 
hypertension. Taken together with our previously discussed findings on NO metabolism, our 
group therefore looked for associations between changes in blood pressure and the incidence of 
hypertension and genetic variation in PEAR1. We measured blood pressure at baseline and 
followed up on 1973 randomly recruited people, all genotyped for PEAR1. All associations of 
systolic and diastolic blood pressure changes with nine SNPs in PEAR1 were found to be non-
significant (p ≥ 0.059), suggesting that PEAR1 is not a hypertension susceptibly gene in 
humans.102 Although this was the first study focussing on a role for PEAR1 in EC function, it must 
be noted that the most discussed SNP that gives the greatest phenotype (rs12041331; Figure 8) 
was not included in our analyses. This should be considered as a major shortcoming in this 
study. Recently it was reported that HUVECs homozygous for the A-allele of PEAR1 rs12041331 
have approximately 117% better wound healing capabilities compared to cells homozygous for 
the major G-allele.30 I believe that additional research on the effect of gain-of-function or loss-
of-function SNPs in PEAR1 on certain diseases (e.g. PAHT, HHT, hypertension, tumour 
angiogenesis, etc) or other effects of genetic variability (e.g. methylation in epigenetics) in PEAR1 
should be encouraged. 
Figure 8 – Overview of reported SNPs in human PEAR1 (chromosome 1) as summarised in Table 1 of the Introduction 
Chapter. Nucleotide positions are according to the December 2013 human reference sequence (NCBI Build 38.3), 
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In this thesis, I investigated the contribution of PEAR1-signalling to the 
(patho)physiologic role of megakaryocytes/platelets and endothelial cells. In addition 
to opening up the way for further studies that unravel more into detail the underlying signalling 
pathways, downstream of PEAR1, these findings also hold the potential for further research 
concerning a potential role for PEAR1 in various diseases. I believe that our findings delivered a 




         We showed that a reduced PEAR1 expression in MK progenitors lowers Akt 
dephosphorylation, secondarily to transcriptional downregulation of PTEN. PEAR1-knockdown 
promoted MK progenitor proliferation, indirectly enhancing megakaryopoiesis and 
thrombopoiesis. This was validated in human MK progenitors in vitro and in a Pear1-morpholino 




         A protein library was created, representing the cell surface receptor repertoire and 
secretome of the human platelet. We postulated that this library will be a valuable tool in 
cardiovascular disease research and identified the high affinity IgE-receptor (FcεR1α) as a platelet 
ligand for PEAR1, making an important contribution towards understanding the mechanistic role 
of this receptor in platelet function and linking IgE-mediated allergy to cardiovascular disease.!
         We identified high molecular DxS as a non-physiological ligand for human and murine 
platelet PEAR1 and showed that DxS-mediated platelet aggregation is induced through parallel 






         We identified PEAR1 as a controller of EC proliferation, migration and tube formation in 
vitro and as a modifier of neo-angiogenesis in vivo in two murine Pear1-/- revascularization 
models. We could link these findings to the sustained phosphorylation status of Akt, a central 
player in vessel assembly. !
!
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ALGEMENE SAMENVATTING  
 
Het cardiovasculair systeem is cruciaal voor het transport van zuurstofrijk bloed, hormonen en 
voedingsstoffen naar de verschillende organen en voor de afvoer van afvalstoffen zoals 
koolstofdioxide (CO2) uit het lichaam. Binnen de systeemcirculatie kunnen we een opdeling maken in 
het arterieel netwerk (slagaders, hoge druk, transport van zuurstofrijk bloed), het veneus netwerk 
(aders, lage druk, transport van zuurstofarm bloed) en het lymfatisch netwerk, met het hart als 
drijvende pomp voor het bloedtransport doorheen dit complexe systeem (Figuur 1).  De helft van dit 
circulerend bloedvolume bestaat uit plasma en de andere helft bestaat uit circulerende bloedcellen: a) 
rode bloedcellen voor het transport van zuurstof, b) witte bloedcellen voor de strijd tegen infecties en 
c) bloedplaatjes, cruciaal voor de bloedstolling (Figuur 1 van de Introductie).  
 
 
Figure 1 – Arterial blood vessels transport plasma and blood cells from the heart to the tissues/organs of the body 
whereas the venous system transports blood from the organs back to the heart.  
 
“Cardiovascular disease” (verzamelnaam voor aandoeningen van het cardiovasculair systeem) vormen 
heden ten dage nog steeds de grootste doodsoorzaak wereldwijd. In 2012 stierven naar schatting 
16,7 miljoen mensen (of 29% van het wereldwijde jaarlijkse sterftecijfer) ten gevolge van 
aandoeningen zoals atheromatose (aderverkalking), arteriële hypertensie en/of diabetes, in de hand 
gewerkt door onder meer obesitas, roken en hypercholesterolemie. Atheromatose is een langzaam en 
complex proces waarbij vetten in de slagaderwand worden afgezet en zich in een later stadium gaan 
organiseren tot een cholesterolplaque in het lumen van het bloedvat (zie Figuur 2 van de Introductie, 
pagina 5). Enerzijds kan dergelijke plaque zo sterk aangroeien dat dit leidt tot het afsluiten van het 
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bloedvatlumen. Frequenter echter zal een scheur van een plaque in de bloedvatwand optreden; 
Hierbij komt de inhoud van de plaque vrij wat ogenblikkelijk resulteert in een activatie van 
circulerende bloedplaatjes, vorming van een bloedplaatjesprop (trombus) en een acuut afsluiten van 
de bloedvatflow met zuurstoftekort (ischemie) en infarcering van het achterliggende weefsel tot 
gevolg. Dit proces leidt – afhankelijk van het bloedvat dat afgesloten wordt – tot een acuut myocard 
infarct (AMI), herseninfarct (stroke), acuut darminfarct etc. Een gevreesd bijkomend probleem is dat 
dergelijke trombus kan losraken van de vaatwand en door het stromende bloed meegevoerd wordt 
tot deze vast komt te zitten in een kleiner bloedvat met volledig afsluiten tot gevolg (embolie).  
 
De vorming van een trombus bij een plaqueruptuur (maar even goed bij het afsluiten van een wonde 
bij een trauma) is een complex proces, bestaande uit verschillende interacties tussen eiwitten op het 
oppervlak van bloedplaatjes (receptoren) onderling en verschillende interacties tussen 
plaatjesreceptoren en circulerende stoffen in het plasma. Grosso modo kunnen we de vorming van 
een trombus opdelen in vier verschillende fasen (zie Figuur 4 van de Introductie, pagina 11). Bij 
plaqueruptuur komen zogenaamde “pro-trombogene” stoffen vrij, dewelke zorgen voor activatie van 
circulerende bloedplaatjes in de bloedstroom (fase van de activatie). Dit zal er voor zorgen dat 
bepaalde bloedplaatjesreceptoren geactiveerd zullen worden, wat zal leiden tot verdere activatie van 
bloedplaatjes en aangroei van de initiële (kleine) trombus (amplificatie fase). Uiteindelijk zal dit leiden 
tot een reeks van complexe interacties tussen een heel aantal oppervlaktereceptoren waarbij de 
gevormde trombus zal evolueren naar een stabiele “klonter” (stabilisatie fase). In een laatste fase zal 
ervoor gezorgd worden dat de stabiliteit van de klonter zal verminderen en uiteindelijk de trombus 
uit elkaar zal vallen (desintegratie fase).  
 
Hoewel de meeste receptoren op bloedplaatjes heden ten dage gekarakteriseerd zijn en hun 
onderliggende werking in de fysiologie van het bloedplaatje goed gekend is, zijn lang niet alle 
receptoren reeds geïdentificeerd.  In 2005 werd door de groep van Nanda et al. (Stanford, California, 
USA) een nieuwe bloedplaatjesreceptor beschreven, die PEAR1 (Platelet Endothelial Aggregation 
Receptor 1) genoemd werd. Nanda et al. rapporteerden dat PEAR1 tussenkwam in de stabilisatie fase 
van de trombus en dat PEAR1 niet alleen op het oppervlak van bloedplaatjes tot expressie kwam 
maar ook op het oppervlak van endotheelcellen (die cellen die de binnenkant van bloedvaten 
aflijnen). Onze groep (Kauskot et al.) toonde in 2012 aan dat er meer PEAR1 tot expressie komt aan 
het oppervlak van een bloedplaatje wanneer dit geactiveerd wordt en dat activatie van PEAR1 in 
bloedplaatjes leidt tot activatie van de αIIbβ3-receptor (een belangrijke receptor voor trombusvorming 
en stabiliteit van de gevormde trombus) via Akt (een centrale speler in activatie en regulatie van 
bloedplaatjesfunctie). Desondanks bleven vele vragen omtrent deze “nieuwe” receptor nog 
onopgelost.  
 
Daarom hebben we als doel gesteld in dit thesis manuscript (zie ook Aims, pagina 21) om de bijdrage 
van PEAR1 aan megakaryopoïese (het vormen van nieuwe bloedplaatjes uit megakaryocyten) te 
bestuderen, het onderwerp van Hoofdstuk I. Vermits onze groep reeds aangetoond had dat PEAR1 
een rol speelt in het stabiliseren van trombi, hebben we verder onderzocht welke partner hiertoe 
bijdraagt.  In hoofdstuk II beschrijven we hoe PEAR1 geactiveerd wordt door een PEAR1-activerend 
eiwit (ligand), gelegen op een naburig bloedplaatje in de gevormde trombus. Tot op heden is het in 
dit hoofdstuk beschreven ligand voor PEAR1 het enige gekende ligand, op bloedplaatjes en op andere 
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cellen. Zoals beschreven in Hoofdstuk III, hebben we echter ook een niet-fysiologisch experimenteel 
ligand geïdentificeerd, dat in staat is om bloedplaatjes krachtig te activeren via het induceren van 
PEAR1-activering. PEAR1 komt niet alleen tot expressie aan het oppervlak van bloedplaatjes maar 
ook aan het oppervlak van humane endotheelcellen (cellen die de binnenkant van het hart, 
bloedvaten en lymfevaten bekleden). Tot dusver was de rol van PEAR1 in endotheelcellen niet 
gekend. In Hoofdstuk IV wordt de bijdrage van PEAR1 aan de functie van endotheelcellen en nieuwe 
bloedvatvorming (angiogenese) uitvoerig besproken.  
 
Hoofdstuk I – De rol van PEAR1 in bloedplaatjesvorming 
 
IN HOOFDSTUK I hebben we aangetoond dat, naast de aanwezigheid van PEAR1 op het oppervlak van 
(mature) bloedplaatjes, PEAR1 ook aanwezig is aan op het oppervlak van megakaryocyten, cellen in 
het beenmerg die instaan voor de productie van circulerende bloedplaatjes in het bloed. We stelden 
vast dat de expressie van PEAR1 stijgt naarmate de megakaryocyt progenitorcel (in celkweek; in vitro) 
meer uitrijpt. Dit bracht er ons toe te onderzoeken wat het effect is op de uitrijping en 
bloedplaatjesproductie van de progenitorcel (voorlopercel) wanneer de PEAR1 expressie fors 
onderdrukt wordt (PEAR1 knockdown) tijdens dit proces. Knockdown van PEAR1 resulteerde in een 
verdubbeling van het aantal progenitoren in vitro (en dus uiteindelijk ook van het aantal 
bloedplaatjes), zonder effect op de maturatie van de megakaryocyt. Zoals eerder verteld is het eiwit 
Akt één van de belangrijkste regulatoren van cel functies (onder andere celgroei) in bloedplaatjes en 
ook in mekaryocyten. Akt wordt geactiveerd door het eiwit PI3K en wordt geïnactiveerd door het eiwit 
PTEN. Binnen de megakaryocyt wordt de balans tussen PI3K en PTEN strikt gereguleerd om een goede 
controle te kunnen uitvoeren op de groei van de megakaryocyt progenitoren. Ons onderzoek toonde 
aan dat knockdown van PEAR1 resulteerde in een overhand van Akt-activiteit door een verminderde 
expressie van PTEN (hoewel de directe link tussen PTEN-daling en knockdown van PEAR1 tot op 
heden nog ongekend is) en dus resulteerde in verhoogde megakaryocytproliferatie.  Dit werd 
aangetoond in vitro met humane megakaryocyten (CD34+ cellen), maar werd ook bevestigd in een 
levend organisme (in vivo) door het uitschakelen van Pear1 in embryo’s van zebravissen. Ook hier 
zagen we dat Pear1-afwezigheid resulteert in een Pten-afhankelijke verhoging van het 
bloedplaatjesaantal in zebravissen.  
 
Hoofdstuk II en III – De liganden van bloedplaatjes PEAR1 
 
Zoals eerder vermeld toonde onze groep aan dat activatie van PEAR1 in bloedplaatjes leidt tot 
activatie van de αIIbβ3-receptor via Akt en dus zorgt voor stabilisatie van de gevormde trombus. Dit 
impliceert dat een bepaald (ongekend) eiwit op het oppervlak van het ene plaatje zorgt voor activatie 
van PEAR1 op een naburig gelegen bloedplaatje binnen de zich vormende trombus. Een cruciale 
vraag die zich stelde, was de identificatie van dit PEAR1 activerende eiwit (het PEAR1 ligand). Hiertoe 
werd – in samenwerking met dr. Y. Sun en dr. G. Wright van het Sanger Institute te Cambridge – een 
“bibliotheek” ontworpen waarbinnen elk eiwit dat aan het oppervlak van een bloedplaatje tot 
expressie komt, kunstmatig nagemaakt werd. Door de bindingen van elk van deze 173 eiwitten 
onderling te verifiëren (in totaal werden meer dan 13.000 interacties gecontroleerd) kon het 
fysiologische ligand voor PEAR1 geïdentificeerd worden, zoals beschreven in Hoofdstuk II: de 
Immuunglobuline E (IgE)-receptor FcεR1α. Dit was erg verrassend voor ons, sinds deze receptor 
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vooral gekend is bij IgE gemedieerde processen in het lichaam zoals astma, allergie en chronisch 
obstructief longlijden. Bovendien konden wij aantonen dat er een competitie optreedt tussen IgE en 
PEAR1 voor de bindingsplaats op FcεR1α. Inderdaad, in een in vitro model voor trombusvorming, 
toonden wij aan dat PEAR1 gemedieerde trombusvorming verminderd kon worden in de 
aanwezigheid van hoge dosissen IgE; of anders gezegd: hoge dosissen IgE verhinderen de activatie 
van PEAR1 door FcεR1α en verhinderen bijgevolg de Akt-gemedieerde αIIbβ3- activatie en dus de 
vorming van trombose. Dit is de eerste keer dat er een verband aangetoond wordt tussen IgE-
gemedieerde allergie en bloedplaatjesactiviteit. Naast het fysiologische ligand voor PEAR1, 
identificeerden wij ook – in aansluiting op een recent manuscript door Getz et al. – een niet-
fysiologisch ligand voor PEAR1, namelijk dextraan sulfaat (DxS). Het werkingsmechanisme van DxS 
wordt in detail besproken in Hoofdstuk III. Deze studie levert een bruikbaar pseudo-ligand op, dat 
kan ingezet worden in verdere PEAR1 studies.  
 
HOOFDSTUK IV - PEAR1 EN ENDOTHEELCELLEN 
 
PEAR1 komt niet alleen tot expressie aan het oppervlak van bloedplaatjes, maar ook op het 
membraanoppervlak van endotheelcellen zoals eerder vermeld. In een eerste reeks van resultaten, 
beschreven in Hoofdstuk IV, bevestigden wij inderdaad de aanwezigheid van PEAR1 in 
endotheelcellen van tal van (humane) weefsels. Tot dusver bleef de functie van PEAR1 in 
endotheelcelbiologie ongekend. Parallel aan onze bevindingen in megakaryocyten, toonden wij aan 
dat PEAR1 knockdown in humane endotheelcellen (in vitro) tevens resulteerde in een verdubbeling 
van de endotheelcelgroei. In lijn met onze bevindingen in megakaryocyten, konden wij aantonen dat 
knockdown van PEAR1 in endotheelcellen gepaard ging met verhoogde activiteit van Akt, wederom 
een belangrijke regulator van proliferatie maar ook van migratie van het endotheel. Inderdaad, 
knockdown van PEAR1 in endotheelcellen, resulteerde eveneens in een versnelde migratie van het 
endotheel. Gezien endotheelcelproliferatie en -migratie de hoeksteen vormen van nieuwe 
bloedvatvorming (neo-angiogenese), trachtten wij onze bevindingen te valideren in twee gevestigde 
modellen van angiogenese in een Pear1 knockout muis (Pear1-/-) in vivo. Na het afbinden van de 
slagader die het onderbeen van de muis bevloeit, bemerkten we (met behulp van Doppler analyse) 
een significant sneller herstel van de bloedflow in het afgebonden been van de knockout muis 
vergeleken met de wildtype muis. Dit kon verklaard worden door snellere vorming van nieuwe 
bloedvaten in de afgebonden poot om de bloedflow te herstellen. Tevens, bij het aanleggen van een 
gestandaardiseerde wonde op de rug van de muis, zien we een dubbel zo snel toegroeien van de 
wonde in de knockout muis vergeleken met wildtype muizen, opnieuw door versnelde 
bloedvatvorming in het ingroeiend weefsel van de wonde en dus versnelde wondsluiting. Ook hier 
konden we aantonen dat dit te verklaren is door verhoogde activiteit van Akt, de regulator van 
endotheelcel proliferatie, migratie en finaal bloedvatvorming. Deze bevindingen identificeerden 
PEAR1 als een nieuwe regulator van neoangiogenese.   
 
Dit thesismanuscript heeft een functionele en mechanistische basis gelegd voor de rol die PEAR1 
speelt tijdens bloedplaatjesvorming en tijdens bloedplaatjesactivering. Bovendien werd een cruciale 
functie voor PEAR1 in endotheelcelbiologie aangetoond, hetgeen verder aan de basis kan liggen voor 





BESTE ALLEN,  
 
 Dit is het dan, dàt moment waarnaar elke PhD’er uitkijkt. Dàt moment waarop net dat toch gelukt is 
waarvan zij/hij nooit gedacht had dat het zou lukken. Dàt moment waarop je vol trots je eigen bijgedragen 
steentje aan “de wetenschap” kan voorstellen. Het waren vier intense jaren; vier jaren van vreugde, plezier 
en vriendschap maar tegelijk ook vier jaren van volharding, vallen en opstaan en blijven werken voor iets 
waar het succes lang niet vanzelfsprekend verzekerd is. En toch, toch is het net dat ongekende, de passie 
om te weten én nieuwe dingen te ontdekken die je elke dag weer verder drijft. Velen onder ons zullen dat 
beamen. Het kan denk ik niet mooier verwoord worden dan in het lievelingscitaat van mijn promotor.  
 
 
“ SUCCES IS THE ABILITY TO GO FROM FAILURE TO FAILURE WITHOUT LOSING YOUR ENTHUSIASM”  
Peter Verhamme (and Winston Churchill) 
 
 
 Dit brengt mij naadloos bij mijn twee promotoren en copromotor. Hoewel het doctoraatsreglement 
van de KU Leuven oplegt dat het “doctoraat gebeurt onder begeleiding van een promotor en eventueel één 
of meerdere copromotoren (Art. 3)”, kan ik vol overtuiging zeggen, Peter en Marc – Marc en Peter, dat jullie 
er beiden meer dan 100% voor mij geweest zijn. Ik was zodanig verwend dat ik vaak een half uur na het 
verzenden van een e-mail al zenuwachtig op mijn stoel zat te draaien omdat het antwoord op zich liet 
wachten. Marc, de luxe dat je gewoon het bureau naast mij zat en élk moment van de dag voor ons tijd 
kon en wou vrijmaken is iets wat elke PhD benijdt. Je brede kennis omtrent de fundamentele wetenschap 
en je drijfveer om te blijven zoeken (hoewel we moeten toegeven dat het soms ook wel flirtte met de 
grenzen van het begrijpbare) is in mijn ogen uniek. Zelfs wanneer ik op een vrijdagnamiddag kwam 
aandraven met versie 14.a.II.bis van één of andere tekst, liet je toch weer alles vallen en had ik binnen het 
uur een gecorrigeerde versie. We hebben heel wat (lange) gesprekken gehad over wetenschap maar ook 
vele andere topics. Wat me telkens weer opviel is dat je oor had voor de mening van anderen en hoewel dit 
soms niet strookte met je eigen visie, gaf je ons toch de ruimte om datgene te doen waarin we zelf het 
meest in geloofden. Ik zou je vandaag dan ook oprecht hiervoor willen bedanken. Peter, wat heb ik immens 
veel van je geleerd. Ik sta hier vandaag met heel wat resultaten die ik enkel kan voorleggen omdat je altijd 
die mensen met wie je nauw samenwerkt, betrekt in je eigen succes. Je doorzettingsvermogen is 
fenomenaal, of het nu gaat om een giga clinical trial, dan wel om een schijnbaar minder belangrijk iets. Je 
grootste belang was dat we konden (mee)werken aan dat waarin we zelf geloofden en je spaarde daarvoor 
kosten noch moeite. Je bent niet alleen een steun voor je eigen PhD’s maar voor velen van ons binnen de 
groep van cardiologie. We hebben samen een heel deel van de wereld gezien en ook heel wat “feestjes” 
voor het labo georganiseerd doch wat ik bovenal geleerd heb is dat je àltijd het aangename aan het nuttige 
moet koppelen. Peter, een érg oprechte merci hiervoor !! Prof. Janssens, ik zou u graag willen bedanken 
voor het enthousiasme waarmee u altijd luisterde naar een update van mijn data. Ik bewonder u omdat u 
telkens na één blik op een figuur of een tabel een nieuwe richting kon aansturen waarin we verder moesten 
zoeken, ideeën die vaak een extra dimensie aan het project hebben gegeven. Daarnaast wil ik u ook 
bedanken voor de mogelijkheden die u aan ons “de klinische PhD’ers” verschaft om op een evenwichtige 
manier onderzoek en kliniek met elkaar te combineren. Uw passie ligt zowel 100% in de kliniek als 100% in 
het onderzoek en dat is - naar mijn mening - uniek.  
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 I would also like to express my gratitude towards the international jury members, Prof. Harrisson 
and Prof. Chiche, for reading the manuscript and for their valuable input and also for coming to Leuven. 
 
 Hoewel mijn naam op de voorkant van dit manuscript staat, is dit geheel het resultaat van het werk 
van velen. Op het einde van dit traject begrijp ik waarom deze zin vrijwel in elk dankwoord van een thesis 
terug te vinden is.  
 
 In de eerste plaats zou ik de mensen van het labo willen bedanken. Hartelijke dank aan Prof. 
Herijgers om binnen het departement cardiovasculaire wetenschappen mijn doctoraat te kunnen 
volbrengen en om vandaag de verdediging voor te zitten en dank aan Prof. Lijnen en zijn voorgangers em. 
Prof. Verstraeten, Vermylen en Collen om te kunnen werken in “het wereldvermaarde stollingsinstituut van 
Leuven”. Ook een bijzonder woord van dank aan Prof. Van Geet, Prof. Freson, Prof. Peerlinck, Prof. Luttun, 
Prof. Jones, Prof. Heying en Prof. Jacquemin voor de bijzondere bijdragen tijdens de labmeetings, de 
gesprekken in de gang en de sfeer bij onze talkrijke labo-etentjes. Zeker en vast een welgemeende dank 
aan Diane, Roos, Karen en Gabriela voor de leuke babbels en jullie uitmuntendheid in het “regelen”.  
 
 In de tweede plaats zou ik – naast aan mijn collega’s – een bijzonder woord van dank willen uiten 
aan “onze laboranten”. Katrien, Soetkin, Serena, Chantal, Christine, Marleen en Hilde, jullie hulp en bijdrage 
was – zoals Alex zou zeggen – impeccable. Katrien, duizendmaal dank voor al het werk dat je voor mij 
gedaan hebt, telkens met de grootste precisie en gemiddeld tweemaal sneller dan ik dacht dat het zou 
gaan. Ik heb het even opgeteld en we hebben samen niet minder dan 400 western blots gedaan! Ik hoop 
dat we in de toekomst nog vaak met elkaar kunnen samenwerken. Soetkin, bedankt voor al die kleuringen 
waar ik je maar mee lastig bleef vallen. Marleen, een topper in dierwerk was ik niet en zal ik ook nooit zijn, 
jouw precies werk was onmisbaar!  
 
 Cher Alex, je voudrais te remercier pour tes idées, pour me confier le projet sur PEAR1 et surtout 
pour ton amitié et gaieté et pour tout ce que t’as fait pour moi et le labo. Dommage que tu ne puisses pas 
être ici aujourd’hui mais on se revoit certainement à Paris.  
 
 I’m also very greatfull to Prof. Wright and dr. Sun of the University of Cambridge, for the tremendous 
efforts made to the “PEAR1 ligand-manuscript” and for the friendly welcome at Cambridge. Also special 
thanks to the team of Prof. Staessen, for their great interest in the PEAR1 project.   
 
 Ook een enorme bedankt aan de collega’s PhDs en postdocs van het CMVB. Marijke, Jorien, Anouck 
en Anne: ik voelde me vaak in ons bureau als een haan in een kippenhok maar ik keek elke avond opnieuw 
uit naar de terugkeer naar dat kippenhok. Benedetta en Maarten, veel succes met het verderzetten van het 
PEAR1-project! Laurens, Elise, Dries, Lotte, Thibault, Maarten, Dieter, Sander, Peter, Ine, Sander, Bianca, 
Ilse, Manisha, Rachel, Lucas en Ward. Bedankt allemaal voor de vele leuke momenten, het delen van leuke 
en minder leuke momenten en de super toffe sfeer. Ik wens jullie allemaal nog enorm veel succes toe met 
jullie lopende projecten en weet zeker dat jullie één voor één zullen uitblinken.  
 
 Thomas, zoals je zelf schreef in je thesisdankwoord, waren we “helplijn-partners-in-crime”. Wat 
hebben we achteraf toch gelachen om die onverstaanbare Indische oproepen en Canadezen in het holst 
van de nacht. Je bent altijd mijn grote voorbeeld geweest en ik kijk enorm naar je op ! Bedankt voor de 
leuke momenten tijdens congressen, in Leuven bij onze befaamde Harvard-pump, in Canada en eender 
waar. Cheers mate !   
 
Graag wil ik ook via deze weg het Fonds voor Wetenschappelijk Onderzoek (FWO) bedanken voor de 
financiële steun aan dit project.  
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Ik ben blij dat ik tijdens mijn PhD-traject ook nog tijd heb gehad voor enkele zijsporen:  
 
 Mijnheer de rector, geachte vice-rectoren, decanen en leden van de Academische Raad. Geachte 
leden van de raad van bestuur van de KU Leuven en UZ Leuven. Geachte leden van het groepsbestuur 
Biomedische Wetenschappen. Het was mij een zeer groot genoegen en een hele eer de voorbije jaren deel 
te mogen uitmaken – als ABAP-vertegenwoordiger van de groep biomedische wetenschappen – van de 
beleidsorganen van deze universiteit. Ik heb veel geleerd uit de verschillende projecten die we gestart zijn 
en uit de talrijk gevoerde discussies en was erg aangenaam verrast hoezeer met onze mening als 
vertegenwoordiger rekening gehouden werd. Ik ben trots dat ik deel heb mogen uitmaken van dit goed 
geolied team. Mijnheer de rector, ik dank u voor de immer grappige gesprekken, de enorme rekening die 
ik u gekost heb aan de Faculty Club (☺) en voor het vertrouwen. Ik zou hierbij ook een bijzonder woord 
van dank willen richten aan Dhr. J. Vaesen.   
 
 Geachte ererector Vervenne en ererector Waer. Graag had ik u – als lid van de hostgroup van de KU 
Leuven - willen bedanken voor de fijne samenwerking tijdens uw rectorschap. Veel succes met uw verder 
lopende projecten waarover u beiden met een aanstekelijke passie kan vertellen. Graag wil ik in één adem 
een dankwoord hieraan koppelen voor mevr. Demin. Beste Katrijn, je hebt me acht jaar lang geleerd wat 
protocol is. We hebben samen heel wat kleine brandjes geblust. Mijn oprechte dank hiervoor ! 
 
 Een speciale merci aan de “dames (en heer) van het rectoraat” en uiteraard ook aan Iris en Margot 
van de dienst communicatie. Beste Iris, Margot, Anne-Mie, Inge, Katrien en Jos. We hebben samen heel wat 
plezier beleefd en menig receptie afgeschuimd, tot gauw ! Beste Rob, bedankt voor de leuke babbels en 
om vandaag ook paraat te willen zijn voor de fotografie. 
 
 Een ander zijspoor was het verzorgen - binnen de dienst bloedings- en vaatziekten – van de 
telefonische hulplijn voor enkele multi-center trials. Ik zou hiervoor dan ook graag mijn dank willen 
betuigen aan Prof. H. Büller, Annelise Segers en het ganse ITREAS-team. Dank voor het vertrouwen dat u in 
ons stelde en de opportuniteit om ons te laten proeven van het wel en wee achter dergelijke trials. 
 
 Naast “doctoreren” was het natuurlijk ook nog “specialiseren”. Bedankt aan Prof. Peetermans om mij 
toe te laten tot de grote groep van de inwendige geneeskunde en bedankt aan de geweldige teams van 
bloedings- en vaatziekten, MIG-A onder leiding van Prof. Wilmer en van de CCU onder leiding van Prof. 
Desmet. De nachten/dagen waren pittig, de pathologie was uitdagend en het geheel functioneerde als een 
team ! Ook een heel speciaal woord van dank aan de verpleging van spoedgevallen en INZO van het AZ St. 
Maarten in Mechelen en aan het artsencorps inwendige geneeskunde en cardiologie. Ik zou mij heel 
speciaal willen richten tot dr. C. Libeer. Beste Christophe, wat je mij geleerd hebt omtrent interne 
geneeskunde en intensieve zorgen had ik nergens zo goed onderricht kunnen krijgen. Je geduld was 
eindeloos en je hebt de kunst om overal rust te brengen, zowel bij de verpleging als bij je patiënten. Je 
hebt mij de smaak doen pakken van de intensieve zorgen en ik hoop dat we in de toekomst nog vaak 
kunnen samenwerken. Uiteraard ook een welgemeende bedankt voor de artsen en verpleging van de dienst 
cardiologie onder leiding van dr. L. Janssens in het Imeldaziekenhuis (Bonheiden) waar ik nu sinds een 
zestal weken mijn aanvullende opleiding cardiologie volbreng. Ik heb me hier vanaf de eerste dag thuis 
gevoeld en heb zelden zo’n warm onthaal ergens gekregen. Hoewel ik hier als “cardiologie-dummie” 
binnen gekomen ben, ben ik ervan overtuigd dat het een boeiend en leerrijk jaar gaat worden.  
 
 Graag had ik via deze weg ook de mensen van Daiichi Sankyo, Boehringer Ingelheim en Bayer willen 
bedanken. Guy, Katrien, Frederik, Sophie, Dirk en Lieselot bedankt voor jullie aanwezigheid en de interesse 
in het werk dat we als groep geleverd hebben. 
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 Last but not least zou ik graag mijn vrienden en familie willen danken voor de onvoorwaardelijke 
steun en vriendschap. Ik prijs me elke dag weer gelukkig dat ik omringd ben met een buitengewoon 
geweldige groep van mensen en dat geluk kan ik alleen maar koesteren. Ik hoop dat jullie nu toch eindelijk 
een beetje begrepen heb wat ik al die jaren in dat labo met die muizen en cellen heb zitten uitsteken.  
 
 Laura, Bert, An, Lien, Joost, Vincent G en Anka: sommigen waren er sinds de eerste dag in Leuven bij 
en sindsdien zijn we alleen maar betere vrienden geworden. Ik kan jullie niet genoeg bedanken voor de 
ongelooflijk mooie momenten die we samen beleefd hebben en voor de steun die ik kreeg van jullie tijdens 
moeilijke momenten. Woorden schieten mij hierbij te kort. BEDANKT! Mathias, Joachim, Katrien, Jan, 
Vincent P, Bart, Wim, Jeroen, Jonas, Peter, Kevin, Bram, Anzor, Ward, Caroline, Beatrijs, Machteld, Geertrui, 
thanks voor de geweldige momenten samen ! Jullie betekenen enorm veel voor mij. Ik hoop dat ik nu terug 
wat meer tijd ga hebben om met jullie op te trekken.  
 
  Een welgemeend dikke merci aan mijn scoutsmaten. Sinds onze 6-7 jaar vormen we een 
onafscheidelijke groep waar niets of niemand tussen kan komen. Wat ons bindt is dat we allemaal weten 
wat we willen en we er dan ook resoluut voor gaan. Bert, Hans, Jo, Kristof, Tom, Maarten, Willem T, Willem 
VDH;  ik kon me geen betere maten indenken. BEDANKT ! 
 
 Mijn allergrootste dank gaat uit naar jullie: mama, papa, Pieter, Frederik, Valerie en mémé. Mama en 
papa, jullie hebben mij altijd alle kansen gegeven die ik me maar kon dromen. Nooit was iets te veel om 
voor ons te doen. Pieter en Frederik, ik beloof dat ik vanaf nu terug wat meer tijd zal hebben. Frederik, je 
bent de beste broer die ik me kon inbeelden, bedankt ! Jammer genoeg is mijn grootmoeder tijdens mijn 
thesisjaren overleden. Ik zou dan ook graag dit werk aan haar willen opdragen ! 
 
Tot slot zou ik graag iedereen willen bedanken die de tijd heeft vrijgemaakt om vandaag hier aanwezig te 
kunnen zijn. Hoewel het onderwerp waarschijnlijk niet iedereen even hard kan boeien hoop ik dat ik het 
doch deels goed gemaakt heb door een lang dankwoord te schrijven ☺. Tot gauw,  
 
 
Christophe VANDENBRIELE 
Leuven, 08/11/2015 
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